S100 05RXSUrWHWDO

Version française Anatomopathologie

Épidémiologie – Facteurs de risque &ODVVLÀFDWLRQ Tumor, Node, Metastasis710

SHW\S

8QHWXPHXUGHODYHVVLH79HVWGLDJQRVWLTXpHRXWUDLWpH
GDQVOHPRQGHFKH]PLOOLRQVGHSHUVRQQHVFKDTXHDQQpH /D GpQRPLQDWLRQ791,0 HVW XWLOLVpH SRXU OHV WXPHXUV GH
HWHOOHDSSDUDvWDSUqVDQVGDQVODPDMRULWpGHVFDV>@(Q YHVVLH 79 Q·LQÀOWUDQW SDV OH PXVFOH HW FHOOH GH 79,0
)UDQFHFHWWHSDWKRORJLHDYHFQRXYHDX[FDVHVWLPpVHW HQ FDV G·LQÀOWUDWLRQ WXPRUDOH GX GpWUXVRU /D FODVVLÀFD-
GpFqVUHFHQVpVHQGRQWFKH]O·KRPPHRFFXSH WLRQ 710  IDLW UpIpUHQFH 7DEOHDX  HW 7DEOHDX GH
ODeSODFHHQLQFLGHQFHHWe rang des décès tous cancers UHFRPPDQGDWLRQ>@
FRQIRQGXV,QVWLWXWGHYHLOOHVDQLWDLUH>,Q9V@HWFRQVWLWXH
OHVHFRQGFDQFHUXURORJLTXHDSUqVFHOXLGHODSURVWDWH/HV79
7DEOHDXGHUHFRPPDQGDWLRQ
VRQWUHVSRQVDEOHVGHGHVGpFqVSDUFDQFHU/HXULQFLGHQFH
HVWHQDXJPHQWDWLRQG·HQYLURQSDUDQDYHFXQHFURLVVDQFH 5HFRPPDQGDWLRQVDQDWRPRSDWKRORJLH Niveau
SOXVLPSRUWDQWHFKH]ODIHPPHTXHFKH]O·KRPPH
/DSUpYHQWLRQGHV79UHSRVHVXUODOXWWHDFWLYHFRQWUHVRQ 8WLOLVHUODFODVVLÀFDWLRQ710SRXUGpÀQLU Fort
SULQFLSDOIDFWHXUGHULVTXHO·LQWR[LFDWLRQWDEDJLTXH>@/D le stade tumoral
VpGHQWDULWpOHV\QGURPHPpWDEROLTXHHWGHVDSSRUWVK\GULTXHV 8WLOLVHUOHVFODVVLÀFDWLRQV2UJDQLVDWLRQ Fort
VXSpULHXUVj/MRXURQWpJDOHPHQWpWpFRUUpOpVjXQHDXJPHQ- PRQGLDOHGHODVDQWp206HW
WDWLRQGXULVTXHGH79>@'DQVXQHSRSXODWLRQjULVTXHGH79 SRXUGpÀQLUOHJUDGHWXPRUDO
GXIDLWG·XQHH[SRVLWLRQSURIHVVLRQQHOOHDQWpULHXUHPRWLYDQWXQ
GpSLVWDJHFLEOpOHVUHFRPPDQGDWLRQVGHOD6RFLpWpIUDQoDLVH /HWHUPH©WXPHXUVXSHUÀFLHOOHGHYHVVLHª Fort
GH PpGHFLQH GX WUDYDLO HQ FROODERUDWLRQ DYHF OD 6RFLpWp QHGRLWSOXVrWUHXWLOLVp
IUDQoDLVHGXFDQFHUHWO·$)8SUpFRQLVHQWGHPHWWUHHQSODFH
OHVH[DPHQVGHGpSLVWDJHDQVDSUqVOHGpEXWGHO·H[SRVLWLRQ
DXFDQFpURJqQHYpVLFDO/HSURWRFROHGHVXUYHLOODQFHPpGLFDOH Cytologie urinaire
SURSRVpHVWUpVXPpGDQVO·DOJRULWKPHGHOD)LJXUH7DEOHDXGH
UHFRPPDQGDWLRQ>@
Tableau de recommandation 1
5HFRPPDQGDWLRQVIDFWHXUVGHULVTXH
)DLUHVWRSSHUO·LQWR[LFDWLRQWDEDJLTXHHVW
SULPRUGLDOSRXUUpGXLUHOHULVTXHpYROXWLIGHV
791,0
6XUYHLOOHUOHVWUDYDLOOHXUVH[SRVpVjGHVDJHQWV
FDQFpURJqQHVSRXUODYHVVLHSDUXQHF\WRORJLH
urinaire régulièrement
/DF\WRORJLHXULQDLUHHVWDYHFODF\VWRVFRSLHXQGHVH[DPHQV
GHUpIpUHQFHSRXUODGpWHFWLRQHWODVXUYHLOODQFHGHV791,0
QRWDPPHQWGHKDXWJUDGH/DF\WRORJLHXULQDLUHDXQHVHQVL-
ELOLWppOHYpHSRXUODGpWHFWLRQGHVFHOOXOHVWXPRUDOHVGHKDXW
Niveau JUDGHDYHFXQHVHQVLELOLWpGHSOXVGHGDQVODGpWHFWLRQ
Fort GX&,6>@PDLVDXQHIDLEOHVHQVLELOLWpSRXUOHVWXPHXUVGHEDV
JUDGH8QHF\WRORJLHXULQDLUHSRVLWLYHSHXWLQGLTXHUODSUpVHQFH
G·XQHWXPHXUQ·LPSRUWHRGDQVODYRLHH[FUpWULFHXULQDLUH
8QHF\WRORJLHQpJDWLYHQ·H[FOXWSDVODSUpVHQFHG·XQHWXPHXU
Fort 'HSXLVGpFHPEUHXQHQRXYHOOHFODVVLÀFDWLRQPRQGLDOH
GHF\WRORJLHXULQDLUHDpWpSXEOLpH>@/DQpFHVVLWpG·XQHWHUPL-
QRORJLHFRQVHQVXHOOHSRXUOHVUpVXOWDWVGHODF\WRORJLHXULQDLUH

Stratégie de surveillance médicale pour les sujets exposés ou ayant été exposés
à des agents cancerogènes pour la vessie
Groupe de travailleurs à risque
Niveau de risque Groupe de travailleurs Groupe de travailleurs
TRÈS ÉLEVÉ (RR ou OR ou SMR
de groupe à risque ÉLEVÉ à risque MODÉRÉ
> 5)* ou professions avec niveaux
professionnel (2 < RR ou OR ou SMR ≤ 5)* (1 < RR ou OR ou SMR ≤ 2)*
d’exposition élevés documentés
Durée d’exposition ≥ 1 an < 1 an ≥ 1 an < 1 an
RECOMMANDÉE
NON RECOMMANDÉE (en l’état actuel
Surveillance (dans tous les PROPOSÉE (au cas par cas)
des performances des tests disponibles)
cas)
Latence minimale
après le début 20 ans
de l’exposition
Examens proposés
en première
Cytologie urinaire
intention et tous
les 6 mois

Figure 1. 6WUDWpJLHGHVXUYHLOODQFHPpGLFDOHSRXUOHVSURIHVVLRQQHOVjULVTXHGH79
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

Tableau 1. &ODVVLÀFDWLRQ710GHVWXPHXUVGHODYHVVLH
Stade T Description Dénomination
pTa 7XPHXUSDSLOODLUHGHJUDGHYDULDEOHVDQVLQÀOWUDWLRQGHODODPLQDSURSULD TVNIM
pTis 7XPHXUSODQHGHKDXWJUDGHVDQVLQÀOWUDWLRQ²&,6
pT1 7XPHXUSDSLOODLUHGHJUDGHYDULDEOHDYHFLQÀOWUDWLRQGHODODPLQDSURSULDPDLVVDQVLQÀOWUDWLRQ
du muscle
S7 Tumeur envahissant la musculeuse TVIM
pT2a7XPHXUHQYDKLVVDQWODPXVFXOHXVHVXSHUÀFLHOOHPRLWLpLQWHUQH
pT2b7XPHXUHQYDKLVVDQWODPXVFXOHXVHSURIRQGHPRLWLpH[WHUQH
pT3 7XPHXUHQYDKLVVDQWOHWLVVXSpULYpVLFDO
pT3a$WWHLQWHPLFURVFRSLTXH
pT3b$WWHLQWHPDFURVFRSLTXHPDVVHH[WUDYpVLFDOH
pT4 7XPHXUHQYDKLVVDQWO·XQHRXO·DXWUHGHVVWUXFWXUHVVXLYDQWHVSURVWDWHYpVLFXOHV
VpPLQDOHVXWpUXVYDJLQSDURLSHOYLHQQHRXSDURLDEGRPLQDOH
T4a Prostate, vésicules séminales, vagin ou utérus
T4b3DURLSHOYLHQQHRXSDURLDEGRPLQDOH

N Ganglions lymphatiques régionaux

Nx5HQVHLJQHPHQWVLQVXIÀVDQWVSRXUFODVVHUO·DWWHLQWHGHVJDQJOLRQVO\PSKDWLTXHVUpJLRQDX[
N0 Pas d’atteinte des ganglions lymphatiques régionaux
N1 Atteinte d’un seul ganglion lymphatique pelvien (hypogastrique, obturateur, iliaque externe ou présacré)
N2 Atteinte de multiples ganglions lymphatiques pelviens (hypogastrique, obturateur, iliaque externe ou pré-sacré)
N3 Atteinte d’un (ou plusieurs) ganglion(s) lymphatique(s) iliaque(s) primitif(s)

M Métastases à distance
M0 Absence de métastase à distance
M1 Métastase(s) à distance

* yp: y : stade réévalué après un traitement néo-adjuvant (chimiothérapie ou radiothérapie)

pWDLWGHYHQXHLQGLVSHQVDEOHQRWDPPHQWFDUOHVWHUPHVGH • SUpVHQFHGHFHOOXOHVXURWKpOLDOHVDW\SLTXHV
F\WRORJLHSRVLWLYHRXQpJDWLYHVRQWLQVXIÀVDQWV/DWHUPLQRORJLH • SUpVHQFHGHFHOOXOHVXURWKpOLDOHVVXVSHFWHVGHFDUFLQRPH
VXLYDQWHGRLWrWUHHPSOR\pHFODVVLÀFDWLRQGH3DULV XURWKpOLDOGHKDXWJUDGH
• PDWpULHOVDWLVIDLVDQWRXQRQVDWLVIDLVDQWSRXUpYDOXDWLRQ • FDUFLQRPHXURWKpOLDOGHKDXWJUDGH
SUpFLVHUODFDXVH • QpRSODVLHXURWKpOLDOHGHEDVJUDGH
• F\WRORJLHQpJDWLYHQpJDWLYHSRXUOHFDUFLQRPHXURWKpOLDO • DXWUHVFDWpJRULHVFDQFHUVSULPLWLIVHWPpWDVWDWLTXHVHW
GHKDXWJUDGH DXWUHVOpVLRQV7DEOHDXGHUHFRPPDQGDWLRQ

Tableau de recommandation 3
5HFRPPDQGDWLRQVFRQGXLWHjWHQLUHQIRQFWLRQGHODF\WRORJLHXULQDLUH Niveau
5pVXOWDWGHODF\WRORJLH &RQGXLWHjWHQLU
0DWpULHOQRQVDWLVIDLVDQWSRXUpYDOXDWLRQ 5HIDLUHSUDWLTXHUXQHF\WRORJLHXULQDLUHGDQVGHVPHLOOHXUHV )DLEOH
SUpFLVHUODFDXVH conditions
&\WRORJLHQpJDWLYHQpJDWLYHSRXU 3DVGHPRGLÀFDWLRQGHODSULVHHQFKDUJH )DLEOH
le carcinome urothélial de haut grade)
3UpVHQFHGHFHOOXOHVXURWKpOLDOHVDW\SLTXHV
3UpVHQFHGHFHOOXOHVXURWKpOLDOHVVXVSHFWHV
de carcinome urothélial de haut grade
Carcinome urothélial de haut grade
1pRSODVLHXURWKpOLDOHGHEDVJUDGH
eOLPLQHUXQHFDXVHLQIHFWLRQSH[SRO\PDYLUXVLQÁDPPDWLRQ )DLEOH
HWUHIDLUHSUDWLTXHUXQHF\WRORJLHXULQDLUHGDQVPRLV
3RXUVXLWHGHVLQYHVWLJDWLRQVKDELWXHOOHVjODUHFKHUFKH )DLEOH
G·XQH79
S102 05RXSUrWHWDO

Marqueurs urinaires &HUWDLQVYDULDQWVGHFDUFLQRPHXURWKpOLDOPLFURSDSLOODLUH

$XFXQPDUTXHXUXULQDLUHQ·HVWDFWXHOOHPHQWUHFRPPDQGp
SRXU XQH XWLOLVDWLRQ GLDJQRVWLTXH RX GH VXUYHLOODQFH HQ
SUDWLTXHFOLQLTXH>@
SODVPRF\WRwGHVDUFRPDWRwGHRQWXQSURQRVWLFSOXVSpMRUDWLI
TXHOHFDUFLQRPHXURWKpOLDOSXU>@.
3RXU OHV FDUFLQRPHV XURWKpOLDX[ TXL Q·RQW SDV H[FOXVL-
vement une différentiation urothéliale, les variants doivent
rWUHUDSSRUWpVHQ
/DSUpVHQFHG·XQHLQYDVLRQO\PSKRYDVFXODLUHRXHPEROV
Variants histologiques O\PSKRYDVFXODLUHGDQVOHVpFKDQWLOORQVGHUpVHFWLRQWUDQV
XUpWUDOH GH YHVVLH 5789 D pWp DVVRFLpH j XQ SURQRVWLF
/D FODVVLÀFDWLRQ 206  GLVWLQJXH SOXVLHXUV W\SHV GH SpMRUDWLI>@HWGRLWrWUHPHQWLRQQpH
WXPHXU>@
• FDUFLQRPHXURWKpOLDOSOXVGHGHVFDV
• FDUFLQRPH XURWKpOLDO DYHF GLIIpUHQFLDWLRQ VTXDPHXVH &ODVVLÀFDWLRQPROpFXODLUH
HWRXJODQGXODLUHRXWURSKREODVWLTXHSDUWLHOOH
• FDUFLQRPHXURWKpOLDOPLFURSDSLOODLUH /HVPDUTXHXUVPROpFXODLUHVHWOHXUU{OHSURQRVWLTXHRQWpWp
• FDUFLQRPHXURWKpOLDOHQQLGV\FRPSULVjJUDQGHVFHOOXOHV pWXGLpV >@ &HV PpWKRGHV HQ SDUWLFXOLHU OHV DSSURFKHV
HWFDUFLQRPHXURWKpOLDOPLFURF\VWLTXH FRPSOH[HV WHOOHV TXH OD VWUDWLÀFDWLRQ GHV SDWLHQWV EDVpH
• FDUFLQRPHSODVPRF\WRwGHjFHOOXOHJpDQWHjFHOOXOHHQ VXU OD FODVVLÀFDWLRQ PROpFXODLUH VRQW SURPHWWHXVHV PDLV
EDJXHjFKDWRQ QHVRQWSDVHQFRUHDGDSWpHVjXQHDSSOLFDWLRQGHURXWLQH
• FDUFLQRPHGHW\SHO\PSKRpSLWKpOLRPH
• FDUFLQRPHjSHWLWHVFHOOXOHV
• FDUFLQRPHXURWKpOLDOVDUFRPDWRwGH Compte-rendu anatomopathologique
,OH[LVWHG·DXWUHVYDULDQWHVH[WUrPHPHQWUDUHVTXLQH
VRQWSDVGpWDLOOpHV 57897DEOHDX

7DEOHDXeOpPHQWVjPHQWLRQQHUGDQVOHFRPSWHUHQGXG·XQHDQDO\VHGH5789
0DWpULHODQDO\Vp 1RPEUHGHFRSHDX[SRLGVWDLOOH
GHFRSHDX[WXPRUDX[
&\WRORJLH *UDGH206HW
Histologie /DPLQDSURSULDYXLQÀOWUpHDXWUHVSH[JUDQXORPHVpSLWKpOLRwGHVHWJLJDQWRFHOOXODLUHV
0XVFXODLUHPXTXHXVHYXLQÀOWUpHDXWUHV
0XVFXOHXVHYXLQÀOWUpHDXWUHV
7\SHWXPHXUYDULDQWKLVWRORJLTXH
(PEROHO\PSKRYDVFXODLUH
$XWUHVOpVLRQVOpVLRQSODQHV
,PPXQRKLVWRFKLPLH En fonction
Diagnostic/ S710S7DS7RXS7•LOQ·HVWSDVSRVVLEOHGHSUpFLVHUS7DS7ERXS7jSDUWLU
Conclusion GHFRSHDX[GH5789

TVNIM HQGRVFRSLTXHHVWRSWLRQQHOOH/·XWLOLVDWLRQGHODÁXRUHVFHQFH
YpVLFDOHHQOXPLqUHEOHXHSDUKH[DPLQROpYXOLQDWHHexvix)
RXGHO·LPDJHULHHQEDQGHVVSHFWUDOHVpWURLWHVNarrow-Band
Bilan diagnostic initial ImagingORUVGHODF\VWRVFRSLHGLDJQRVWLTXHDPpOLRUHVLJQLÀ-
(QGRVFRSLHÀEURVFRSLHYpVLFDOH
/DF\VWRVFRSLHGLDJQRVWLTXHHVWKDELWXHOOHPHQWUpDOLVpHSDU
ÀEURVFRSLHVRXVDQHVWKpVLHORFDOH,OHVWSRVVLEOHGHGpSLVWHU
FDWLYHPHQWODGpWHFWLRQGHOpVLRQVWXPRUDOHV7D7HWSOXV
SDUWLFXOLqUHPHQWGX&,6>@'DQVOHFDVGHODÁXRUHVFHQFH
OHJDLQHVWFHSHQGDQWPRLQGUHORUVG·XQHÀEURVFRSLHTX·DYHF
O·HPSORLG·XQHQGRVFRSHULJLGH/·LQWpUrWGHVRQXWLOLVDWLRQDX
FRXUVGHO·HQGRVFRSLHGLDJQRVWLTXHLQLWLDOHQ·HVWSDVGpPRQWUp
GDQVODPHVXUHRODUpVHFWLRQHQGRVFRSLTXHGHWXPHXUGH
HWWUDLWHURXGHQHSDVGpSLVWHUOHVEDFWpULXULHVDYDQWXQH
F\VWRVFRSLHGLDJQRVWLTXH>@&HWWHHQGRVFRSLHHVWLQGLTXpH
HQFDVGHVXVSLFLRQGHWXPHXUYpVLFDOHORUVTXHO·pFKRJUDSKLH
HVWQpJDWLYH6DVHQVLELOLWpHVWDORUVGHHWVDVSpFLÀFLWp
GH>@/DÀEURVFRSLHSHUPHWGHSUpFLVHUOHQRPEUHOD
WDLOOHODWRSRJUDSKLHO·DVSHFWGHODWXPHXUHWGHODPXTXHXVH
YpVLFDOH/RUVTXHOHSDWLHQWHVWDGUHVVpDYHFXQHpFKRJUDSKLH
GpFULYDQWXQH79ODF\VWRVFRSLHGLDJQRVWLTXHDYDQWODUpVHFWLRQ
YHVVLH5789VHUDHOOHPrPHIDLWHHQÁXRUHVFHQFH
Indication des examens d’imagerie
Échographie de l’appareil urinaire
/·HIÀFDFLWpGHO·pFKRJUDSKLHSRXUOHGLDJQRVWLFGHWXPHXUXUR-
WKpOLDOHYpVLFDOHGDQVOHVELODQVG·KpPDWXULHHVWPRGpUpHDYHF
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

XQHVHQVLELOLWpG·HQYLURQ>@HWGpSHQGGXPRUSKRW\SH 5HFRPPDQGDWLRQVELODQGLDJQRVWLFLQLWLDO Niveau

GXSDWLHQWGHO·pWDWGHODUpSOpWLRQYpVLFDOHHWGHO·H[SpULHQFH
GHO·RSpUDWHXU /DÀEURVFRSLHGRLWSUpFLVHUOHQRPEUH Fort
%LHQ TXH O·XURVFDQQHU XURWRPRGHQVLWRPpWULH >7'0@
GRLYHrWUHSULYLOpJLpXQHpFKRJUDSKLHGHO·DSSDUHLOXULQDLUH
HVWSDUIRLVUpDOLVpHGDQVOHFDGUHG·XQHKpPDWXULHHQUDLVRQGH
VRQLQQRFXLWpHQWHUPHVGHUD\RQQHPHQWVLRQLVDQWVHWG·LQMHF-
WLRQGHSURGXLWGHFRQWUDVWH'DQVFHFDVVLO·pFKRJUDSKLH
QHUHWURXYHSDVG·H[SOLFDWLRQjO·KpPDWXULHXQFRPSOpPHQW
GHELODQSDUXURVFDQQHUF\VWRVFRSLHGHYUDrWUHUpDOLVp
Uro-TDM
ODWDLOOHODWRSRJUDSKLHO·DVSHFWGHODWXPHXU
HWGHODPXTXHXVHYpVLFDOH
5pDOLVHUXQHXUR7'0RXXQHXUR,50ORUVTXH )DLEOH
ODF\VWRVFRSLHUpYqOHGHVWXPHXUVPXOWLSOHV
HWRXWULJRQDOHVRXORUVTXHO·H[DPHQFOLQLTXH
VXVSHFWHXQH79,0
)DLUHXQHF\WRORJLHXULQDLUHV\VWpPDWLTXH )DLEOH
SRXUGpWHFWHUGHVOpVLRQVGHKDXWJUDGH
/·XURVFDQQHUXUR7'0HVWLQGLTXpGDQVOHVELODQVG·KpPD
WXULHHWFHX[GHWXPHXUXURWKpOLDOHDYpUpHSUpVHQWDQWXQ 3URSRVHUXQHXUR7'0RXXQHXUR,50 )DLEOH
ULVTXHG·DWWHLQWHGHVYRLHVH[FUpWULFHVVXSpULHXUHV ORFD- HQSUHPLqUHLQWHQWLRQGDQVOHELODQ
OLVDWLRQ WULJRQDOH >@ F\WRORJLH GH KDXW JUDGH DWWHLQWH G·XQHKpPDWXULHPDFURVFRSLTXH
vésicale multifocale.
,OpWXGLHO·HQVHPEOHGHO·DSSDUHLOXULQDLUHSDUSOXVLHXUV
DFTXLVLWLRQV UpDOLVpHV DYDQW HW DSUqV LQMHFWLRQ GH SURGXLW
GH FRQWUDVWH HW FRPSRUWH REOLJDWRLUHPHQW XQH pWXGH j OD RTUV
SKDVHH[FUpWRLUHGHO·pOLPLQDWLRQGXSURGXLWGHFRQWUDVWH
/·XWLOLVDWLRQ G·XQ SURWRFROH DYHF LQMHFWLRQ GH IXURVpPLGH
/DVLOL[
HWGRXEOHLQMHFWLRQGHSURGXLWGHFRQWUDVWH6SOLW Principes techniques et critères qualitatifs de la RTUV
EROXVHVWUHFRPPDQGpHSRXUDPpOLRUHUOHVSHUIRUPDQFHVGH
O·H[DPHQHWGLPLQXHUO·LUUDGLDWLRQGHVSDWLHQWV>@ /HGLDJQRVWLFGHOD79GpSHQGSULQFLSDOHPHQWGHO·H[DPHQ
/HV SHUIRUPDQFHV GH O·XUR7'0 SRXU OD GpWHFWLRQ GHV KLVWRORJLTXHGHODWRWDOLWpGHODOpVLRQUpVpTXpH,OHVWUHFRP-
lésions urothéliales vésicales varient selon les études avec PDQGpGHUpDOLVHUDXSDUDYDQWXQH[DPHQF\WREDFWpULRORJLTXH
GHVVHQVLELOLWpVGHO·RUGUHGHHWVSpFLÀFLWpVGHO·RUGUH GHVXULQHV(&%8DÀQG·pOLPLQHUXQHLQIHFWLRQXULQDLUH>@
GH>@ 8QH FDUWRJUDSKLH GHV OpVLRQV GRLW SUpFLVHU OH QRPEUH GH
WXPHXUVOHXUWRSRJUDSKLHSDUUDSSRUWjO·XUqWUHSURVWDWLTXH
Uro-IRM HWDX[RULÀFHVXUpWpUDX[OHXUWDLOOHHWOHXUDVSHFWSpGLFXOpRX
/·LPDJHULH SDU UpVRQQDQFH PDJQpWLTXH XULQDLUH 8UR,50 VHVVLOH/DUpVHFWLRQGRLWrWUHFRPSOqWHHWSURIRQGHSUpVHQFH
SHUPHWpJDOHPHQWG·pWXGLHUO·HQVHPEOHGHO·DSSDUHLOH[FUp-
WRLUH XULQDLUH HW FRQVWLWXH XQH DOWHUQDWLYH LQWpUHVVDQWH j
O·XUR7'0QRWDPPHQWVLFHOXLFLHVWFRQWUHLQGLTXp>@
/·LQWpUrWSDUWLFXOLHUGHO·XUR,50UpVLGHGDQVODFRQWUL
EXWLRQGHVVpTXHQFHVG·LPDJHULHIRQFWLRQQHOOHQRWDPPHQWGH
GHIDLVFHDX[GXGpWUXVRU/·DEVHQFHGHPXVFOHVXUOHVFRSHDX[
GHUpVHFWLRQHVWDVVRFLpHjXQULVTXHVLJQLÀFDWLYHPHQWSOXV
pOHYpGHPDODGLHUpVLGXHOOHHWGHUpFLGLYHSUpFRFHHQFDVGH
WXPHXUS7HWRXGHKDXWJUDGH>@/D5789GRLWrWUHIDLWHHQ
PRQREORFGDQVODPHVXUHGXSRVVLEOHHPSRUWDQWGXGpWUXVRU
diffusion (Diffusion Weighted Images>':,@TXLDPpOLRUHQW
GH IDoRQ VLJQLÀFDWLYH OHV SHUIRUPDQFHV GH O·H[DPHQ /HV
VHQVLELOLWpHWVSpFLÀFLWpGHODVpTXHQFHGHGLIIXVLRQSRXUOD
GpWHFWLRQGHVOpVLRQVYpVLFDOHVVRQWUHVSHFWLYHPHQWGH
HW>@
­O·pWDJHYpVLFDOO·,50VHPEOHSHUPHWWUHpJDOHPHQWG·pYD-
OXHUOHULVTXHG·LQÀOWUDWLRQGHODFRXFKHPXVFXODLUH>@
Des recommandations concernant la réalisation, l’inter-
SUpWDWLRQ HW OD VWDQGDUGLVDWLRQ GHV FRPSWHVUHQGXV G·,50
VRXVMDFHQWSRXUSHUPHWWUHXQHPHLOOHXUHDQDO\VHWXPRUDOH
HWSRWHQWLHOOHPHQWDPpOLRUHUODTXDOLWpGHODUpVHFWLRQDYHF
OD UpGXFWLRQ GX ULVTXH GH UpFLGLYH WXPRUDOH >@ /D
WHFKQLTXHGHUpVHFWLRQGHUpIpUHQFHHVWO·pOHFWURFRDJXODWLRQ
PRQRSRODLUH/DUpVHFWLRQSDUpOHFWURFRDJXODWLRQELSRODLUH
HW O·pQXFOpDWLRQ DX ODVHU VRQW GHV DOWHUQDWLYHV WHFKQLTXHV
SURSRVDEOHV>@/HVELRSVLHVUDQGRPLVpHVGHODPXTXHXVH
RSWLTXHPHQWVDLQHQ·RQWSDVG·LQWpUrWGpPRQWUpHQURXWLQH
FDUODSUREDELOLWpGHGpWHFWHUGHVOpVLRQVGH&,6DVVRFLpHVW
YpVLFDOH RQW pWp SXEOLpHV HQ  VRXV OD GpQRPLQDWLRQ WUqVIDLEOH(OOHVVRQWHQUHYDQFKHLQGLTXpHVHQFDV
Vesical Imaging-Reporting and Data System9,5$'6>@ GHF\WRORJLHXULQDLUHSRVLWLYHVDQVOpVLRQYLVLEOHRXHQFDVGH
4XDQGOHVGpODLVG·REWHQWLRQGHO·H[DPHQQHUHWDUGHQWSDV ]RQHVRSWLTXHPHQWDQRUPDOHVpYRTXDQWXQ&,6 >@$SUqV
ODSULVHHQFKDUJHGXSDWLHQWLOHVWVRXKDLWDEOHGHUpDOLVHU UpVHFWLRQODPpWDDQDO\VHGHpWXGHVGHSKDVH,,,FRPSDUDQW
FHWWH,50YpVLFDOHPXOWLSDUDPpWULTXHDYDQWOHJHVWHGHUpVHF- XQH LUULJDWLRQ FRQWLQXH GH VpUXP SK\VLRORJLTXH MXVTX·j OD
WLRQSRXURSWLPLVHUO·pYDOXDWLRQGHODPDODGLH7DEOHDXGH 18eKHXUHjXQHLQVWLOODWLRQSRVWRSpUDWRLUHSUpFRFH,323GH
UHFRPPDQGDWLRQ>@ PLWRP\FLQH&00&Q·DSDVPLVHQpYLGHQFHGHGLIIpUHQFHGH
O·HIIHWSURSK\ODFWLTXHYLVjYLVGHODUpFLGLYHGHV791,0>@
Tableau de recommandation 4

5HFRPPDQGDWLRQVELODQGLDJQRVWLFLQLWLDO Niveau Utilisation des techniques d’optimisation visuelle

5pDOLVHUXQHÀEURVFRSLHYpVLFDOHHQFDV Fort /XPLQRÁXRUHVFHQFHYpVLFDOH

GHVXVSLFLRQGHFDQFHUGHODYHVVLHQRQpWDEOLH /RUVTX·HOOHHVWGLVSRQLEOHODOXPLQRÁXRUHVFHQFHYpVLFDOH
SDUXQH[DPHQG·LPDJHULH SDUKH[DPLQROpYXOLQDWHHVWUHFRPPDQGpHORUVGHODSUH-
PLqUHUpVHFWLRQRXWLOGLDJQRVWLTXHGH791,0HWSRXUOD
6 05RXSUrWHWDO

UHFKHUFKHGH&,6>@(OOHDGpPRQWUpXQHDXJPHQWDWLRQ Quality Adjusted Life Year4$/<LQGLFDWHXUpFRQRPLTXH

VLJQLÀFDWLYH GX WDX[ GH GpWHFWLRQ GHV WXPHXUV DX SUL[ YLVDQW j HVWLPHU OD YDOHXU GH OD YLH j O·XWLOLVDWLRQ GH
G·XQFHUWDLQWDX[GHIDX[SRVLWLIVHWXQDOORQJHPHQWGH OD OXPLQRÁXRUHVFHQFH YpVLFDOH SDU KH[DPLQRO pYXOLQDWH
O·LQWHUYDOOHOLEUHVDQVUpFLGLYH8QHpWXGHGHFR€WHIÀFDFLWp GqV OD SUHPLqUH 5789 GH WRXWH 791,0 7DEOHDX GH
DSSOLTXpHDXV\VWqPHIUDQoDLVDPLVHQpYLGHQFHXQJDLQ UHFRPPDQGDWLRQ>@

Tableau de recommandation 5

5HFRPPDQGDWLRQVXWLOLVDWLRQGHODOXPLQRÁXRUHVFHQFHYpVLFDOH Niveau

Première résection 7RXWHVOHVWXPHXUVVDXIHQFDVGHWXPHXUXQLIRFDOHFP Fort

GHSULPRGLDJQRVWLF DYHFF\WRORJLHXULQDLUHQRUPDOH

Résection de second look 8QLTXHPHQWORUVTXHODF\WRORJLHXULQDLUHHVWVXVSHFWHGHSUpVHQFH Fort

G·XQHWXPHXUGHKDXWJUDGHHWODF\VWRVFRSLHHQOXPLqUHEODQFKH
QHUpYqOHSDVGHOpVLRQSDSLOODLUHUHFKHUFKHGH&,6

5pFLGLYHG·XQH791,0LQLWLDOHPHQW Toutes situations Fort

FODVVpHFRPPHGHIDLEOHULVTXH

5pFLGLYHG·XQH791,0LQLWLDOHPHQW 8QLTXHPHQWSRXUOHVUpFLGLYHVGHWDLOOHFPHWSUpVXPpHVGHVWDGH Fort

FODVVpHFRPPHGHULVTXH 7DHWGH%DV*UDGH*F\WRORJLHXULQDLUHQpJDWLYH
intermédiaire

5pFLGLYHG·XQH791,0LQLWLDOHPHQW 8QLTXHPHQWORUVTXHODF\WRORJLHXULQDLUHHVWVXVSHFWHGHSUpVHQFH Fort

FODVVpHFRPPHGHKDXWULVTXH G·XQHWXPHXUGHKDXWJUDGHHWODF\VWRVFRSLHHQOXPLqUHEODQFKH
QHUpYqOHSDVGHOpVLRQSDSLOODLUHUHFKHUFKHGH&,6
Narrow-Band Imaging (NBI)
/RUVTX·HOOH HVW GLVSRQLEOH O·LPDJHULH HQ 1%, HVW UHFRP-
PDQGpHORUVGHOD5789/DPpWDDQDO\VHGHVUpVXOWDWVGH
 pWXGHV VXU O·XWLOLVDWLRQ GH OD PDJQLÀFDWLRQ RSWLTXH SDU
1%,ORUVGHOD5789DPRQWUpXQEpQpÀFHSRXUUpGXLUHOH
ULVTXH GH UpFLGLYH WXPRUDOH j PRLV  HW  DQV >@ /D
TXDOLWpGHVGRQQpHVLVVXHVGHFHVpWXGHVQHSHUPHWWDLWSDV
GH GpÀQLU TXHOV SDWLHQWV EpQpÀFLHQW GH OD UpVHFWLRQ DYHF
1%,HWODPpWKRGRORJLHGHVHVVDLVUDQGRPLVpVLQFOXVGDQV
ODPpWDDQDO\VHLQGXLWGHVELDLVHQIDYHXUG·XQHPHLOOHXUH
GpWHFWLRQWXPRUDOHGDQVOHVEUDVWUDLWpVDYHF1%,

UpFLGLYH XOWpULHXUH DSUqV OD UpVHFWLRQ GH 791,0 GRQW OH
VFRUH(257&HVWVRLW>@
• DXPD[LPXPWXPHXUVFPHWVXSSRVpPHQWS7D*”
RX7*%*
• XQHWXPHXUXQLTXH•FPHWVXSSRVpPHQWS7D*”RX
7*%*
/DF\WRORJLHXULQDLUHSHUPHWG·H[FOXUHODSUpVHQFHG·XQH
WXPHXUGHKDXWJUDGH$LQVLXQH,323GH00&HVWUHFRP-
PDQGpHDSUqVODSUHPLqUHUpVHFWLRQGHSULPRGLDJQRVWLFGH
791,0
Indication de la RTUV de réévaluation
Indication de l’instillation postopératoire (dite « de second look ª
SUpFRFHGHFKLPLRWKpUDSLH,323
$SUqV OD 5789 O·,323 GH 00& RX G·pSLUXELFLQH HVW XQH
RSWLRQ WKpUDSHXWLTXH HQ UHVSHFWDQW V\VWpPDWLTXHPHQW
OHV FRQWUHLQGLFDWLRQV KpPDWXULH HW SHUIRUDWLRQ YpVL-
8QH5789GHUppYDOXDWLRQV\VWpPDWLTXHGDQVXQGpODLGH
jVHPDLQHVDSUqVXQH5789HVWLPpHFRPSOqWHHVWUHFRP-
PDQGpHVHXOHPHQWHQFDVGHWXPHXUGHVWDGHS7
8QH5789FRPSOpPHQWDLUHGRLWrWUHUpDOLVpHHQFDV
FDOH >@ &RPSWH WHQX GH FRPSOLFDWLRQV JUDYHV PDLV • G·DEVHQFHGHPXVFOHLGHQWLÀpVXUODSLqFHGHUpVHFWLRQ
UDUHV QpFURVH YpVLFDOH LO FRQYLHQW GH WRXMRXUV ELHQ LQLWLDOHVDXIHQFDVGHS7DGHEDVJUDGH
pYDOXHUODEDODQFHEpQpÀFHULVTXHSRXUOHSDWLHQW/·,323 • ou de tumeur volumineuse et/ou multifocale (résection
GRLWrWUHUpDOLVpHLGpDOHPHQWGDQVOHVSUHPLqUHVKHXUHV LQFRPSOqWH
RXDXSOXVWDUGGDQVOHVKHXUHVTXLVXLYHQWOD5789 /·REMHFWLIGHFHWWHUppYDOXDWLRQHQGRVFRSLTXHHWKLVWR-
8QH DOFDOLQLVDWLRQ XULQDLUH HVW QpFHVVDLUH SRXU OD 00& ORJLTXH HVW GH SHUPHWWUH GH UpGXLUH OH ULVTXH GH PDODGLH
(OOH QH O·HVW SDV DYHF O·pSLUXELFLQH /·,323 GLPLQXHUDLW UpVLGXHOOH XQH VWDGLÀFDWLRQ SOXV SUpFLVH GH OD WXPHXU
DLQVLOHULVTXHGHUpFLGLYHWXPRUDOHjHWDQVGHHW G·DPpOLRUHUODVpOHFWLRQHWGRQFODUpSRQVHGHVSDWLHQWV
 UHVSHFWLYHPHQW >@ /D PpWDDQDO\VH GHV GRQQpHV DXWUDLWHPHQWHQGRYpVLFDOGHUpGXLUHODIUpTXHQFHGHVUpFL-
LQGLYLGXHOOHVGHSDWLHQWVLQFOXVGDQVGHVpWXGHVVXU GLYHVHWGHUHWDUGHUODSURJUHVVLRQGHODWXPHXU7DEOHDXGH
O·XWLOLVDWLRQG·,323GH00&JHPFLWDELQHRXSLUDUXELFLQH UHFRPPDQGDWLRQ  >@'HV DUJXPHQWVFRPSOpPHQWDLUHV
DPRQWUpXQEpQpÀFHHQUpGXFWLRQGHGXULVTXHGH VRQWSURSRVpVGDQVO·annexe 1.
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

Tableau de recommandation 6
5HFRPPDQGDWLRQV5789GHSULPRGLDJQRVWLF Niveau
/DUpVHFWLRQGRLWrWUHFRPSOqWHHWSURIRQGHSUpVHQFHGHIDLVFHDX[GXGpWUXVRU Fort
/D5789GRLWrWUHIDLWHHQPRQREORFGDQVODPHVXUHGXSRVVLEOH )DLEOH
5pDOLVHUGHVELRSVLHVUDQGRPLVpHVGHODPXTXHXVHRSWLTXHPHQWVDLQHHQFDVGHF\WRORJLHXULQDLUHSRVLWLYH Fort
VDQVOpVLRQYLVLEOHRXHQFDVGH]RQHVRSWLTXHPHQWDQRUPDOHVpYRTXDQWXQ&,6
/RUVTX·HOOHHVWGLVSRQLEOHODOXPLQRÁXRUHVFHQFHYpVLFDOHSDUKH[DPLQROpYXOLQDWHHVWUHFRPPDQGpH Fort
ORUVGHODSUHPLqUHUpVHFWLRQRXWLOGLDJQRVWLTXHGH791,0HWSRXUODUHFKHUFKHGH&,6
/RUVTX·HOOHHVWGLVSRQLEOHO·LPDJHULHHQ1%,HVWUHFRPPDQGpHORUVGHOD5789 Fort
)DLUHXQH,323LGpDOHPHQWGDQVOHVKHXUHVHWDXPD[LPXPGDQVOHVKHXUHVTXLVXLYHQWODSUHPLqUH Fort
5789HWHQO·DEVHQFHG·KpPDWXULHHWRXGHSHUIRUDWLRQYpVLFDOHSRXU
²DXPD[LPXPWXPHXUVFPHWVXSSRVpPHQWS7D*”RX7*F\WRORJLHQpJDWLYH
²XQHWXPHXUXQLTXH•FPHWVXSSRVpPHQWS7D*”RX7*F\WRORJLHQpJDWLYH
/RUVTX·XQH,323Q·HVWSDVUHFRPPDQGpHPHWWUHHQSODFHXQHLUULJDWLRQFRQWLQXHGHVpUXPSK\VLRORJLTXH )DLEOH
DSUqV5789
)DLUHXQHDQDO\VHGHO·HQVHPEOHGHVSUpOqYHPHQWVGHOD5789SRXUOHGLDJQRVWLFGH79VWDGHJUDGH Fort
et histologie.
8QH5789GH second lookGRLWrWUHUpDOLVpHDSUqVXQH5789HVWLPpHFRPSOqWHVHXOHPHQWHQFDVGHWXPHXU Fort
GHVWDGHS7

&ODVVLÀFDWLRQSURQRVWLTXH
/H WUDLWHPHQW GHV 791,0 GpSHQG GX ULVTXH GH UpFLGLYH
GH SURJUHVVLRQ HW G·pFKHF GX WUDLWHPHQW GH OD WXPHXU
DSUqVUpVHFWLRQFRPSOqWHLQLWLDOHHQXQRXSOXVLHXUVWHPSV
GHVWDEOHVGHO·(257&>@RXGX&8(72>@PDLVDXFXQH
Q·HVWXQDQLPHPHQWDFFHSWpHHWXWLOLVpHSDUODFRPPXQDXWp
XURORJLTXHHQUDLVRQGHODVXUHVWLPDWLRQGXULVTXHGHUpFLGLYH
HW GH SURJUHVVLRQ HW GH OHXU XWLOLVDWLRQ SHX DGDSWpH j OD
SUDWLTXHFOLQLTXH8QHVWUDWLÀFDWLRQDFWXDOLVpHDpWppWDEOLH
()LJXUH/·pYDOXDWLRQGXULVTXHSHXWrWUHUpDOLVpHjO·DLGH GDQVOH7DEOHDX

Tableau 3. 6WUDWLÀFDWLRQHWWUDLWHPHQWGHV791,0
Risque Critères Traitement
Faible 7XPHXUXURWKpOLDOHS7DGHEDVJUDGHGHPRLQVGHFP ,323
unifocale, sans antécédent de tumeur de vessie,
LQFOXDQWOHVWXPHXUVjIDLEOHSRWHQWLHOGHPDOLJQLWp
Intermédiaire 7XPHXUXURWKpOLDOHS7DGHEDVJUDGHTXLQHSUpVHQWH ,QVWLOODWLRQVHQGRYpVLFDOHV
DXFXQGHVFULWqUHVGHKDXWRXWUqVKDXWULVTXH ²00&RXpSLUXELFLQHRX
²%&*WKpUDSLHDYHFHQWUHWLHQG·XQDQ
Haut risque 7XPHXUXURWKpOLDOHSUpVHQWDQWDXPRLQVXQGHVFULWqUHV ,QVWLOODWLRQVHQGRYpVLFDOHV
suivants : ²%&*WKpUDSLHDYHFHQWUHWLHQGHDQV
²S7 /DWXPHXUGRLWDYRLUpWpUHUpVpTXpH
²KDXWJUDGH* DXPRLQVXQHIRLVDYHFSUpVHQFH
²SUpVHQFHGH&,6 de détrusor
Très haut risque – pT1G3 + CIS* – Proposer une cystectomie avec curage
– pT1G3 multifocal* – Instillations endovésicales
– pT1G3 > 3 cm* BCG-thérapie avec entretien de 3 ans
– pT1G3 + envahissement lympho-vasculaire* La tumeur doit avoir été reréséquée
– pT1G3 de l’urètre prostatique au moins une fois avec présence
– pT1 de formes anatomopathologiques agressives de détrusor
&HVWXPHXUVSHXYHQWrWUHUHFODVVpHVjKDXWULVTXHVLODGHUQLqUHUHUpVHFWLRQHVWS7HWTXHOHPXVFOHHVWYX/DF\VWHFWRPLHHVW
alors optionnelle.
S106 05RXSUrWHWDO

TVNIM Faible Risque

Cystoscopie
au 3e mois
Premier diagnostic, Instillation Sans récidive
ET pTa post-opératoire Suivi
ET Bas Grade (G1) précoce ET < 5 tumeurs ET ≤ 5 tumeurs
ET < 3 cm
Récidive ET ≤ 5 mm Récidive > 1 an ≤ 10 mm
ET sans Carcinome in situ
ET
ET cytologie Nale ET cytologie Nale

Récidive Récidive Fulguration Surveillance active

RTUV
Récidive Récidive

Sans récidive ±
Chimiothérapie

Cystoscopie
Chimiothérapie Suivi
post-opératoire d’entretien 1 an

au 3e mois
TVNIM Risque Intermédiare
Toute tumeur non définie par Instillation
post-opératoire
les catégories adjacentes. précoce
(exemple : pTa Bas Grade multifocal) Sans récidive
BCG entretien
BCG x6 1 an
Suivi
RTUV

TVNIM Haut Risque

pT≤1G1 Sans récidive
pT1
ET/OU Haut grade (G3)
BCG x6 BCG entretien 3 ans Suivi
(entre 2 et 6 semaines après la 1re RTUV ; optionnelle si pTa)

ET/OU Carcinome in situ (CIS)

± guidées par Acide Hexaminolevulinique

Cystoscopie
+ Biopsies
+ Biopsies de vessie si CIS
TVNIM Très Haut Risque Sans récidive
BCG entretien
Suivi
BCG x6 3 ans
Cystoscopie

pT1G3 + CIS C/S isolé

Seconde RTUV

ou pT1G3 multifocal
Sans récidive
ou pT1G3 > 3 cm
ou pT1G3 + ELV Récidive

Cystoscopie
ou pT1G3 prostatique
ou pT1 de formes agressives TVNIM BCG x6
Risque Intermédiaire
Cystectomie Totale
RTUV

Récidive
pT≥1G2 TVNIM / TVIM
Cystectomie Totale Haut Risque Récidive

TVIM TVIM Cystectomie Totale

)LJXUH$OJRULWKPHGHSULVHHQFKDUJHGHV791,0

Tumeurs de faible risque Tumeurs de haut risque

(OOHV FRUUHVSRQGHQW DX[ WXPHXUV XURWKpOLDOHV S7D GH EDV (OOHVRQWDXPRLQVXQGHVIDFWHXUVGHULVTXHVXLYDQWVWDGH

grade, unifocales et de moins de 3 cm sans antécédent S7JUDGHpOHYpSUpVHQFHGH&,6&HVWXPHXUVRQWXQULVTXH
GHWXPHXUGHYHVVLH(OOHVRQWXQULVTXHGHUpFLGLYHHWGH GH UpFLGLYH HW GH SURJUHVVLRQ pOHYp /HXU WUDLWHPHQW IDLW
SURJUHVVLRQTXLHVWIDLEOH2XWUHXQH,323HOOHQHQpFHVVLWH DSSHODX[LQVWLOODWLRQVHQGRYpVLFDOHVSDU%&*WKpUDSLHDYHF
DXFXQWUDLWHPHQWFRPSOpPHQWDLUH>@ XQHQWUHWLHQGHDQV>@

Tumeurs de risque intermédiaire Tumeurs de très haut risque

(OOHVFRUUHVSRQGHQWjWRXWHVOHVDXWUHVWXPHXUVXURWKpOLDOHV (OOHVRQWXQULVTXHGHSURJUHVVLRQpOHYpGHO·RUGUHGH

S7D GH EDV JUDGH TXL QH SUpVHQWHQW DXFXQ GHV FULWqUHV HW SUpFRFH VRLW SDUFH TXH OD SUREDELOLWp G·pUDGLFDWLRQ
GH ULVTXH pOHYp RX WUqV pOHYp &HV WXPHXUV RQW XQ ULVTXH FRPSOqWH DYDQW WUDLWHPHQW HVW IDLEOH VRLW SDUFH TX·HOOHV
GHSURJUHVVLRQIDLEOHPDLVXQULVTXHGHUpFLGLYHpOHYp/HXU VRQWWUqVDJUHVVLYHVTX·HOOHVSUpVHQWHQWXQULVTXHG·pFKHF
WUDLWHPHQW IDLW DSSHO DX[ LQVWLOODWLRQV HQGRYpVLFDOHV SDU GX WUDLWHPHQW HQGRYpVLFDO pOHYp RX TX·LO H[LVWH XQ ULVTXH
FKLPLRWKpUDSLH>@RXjOD%&*WKpUDSLHDYHFXQHQWUHWLHQ G·HQYDKLVVHPHQWJDQJOLRQQDLUHGqVOHVWDGHS7>@
GH  DQ SRXU GLPLQXHU OH ULVTXH GH UpFLGLYH>@ /H %&* ,OV·DJLWGHVWXPHXUVFRPELQDQWO·HQVHPEOHGHVIDFWHXUV
HVWSOXVHIÀFDFHVXUOHULVTXHGHUpFLGLYHPDLVVRQSURÀO GHULVTXHS7GHKDXWJUDGHDYHF&,6GHVWXPHXUVDYHF
GH WROpUDQFH pWDQW PRLQV ERQ HW OH ULVTXH GH SURJUHVVLRQ HQYDKLVVHPHQW O\PSKRYDVFXODLUH HW GHV WXPHXUV QRQ XUR-
pWDQWIDLEOHRQSURSRVHKDELWXHOOHPHQWOD00&HQSUHPLqUH WKpOLDOHV RX SUpVHQWDQW GHV IRUPHV DQDWRPRSDWKRORJLTXHV
LQWHQWLRQHWOH%&*HQFDVG·pFKHF>@ DJUHVVLYHV6RQWpJDOHPHQWFRQVLGpUpHVjWUqVKDXWULVTXHOHV
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

WXPHXUVGHKDXWULVTXHQRQUHUpVpTXpHVRXSHUVLVWDQWHVDSUqV $160G·XWLOLVHUO·pSLUXELFLQHFRPPHDJHQWGHFKLPLRWKpUDSLH

OHWUDLWHPHQWGHSUHPLqUHOLJQHLQGXFWLRQSDU%&*/D%&* DOWHUQDWLI/·pSLUXELFLQHDGpPRQWUpVRQHIÀFDFLWpHWHVWXWLOL-
WKpUDSLHHWODF\VWHFWRPLHGHSUHPLqUHLQWHQWLRQSHXYHQW VpHGDQVGHQRPEUHX[SD\VGDQVOHVLQGLFDWLRQVpTXLYDOHQWHV
rWUH SURSRVpHV SRXU OHV WUDLWHU DSUqV DYRLU GLVFXWp GH OD j FHOOHV GH OD 00& >@ 3RXU O·pSLUXELFLQH OH WUDLWHPHQW
PRUELGLWpGHO·LQWHUYHQWLRQDYHFOHSDWLHQW>@7DEOHDXGH FODVVLTXHHVWGHKXLWLQVWLOODWLRQVKHEGRPDGDLUHVGHPJ
recommandation 7). LQVWLOODWLRQGDQVjPOGHVROXWLRQVDOLQHjPJPO
Tableau de recommandation 7
5HFRPPDQGDWLRQVFODVVLÀFDWLRQ
pronostique
/HV791,0GRLYHQWrWUHFODVVpHVVHORQ
OHXUULVTXHGHUpFLGLYHHWGHSURJUHVVLRQ
/HV791,0jIDLEOHULVTXHMXVWLÀHQWG·XQH,323
(QFDVGHWR[LFLWpORFDOHF\VWLWHFKLPLTXHXQHUpGXFWLRQGH
GRVHDOODQWMXVTX·jPJHVWUHFRPPDQGpH3RXUOHV&,6HQ
IRQFWLRQGHODWROpUDQFHLQGLYLGXHOOHGXSDWLHQWODGRVHSHXW
Niveau rWUHDXJPHQWpHMXVTX·jPJ
Thermochimiothérapie
Fort /DWKHUPRFKLPLRWKpUDSLHHVWXQWUDLWHPHQWHQFRXUVG·pYDOXD-
WLRQ&HWWHPRGDOLWpGHWUDLWHPHQWIDLWDSSHOjXQGLVSRVLWLI
Fort PDLQWHQDQWOD00&jƒ&SHQGDQWODWRXWHODGXUpHGH
VDQVWUDLWHPHQWDGMXYDQWFRPSOpPHQWDLUH
/HV791,0jULVTXHLQWHUPpGLDLUHMXVWLÀHQW
G·XQWUDLWHPHQWDGMXYDQWSDULQVWLOODWLRQV
HQGRYpVLFDOHVGHFKLPLRWKpUDSLH
RXGH%&*WKpUDSLH
/HV791,0jKDXWULVTXHMXVWLÀHQW
G·XQWUDLWHPHQWDGMXYDQWSDULQVWLOODWLRQV
HQGRYpVLFDOHVGH%&*WKpUDSLH
/HV791,0jWUqVKDXWULVTXHMXVWLÀHQW
G·XQWUDLWHPHQWDGMXYDQWSDULQVWLOODWLRQV
HQGRYpVLFDOHVGH%&*WKpUDSLH
RXG·XQHF\VWHFWRPLHWRWDOHDYHFFXUDJH
Traitements endovésicaux adjuvants
O·LQVWLOODWLRQKHXUH/·pSLUXELFLQHQ·DSDVpWppYDOXpHDYHF
FHVWHFKQLTXHV/RUVTX·HOOHHVWGLVSRQLEOHFHWWHPRGDOLWp
Fort SHXWrWUHSURSRVpHSRXUOHV791,0GHULVTXHLQWHUPpGLDLUH
DSUqVpFKHFGHOD00&HWGX%&*RXSRXUOHV791,0GHKDXW
ULVTXHHQO·DEVHQFHGHGLVSRQLELOLWpGX%&*RXG·LQWROpUDQFH
SRVVLEOHHQFDVGHUHIXVRXG·LQpOLJLELOLWpjODFKLUXUJLHUDGL-
FDOHPDLVDYHFGHVUpVXOWDWVRQFRORJLTXHVLQIpULHXUV>@
Fort
Optimisation des instillations et prévention
des effets secondaires
Fort
/·HIÀFDFLWp GH OD 00& HW GH O·pSLUXELFLQH GpSHQG GH OHXU
mode d’utilisation et de leur concentration. Les instillations
GH00&jODGRVHGHPJPOVRQWSOXVHIÀFDFHVPDLVPRLQV
ELHQWROpUpHVHWQHVHURQWSDVSURSRVpHVHQSUHPLqUHLQWHQ-
WLRQ,OHQHVWGHPrPHDYHFOHVLQVWLOODWLRQVG·pSLUXELFLQHj
PJPO,OHVWUHFRPPDQGpGHIDLUH>@
• XQHUpGXFWLRQGHODGLXUqVHKHXUHVDYDQWO·LQVWLOODWLRQ
/HWUDLWHPHQWDGMXYDQWYLVHjUpGXLUHOHULVTXHGHUpFLGLYH
SRXUOHVWXPHXUVLQWHUPpGLDLUHVHWGHSURJUHVVLRQSRXUOHV
WXPHXUVjKDXWULVTXH/HFDUDFWqUHLQFRPSOHWGHODUpVHFWLRQ
HVW OH IDFWHXU GH ULVTXH G·pFKHF OH SOXV LPSRUWDQW &·HVW
SOXVVRXYHQWOHFDVORUVTXHOHPXVFOHQ·DSDVpWpYXTXH
ODWDLOOHWXPRUDOHHVW!FPRXTXHODWXPHXUHVWPXOWL-
focale. A contrario OH WDX[ GH UpFLGLYH RX GH SURJUHVVLRQ
DSUqVWUDLWHPHQWHQGRYpVLFDOHVWPLQLPDOORUVTXHOD5789
GH ©VHFRQG ORRNª QH PHW SDV HQ pYLGHQFH GH WXPHXU RX
VHXOHPHQWGHVOpVLRQVS7DGHEDVJUDGH>@
Chimiothérapie endovésicale
Mitomycine C (MMC)
/HWUDLWHPHQWFODVVLTXHHVWGHLQVWLOODWLRQVKHEGRPDGDLUHV
• SRXUOD00&XQHDOFDOLQLVDWLRQGHVXULQHVS+!
$SUqVO·LQVWLOODWLRQSRXUFKDTXHPLFWLRQVXUYHQDQWGDQV
OHVKHXUHVLOHVWQpFHVVDLUHGHQHXWUDOLVHUOHVXULQHVMHWpHV
SDU  PO G·HDX GH -DYHO SUrWH j O·HPSORL /D SUHPLqUH
PLFWLRQDSUqVO·LQVWLOODWLRQGDQVOHVGHX[SUHPLqUHVKHXUHV
VHIHUDVXUOHOLHXPrPHGHO·LQVWLOODWLRQ/HVDXWUHVPLFWLRQV
SHXYHQWUDLVRQQDEOHPHQWDYRLUOLHXDXGRPLFLOHGXSDWLHQW
BCG-thérapie endovésicale
Modalité d’administration
/H %&* QH VHUD GpEXWp TX·DSUqV FLFDWULVDWLRQ YpVLFDOH
JpQpUDOHPHQWjVHPDLQHVDSUqVODUpVHFWLRQHWDXSOXV
WDUGDXERXWGHVHPDLQHVHWHQO·DEVHQFHGHWRXWHWXPHXU
UpVLGXHOOH/HWUDLWHPHQWG·LQGXFWLRQFRPSRUWHLQVWLOODWLRQV
LQWUDYpVLFDOHV KHEGRPDGDLUHV LGpDOHPHQW GH  KHXUHV /H
GHPJLQVWLOODWLRQGDQVPOGHVROXWLRQVDOLQHPJ traitement d’entretien est recommandé dans tous les cas et
POVXLYLHVRXQRQG·LQVWLOODWLRQVPHQVXHOOHVSHQGDQWDQ FRPSRUWHLQVWLOODWLRQVKHEGRPDGDLUHVjHWPRLVGHOD
PD[LPXPWUDLWHPHQWG·HQWUHWLHQ/·HIÀFDFLWpGHOD00&HVW UpVHFWLRQSRXUOHVWXPHXUVGHULVTXHLQWHUPpGLDLUHHQWUHWLHQ
FRUUpOpHjODGXUpHGHFRQWDFWHQWUHOHSURGXLWHWO·XURWKpOLXP GHDQSRXUVXLYLHVWRXVOHVPRLVMXVTX·DXePRLVSRXU
8QHGXUpHPLQLPXPG·LQVWLOODWLRQGHKHXUHHVWUHTXLVH>@
/D00&DYHFHQWUHWLHQUpGXLWOHULVTXHGHUpFLGLYHGHSDU
UDSSRUWDX[LQVWLOODWLRQVGH%&*VDQVHQWUHWLHQ
Épirubicine
'DQVOHFRQWH[WHGHSpQXULHGH00&OH&RPLWpGHFDQFpURORJLH
OHVWXPHXUVjULVTXHpOHYpHQWUHWLHQGHDQV>@
Contre-indications
/H%&*QHGRLWSDVrWUHDGPLQLVWUpGDQVOHVFDVVXLYDQWV
Formelles
GHO·$VVRFLDWLRQIUDQoDLVHG·XURORJLH&&$)8DSURSRVpHQ • $QWpFpGHQW GH UpDFWLRQ V\VWpPLTXH DX %&* LQIHFWLRQ
QRYHPEUHjO·$JHQFHQDWLRQDOHGHVpFXULWpGXPpGLFDPHQW G·RUJDQHRXVHSWLFpPLHj%&*
S108 05RXSUrWHWDO

• 'pÀFLWLPPXQLWDLUHVpYqUH GHV PHVXUHV SURSK\ODFWLTXHV PD[LPDOHV TXL SRXUURQW

• &\VWLWHUDGLTXH
• 7XEHUFXORVHDFWLYH
Relatives
• 3HUVLVWDQFHG·HIIHWVVHFRQGDLUHVOLpVjODSUpFpGHQWHLQV-
tillation au moment de la nouvelle instillation (stade 3).
• ,QIHFWLRQGHVYRLHVXULQDLUHVV\PSWRPDWLTXH
• $EVHQFH RX LQFHUWLWXGH GH O·LQWpJULWp GH O·XURWKpOLXP
KpPDWXULHPDFURVFRSLTXHVRQGDJHWUDXPDWLTXHRXOHV
rWUH DMXVWpHV j OD WROpUDQFH REVHUYpH VWDGH  >@
/·KpPDWXULHPLFURVFRSLTXHODOHXFRF\WXULHHWODEDFWp-
ULXULHDV\PSWRPDWLTXHQHVRQWSDVGHVFRQWUHLQGLFDWLRQV
jODUpDOLVDWLRQGHVLQVWLOODWLRQVGH%&*HWQHQpFHVVLWHQW
SDVGHWUDLWHPHQW>@
Prévention et prise en charge des effets secondaires
/D SULVH HQ FKDUJH GHV HIIHWV VHFRQGDLUHV HVW EDVpH VXU
GHVDYLVGHJURXSHVH[SHUWV,QWHUQDWLRQDO%ODGGHU&DQFHU
jVHPDLQHVTXLVXLYHQWXQJHVWHVXUOHEDVDSSDUHLO *URXS >,%&*@ &&$)8 HW GRLW rWUH DGDSWpH j OHXU VpYp-
urinaire).
'HVpWXGHVDYHFGHSHWLWVpFKDQWLOORQVGHSDWLHQWVRQW
UDSSRUWpO·DEVHQFHG·DXJPHQWDWLRQGHVHIIHWVVHFRQGDLUHV
et une efficacité maintenue en cas d’antécédent de radio-
WKpUDSLH GH O·DLUH YpVLFDOH VDQV F\VWLWH UDGLTXH RX HQ
cas de déficit immunitaire modéré (traitement immuno-
VXSSUHVVHXUYLUXVGHO·LPPXQRGpILFLHQFHKXPDLQH>9,+@
ULWp >@ 2Q GLVWLQJXH 7DEOHDX  OHV HIIHWV VHFRQGDLUHV
PLQHXUVSRXUOHVTXHOVODSRXUVXLWHGX%&*HVWSRVVLEOHVRXV
UpVHUYHGHODPLVHHQSODFHGHPHVXUHVV\PSWRPDWLTXHV
SURSK\ODFWLTXHVRXG·XQHLQWHUUXSWLRQWHPSRUDLUHGX%&*
GHV HIIHWV VHFRQGDLUHV PDMHXUV SRXU OHVTXHOV O·DUUrW GX
%&* HVW OH SOXV VRXYHQW GpÀQLWLI 2XWUH O·LQWHUURJDWRLUH
LO HVW UHFRPPDQGp G·XWLOLVHU XQH FKHFNOLVW RX XQ DXWR
DYHFFKDUJHYLUDOHELHQFRQWU{OpH(QO·DEVHQFHG·DOWHU- TXHVWLRQQDLUH DYDQW FKDTXH LQVWLOODWLRQ SRXU O·pYDOXDWLRQ
QDWLYH WKpUDSHXWLTXH LO HVW UHFRPPDQGp G·\ DVVRFLHU des effets secondaires.

Tableau 4. &ODVVLÀFDWLRQHWSURSRVLWLRQVGHSULVHHQFKDUJHGHVHIIHWVVHFRQGDLUHVPLQHXUV
Durée des effets secondaires
!KHWK
•KHWMRXUV
•MRXUVRXVXVSLFLRQG·LQIHFWLRQ
Sévérité Traitement
6WDGH, 3RXUVXLWHGX%&*
0HVXUHVV\PSWRPDWLTXHV
6WDGH,, 3RXUVXLWHGX%&*
0HVXUHVSURSK\ODFWLTXHV
6WDGH,,, ,QWHUUXSWLRQGX%&*•V
0HVXUHVWKpUDSHXWLTXHV
Mesures symptomatiques/prophylactiques
²$,16
– Paracétamol
²2ÁR[DFLQHPJjKHWK
²5pGXFWLRQGHGRVHjѿ
²7HPSVGHFRQWDFWUpGXLWjK
²2ÁR[DFLQHPJM
²&RUWLFRwGHVPJNJM
²,VRQLD]LGHHWULIDPSLFLQH

/HVHIIHWVVHFRQGDLUHVPLQHXUV7DEOHDXSHXYHQWrWUH
FODVVpVHQWURLVVWDGHVGHVpYpULWpGRQWGpSHQGOHXUSULVH
en charge.
Tableau 5. (IIHWVVHFRQGDLUHVOLpVDX[LQVWLOODWLRQVGH%&*
/HVHIIHWVVHFRQGDLUHVPDMHXUVFRUUHVSRQGHQWDX[HIIHWV
VHFRQGDLUHVGHVWDGHGHVpYpULWp,OVVRQWJpQpUDOHPHQW
VHFRQGDLUHVjXQSDVVDJHV\VWpPLTXHGX%&*/DSUpVHQFH
GH V\PSW{PHV IDLVDQW pYRTXHU FHV DIIHFWLRQV GRLW IDLUH
LQWHUURPSUHOHVLQVWLOODWLRQVHWHQYLVDJHUXQHKRVSLWDOLVDWLRQ
HWXQHSULVHHQFKDUJHVSpFLDOLVpH/HWUDLWHPHQWFRPSUHQG
Mineurs /RFDX[F\VWLWH JpQpUDOHPHQWXQWUDLWHPHQWSDUFRUWLFRwGHVjIRUWHGRVHHW
²K\SHUDFWLYLWpYpVLFDOH XQHDQWLELRWKpUDSLHDQWLWXEHUFXOHXVH
²KpPDWXULH /DSHUVLVWDQFHG·XQHKpPDWXULHRXGHVLJQHVXULQDLUHV
²LQFRQWLQHQFHXULQDLUH LVROpV UpVLVWDQWV DX WUDLWHPHQW GRLW IDLUH VXVSHFWHU XQH
²GRXOHXUVVXVSXELHQQHV UpFLGLYH WXPRUDOH RX XQH FRPSOLFDWLRQ HW HQYLVDJHU OD
²EU€OXUHVPLFWLRQQHOOHV UpDOLVDWLRQG·XQHF\VWRVFRSLH/HVFRUWLFRwGHVVRQWJpQpUD-
*pQpUDX[V\QGURPHJULSSDO OHPHQWDGPLQLVWUpVVXUXQHSpULRGHGHPRLQVGHMRXUV
²DVWKpQLH MXVTX·j OD GLVSDULWLRQ GHV V\PSW{PHV /HV LQVWLOODWLRQV
²P\DOJLH GH %&* VRQW LQHIÀFDFHV HQ FDV GH UpVHFWLRQ LQFRPSOqWH
²ÀqYUHƒK PDFURVFRSLTXHPHQW/HVGLIIpUHQWHVVRXFKHVGH%&*QH
Majeurs ²'pWUHVVHUHVSLUDWRLUHRXFLUFXODWRLUH VRQWSDVVLPLODLUHVVXUOHSODQJpQRPLTXH8QHVHXOHpWXGH
²6HSWLFpPLHRXLQIHFWLRQG·RUJDQHSURVWDWH UDQGRPLVpH pWDLW HQ IDYHXU G·XQH OpJqUH VXSpULRULWp GH
SRXPRQpSLGLG\PHWHVWLFXOHUHLQIRLH la souche Connaught sur la souche Tice. Toutefois les
articulation). OLPLWHV GH O·pWXGH QH SHUPHWWHQW SDV j FH MRXU GH SUL-
²,QVXIÀVDQFHKpSDWLTXH YLOpJLHUXQHVRXFKHSDUUDSSRUWjXQHDXWUH7DEOHDXGH
²5pDFWLRQDOOHUJLTXHUDVKFXWDQpDUWKUDOJLHV recommandation 8).
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU
Tableau de recommandation 8
5HFRPPDQGDWLRQVWUDLWHPHQWV
endovésicaux adjuvants
Faire une réduction de la diurèse
SRXURSWLPLVHUODWROpUDQFHHWO·HIÀFDFLWp
des instillations endovésicales.
Faire une alcalinisation des urines
SRXURSWLPLVHUO·HIÀFDFLWpGHOD00&
1HSDVIDLUHG·DOFDOLQLVDWLRQGHVXULQHVHQFDV
G·LQVWLOODWLRQG·pSLUXELFLQH
)DLUHGHVLQVWLOODWLRQVGH%&*DYHFXQVFKpPD
G·HQWUHWLHQGHDQSRXUOHV79GHULVTXH
LQWHUPpGLDLUHHWGHDQVSRXUOHV79
GHKDXWULVTXH
Les instillations endovésicales de MMC
DYHFHQWUHWLHQGHDQVRQWSOXVHIÀFDFHV
TXHOHVLQVWLOODWLRQVGH%&*VDQVHQWUHWLHQ
SRXUUpGXLUHOHULVTXHGHUpFLGLYHSRXUOHV79
GHULVTXHLQWHUPpGLDLUH
/HVLQVWLOODWLRQVGH%&*VRQWLQHIÀFDFHVHQFDV
GH79UpVLGXHOOH
3URSRVHUXQHF\VWHFWRPLHHQSUHPLqUH
LQWHQWLRQHQFDVGH79GHWUqVKDXWULVTXH
8WLOLVHUXQHFKHFNOLVWRXXQDXWRTXHVWLRQQDLUH
DYDQWFKDTXHLQVWLOODWLRQGH%&*
SRXUO·pYDOXDWLRQGHVHIIHWVVHFRQGDLUHV
5HSRUWHUO·LQVWLOODWLRQGH%&*HQFDV Fort
GHV\PSW{PHVSHUVLVWDQWVDXERXWG·XQHVHPDLQH
6
5HFRPPDQGDWLRQVWUDLWHPHQWV Niveau
Niveau endovésicaux adjuvants
(QFDVG·LQWROpUDQFHGHVLQVWLOODWLRQVGH%&* Fort
Fort SURSRVHUXQHRXSOXVLHXUVGHFHVRSWLRQV
SDUDFpWDPRO$,16RÁR[DFLQHKHWKDSUqV
O·LQVWLOODWLRQUHSRUWGHO·LQVWLOODWLRQUpGXFWLRQ
GHGRVHMXVTX·j1 3GLPLQXWLRQGXWHPSVGH
Fort FRQWDFW/HVDQWLFKROLQHUJLTXHVVRQWLQHIÀFDFHV
/·KpPDWXULHPLFURVFRSLTXHODOHXFRF\WXULH Fort
Fort HWODEDFWpULXULHDV\PSWRPDWLTXHQHVRQW
SDVGHVFRQWUHLQGLFDWLRQVjODUpDOLVDWLRQ
Fort GHVLQVWLOODWLRQVGH%&*HWQHQpFHVVLWHQWSDV
GHWUDLWHPHQW/DUpDOLVDWLRQG·XQ(&%8
DYDQWFKDTXHLQVWLOODWLRQHVWRSWLRQQHOOH
'pEXWHULPPpGLDWHPHQWXQWUDLWHPHQW Fort
SDURÁR[DFLQHHWFRUWLFRwGHSXLV
)DLEOH SDUDQWLWXEHUFXOHX[DSUqVDYLVVSpFLDOLVp
HQFDVG·HIIHWVHFRQGDLUHPDMHXUGX%&*
3HQVHUjXQHUpFLGLYHWXPRUDOH )DLEOH
RXjXQHFRPSOLFDWLRQGHYDQWODSHUVLVWDQFH
d’une hématurie ou de signes urinaires
Fort isolés résistants au traitement et faire une
F\VWRVFRSLH
Fort
)DLEOH Surveillance des TVNIM
/D VXUYHLOODQFH GHV791,0 HVW LQGLVSHQVDEOH FDU OH ULVTXH
de récidive est élevé. Les modalités de surveillance sont
EDVpHVVXUGHVpWXGHVUpWURVSHFWLYHVHWGHVDYLVG·H[SHUWV
7DEOHDX>@

Tableau 6. 0RGDOLWpVGHVXLYLGHV791,0

Cystoscopie Cytologie Uro-TDM

Risque faible – 3e et 12ePRLVSXLV 1RQ
²DQQXHOOHSHQGDQWDQV
1RQV\VWpPDWLTXH
Risque intermédiaire – 3e et 6ePRLVSXLV Oui
²WRXVOHVPRLVSHQGDQWDQVSXLV
²DQQXHOOHSHQGDQWDXPRLQVDQV
Risque élevé – 3e et 6ePRLVSXLV Oui
²WRXVOHVPRLVSHQGDQWDQVSXLV Annuel
²WRXVOHVPRLVMXVTX·jDQV
²SXLVWRXVOHVDQVjYLH
/DUpDOLVDWLRQG·XQVFDQQHUDQQXHOSRXUOHVWXPHXUVjKDXWULVTXHHVWUHFRPPDQGpH

791,0GHIDLEOHULVTXHOHVUpFLGLYHVGDQVFHJURXSHVRQW
SUHVTXHWRXMRXUVGHVWXPHXUVGHEDVJUDGHGRQWOHULVTXHGH
SURJUHVVLRQHVWTXDVLPHQWQXO
791,0GHULVTXHLQWHUPpGLDLUHFHJURXSHHVWFDUDFWp-
ULVpSDUXQIRUWULVTXHGHUpFLGLYHPDLVXQIDLEOHULVTXHGH
SURJUHVVLRQ /HV IDFWHXUV DVVRFLpV DX[ UpFLGLYHV VRQW SDU
RUGUHGpFURLVVDQWG·LPSRUWDQFHODPXOWLIRFDOLWpXQWDX[
GHUpFLGLYH!SDUDQHWODWDLOOH!FP/HULVTXHSHXWrWUH
FDOFXOpjO·DLGHGHVWDEOHVGHO·(257&>@
791,0 GH ULVTXH pOHYp  OH ULVTXH GH SURJUHVVLRQ HVW
SDUWLFXOLqUHPHQW LPSRUWDQW OHV GHX[ SUHPLqUHV DQQpHV R
OD VXUYHLOODQFH GRLW rWUH WULPHVWULHOOH /H U\WKPH GLPLQXH
HQVXLWHSURJUHVVLYHPHQW
S110
Cystoscopie et biopsies
/D VXUYHLOODQFH HVW SULQFLSDOHPHQW EDVpH VXU OD F\VWRV
FRSLH TXL QH SHXW rWUH UHPSODFpH SDU DXFXQH DXWUH
PRGDOLWp GH GLDJQRVWLF /D F\VWRVFRSLH j  PRLV HVW
LQGLVSHQVDEOHHWDXQU{OHSURQRVWLTXHLPSRUWDQWDILQGH
QHSDVPpFRQQDvWUHXQHWXPHXUUpVLVWDQWHDXWUDLWHPHQW
'HVELRSVLHVV\VWpPDWLTXHVFRXSOpHVjODF\VWRVFRSLHVRQW
UHFRPPDQGpHVjPRLVORUVTXHGX&,6pWDLWSUpVHQWDX
GLDJQRVWLFDILQGHYpULILHUO·HIILFDFLWpGXWUDLWHPHQWSDU
%&*(OOHVVHURQWpJDOHPHQWUpDOLVpHVHQFDVGHOpVLRQV
VXVSHFWHVHQF\VWRVFRSLHVDXIHQFDVGHWXPHXUGHIDLEOH
ULVTXHRXQHpOHFWURIXOJXUDWLRQHVWSRVVLEOH$SUqVDQV
OHV UpFLGLYHV GHV 791,0 GH IDLEOH ULVTXH VRQW UDUHV RX
SHXPHQDoDQWHVHWODVXUYHLOODQFHSDUF\VWRVFRSLHSHXW
05RXSUrWHWDO
Cytologie urinaire et marqueurs
/DF\WRORJLHXULQDLUHHVWXWLOHSRXUOHGLDJQRVWLFGHVWXPHXUVGH
KDXWJUDGH/HV791,0GHIDLEOHULVTXHSURJUHVVHQWUDUHPHQW
YHUVFHVWXPHXUV/DVXUYHLOODQFHSDUF\WRORJLHHVWGRQFLQXWLOH
GDQVFHJURXSH3RXUOHVDXWUHVJURXSHVHQUHYDQFKHHOOHHVW
V\VWpPDWLTXHPHQWDVVRFLpHjODF\VWRVFRSLH8QHF\WRORJLH
XULQDLUHSRVLWLYHLVROpHGRLWIDLUHUHFKHUFKHUXQ&,6RXXQH
WXPHXUGXKDXWDSSDUHLOXULQDLUH$XFXQDXWUHPDUTXHXUXUL-
QDLUHQ·HVWDXMRXUG·KXLUHFRPPDQGpSRXUODVXUYHLOODQFH>@
Imagerie
/HULVTXHG·DWWHLQWHGHWXPHXUGHODYRLHH[FUpWULFHVXSp-
rWUH LQWHUURPSXH /HV 791,0 GH ULVTXH LQWHUPpGLDLUH
SURJUHVVHQW UDUHPHQW DSUqV  DQV HW OHXU VXUYHLOODQFH
SHXW rWUH LQWHUURPSXH RX IDLUH DSSHO j GHV PRGDOLWpV
PRLQVLQYDVLYHVWHOOHVTXHO·pFKRJUDSKLH/DVXUYHLOODQFH
HVW SRXUVXLYLH j YLH SRXU OHV 791,0 GH ULVTXH pOHYp
RX ORUVTXH O·LQWR[LFDWLRQ WDEDJLTXH HVW PDLQWHQXH
La figure 3 résume le calendrier de suivi en fonction du
ULVTXH /·XWLOLVDWLRQ GH OD OXPLQRIOXRUHVFHQFH Hexvix)
HQDVVRFLDWLRQjODILEURVFRSLHYpVLFDOHGHVXUYHLOODQFH
Q·HVWSDVUHFRPPDQGpH>@
ULHXUH 79(6 FKH] OHV SDWLHQWV SULV HQ FKDUJH SRXU XQH
WXPHXUGHYHVVLHHVWG·HQYLURQDXFRXUVGHOHXUVXLYL
/HVIDFWHXUVGHULVTXHSULQFLSDX[VRQWOHVWXPHXUVGHKDXW
grade, les atteintes touchant le trigone et les atteintes
PXOWLIRFDOHV>@3RXUFHVSDWLHQWVjULVTXHO·XUR7'0GDQV
OHFDGUHGHODVXUYHLOODQFHGRLWrWUHDQQXHOOH
4XHO TXH VRLW OH JURXSH j ULVTXH HQ FDV G·DSSDULWLRQ
GHV\PSW{PHVFOLQLTXHVRXGHVLJQHVELRORJLTXHVpYRTXDQW
XQHDWWHLQWHGHODYRLHH[FUpWULFHVXSpULHXUHODUpDOLVDWLRQ
G·XQHXUR7'0HVWUHFRPPDQGpH>@

Nombre de mois après RTUV

3 6 9 12 15 18 21 24 30 36 42 48

Cytoscopie
TVNIM à faible risque : Suivi
Cytologie

3 6 9 12 15 18 21 24 30 36 42 48

Cytoscopie
TVNIM à risque intermédiaire : Suivi
Cytologie

Instillations de MMC

8
Induction 9 instillations mensuelles d'entretien (optionnelles)
Instillations de BCG
6 3 3 3 3

Induction 12 instillations d’entretien

3 6 9 12 15 18 21 24 30 36 42 48

Cytoscopie
TVNIM à haut risque : Suivi
Cytologie

Instillations de BCG
6 3 3 3 3 3 3 3

Induction 21 instillations d’entretien

Figure 3. &DOHQGULHUGHWUDLWHPHQWHQGRYpVLFDOHWGHVXLYLGHV791,0HQIRQFWLRQGHOHXUJURXSHGHULVTXH
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

/·XUR,50 SHUPHW pJDOHPHQW G·pWXGLHU O·HQVHPEOH GH 3ODFHGHO·RSWLPLVDWLRQYLVXHOOH

O·DSSDUHLOH[FUpWRLUHXULQDLUHHWFRQVWLWXHXQHDOWHUQDWLYHj /DOXPLQRÁXRUHVFHQFHYpVLFDOHSDUKH[DPLQROpYXOLQDWHHVW
O·XUR7'0QRWDPPHQWVLFHOOHFLHVWFRQWUHLQGLTXpHRXHQ UHFRPPDQGpHORUVGHOD5789GHVUpFLGLYHVGH791,0LQLWLD-
FDVG·H[DPHQVUpSpWpVSRXUGpFURvWUHO·LUUDGLDWLRQGXSDWLHQW OHPHQWGHEDVULVTXH/·XWLOLVDWLRQGHODOXPLQRÁXRUHVFHQFH
7DEOHDXGHUHFRPPDQGDWLRQ>@
Tableau de recommandation 9
5HFRPPDQGDWLRQVVXUYHLOODQFHGHV791,0
5pDOLVHUV\VWpPDWLTXHPHQWXQHF\VWRVFRSLH
jPRLVHWIDLUHGHVELRSVLHVYpVLFDOHVORUVTXH
GX&,6pWDLWSUpVHQWDYDQWOHVLQVWLOODWLRQV
/DIUpTXHQFHGHVF\VWRVFRSLHVGHFRQWU{OH
DVVRFLpHjODOXPLqUHEODQFKHDPpOLRUHODGpWHFWLRQGHVUpFL-
GLYHVGHV791,0&HWWHWHFKQLTXHSHUPHWXQHDPpOLRUDWLRQ
GHODVXUYLHVDQVUpFLGLYH>@
Niveau 3ODFHGHO·LQVWLOODWLRQSRVWRSpUDWRLUH
SUpFRFHGHFKLPLRWKpUDSLH
Fort
(OOHSHXWrWUHUHFRPPDQGpHDSUqVOD5789GHVUpFLGLYHVGH
791,0LQLWLDOHPHQWGHEDVULVTXHVRXVFHUWDLQHVFRQGLWLRQV
/DPpWDDQDO\VHGHVGRQQpHVLQGLYLGXHOOHVGHSDWLHQWV
Fort LQFOXVGDQVGHVpWXGHVVXUO·XWLOLVDWLRQG·,323GHPLWRP\-
GpSHQGGXULVTXHGHUpFLGLYHHWGHSURJUHVVLRQ
(OOHGRLWrWUHDVVRFLpHjXQHF\WRORJLHSRXU
les tumeurs de haut grade. Aucun autre test
XULQDLUHQHSHXWUHPSODFHUFHVH[DPHQV
3DVGHVXUYHLOODQFHV\VWpPDWLTXHSDULPDJHULH )DLEOH
GXKDXWDSSDUHLOXULQDLUHGDQVOHV791,0
FLQHJHPFLWDELQHRXSLUDUXELFLQHDPRQWUpXQEpQpÀFHHQ
UpGXFWLRQ GX ULVTXH GH UpFLGLYH XOWpULHXUH XQLTXHPHQW HQ
FDVGHUpFLGLYH>@
• XQLTXH
• WDLOOHFP
• VXSSRVpPHQW7D EDV JUDGH RX * F\WRORJLH XULQDLUH
QpJDWLYH
)DLUHXQHXUR7'0jODUHFKHUFKHG·XQHWXPHXU Fort • DSUqV  DQ GH UpPLVVLRQ GpODL VDQV UpFLGLYH VXSpULHXU
GXKDXWDSSDUHLOGDQVOHVVLWXDWLRQVVXLYDQWHV jDQ
²HQSUpVHQFHGHV\PSW{PHVpYRFDWHXUV • HWO·DEVHQFHGHFRQWUHLQGLFDWLRQSHUIRUDWLRQYpVLFDOH
G·XQH79(6,QIRUPHUOHVSDWLHQWV KpPDWXULHPDFURVFRSLTXHUpVHFWLRQpWHQGXH
GHODQDWXUHGHFHVV\PSW{PHV
HWGHODQpFHVVLWpGHFRQVXOWHU Traitement adjuvant à la résection
– lors d’une récidive uni- ou multifocale /HWUDLWHPHQWDGMXYDQWGpSHQGUDGXVWDGHHWGXJUDGHGH
G·XQHWXPHXUGHKDXWJUDGH la récidive.
– lors d’une récidive multifocale d’une tumeur
GHEUDVJUDGHWRXFKDQWOHV]RQHV 5pFLGLYHVRXVODIRUPHG·XQH791,0
SpULPpDWLTXHVXUpWpUDOHVRXOHWULJRQH GHULVTXHLQWHUPpGLDLUH
²HQSUpVHQFHG·XQHF\WRORJLHXULQDLUH /HVWUDLWHPHQWVDGMXYDQWVGLVSRQLEOHVVRQW
SRVLWLYHVDQVOpVLRQYpVLFDOHYLVLEOH • OD FKLPLRWKpUDSLH HQGRYpVLFDOH  LQVWLOODWLRQV KHEGR-
madaires) avec traitement d’entretien. Les modalités
LGpDOHVGXWUDLWHPHQWG·HQWUHWLHQQHVRQWSDVFODLUHPHQW
Traitement des récidives de TVNIM GpÀQLHVLOVHPEOHTX·XQHGXUpHGHWUDLWHPHQWVXSpULHXUH
jDQQHVRLWSDVMXVWLÀpH>@
• OHVLQVWLOODWLRQVGH%&*DYHFXQWUDLWHPHQWG·HQWUHWLHQ
Récidive d’une TVNIM initialement SHQGDQW  DQ LQGXFWLRQ  KHEGRPDGDLUHV  HQWUHWLHQ
classée à faible risque KHEGRPDGDLUHVjHWPRLV>@

Principes techniques 5pFLGLYHVRXVODIRUPHG·XQH791,0GHKDXWULVTXH

Dans cette forme de récidive, les instillations endovésicales
Place de la surveillance active GH%&*VRQWUHFRPPDQGpHVLQVWLOODWLRQVKHEGRPDGDLUHV
/D VXUYHLOODQFH DFWLYH SHXW rWUH SURSRVpH HQ RSWLRQ DX[ HWKHEGRPDGDLUHVjSXLVWRXVOHVPRLVSHQGDQW
SDWLHQWVDYHFXQHUpFLGLYHDSUqVSOXVGHDQGHVXLYLG·XQH DQV>@
791,0S7DGHEDVJUDGHG·DXPD[LPXPWXPHXUVGHWDLOOH
”FPD\DQWXQHF\WRORJLHXULQDLUHQpJDWLYHHWDFFHSWDQWOD
VXUYHLOODQFHSOXVUDSSURFKpHREVHUYDQFH>@ Récidive d’une TVNIM initialement
classée à risque intermédiaire
Place de la fulguration
/HWUDLWHPHQWFKLUXUJLFDOGHUpIpUHQFHHVWOD5789(OOHGRLW Principes techniques
rWUHDVVRFLpHjXQVHFRQGORRNHQFDVGHUpVHFWLRQLQFRP-
SOqWHG·DEVHQFHGHPXVFOHVDXI7DEDVJUDGHRX*GH Place de la surveillance active
S7(QO·DEVHQFHG·HVVDLFRQWU{OpUDQGRPLVpODIXOJXUDWLRQ /D VXUYHLOODQFH DFWLYH SHXW rWUH SURSRVpH HQ RSWLRQ DX[
SHXW rWUH SURSRVpH FRPPH XQH RSWLRQ FKLUXUJLFDOH SRXU SDWLHQWV UpSRQGDQWV SUpVHQWDQW XQH UpFLGLYH DSUqV SOXV
OH WUDLWHPHQW GHV UpFLGLYHV SDSLOODLUHV GHV791,0 GH EDV GHDQGHVXLYLG·XQH791,0S7DGHEDVJUDGHG·DXPD[LPXP
ULVTXHPRLQVGHWXPHXUVWDLOOHFPSHUPHWWDQWGH WXPHXUVGHWDLOOH”FPD\DQWXQHF\WRORJLHXULQDLUHQRU-
GLPLQXHUOHVULVTXHVSpULRSpUDWRLUHV>@ PDOHHWDFFHSWDQWODVXUYHLOODQFHSOXVUDSSURFKpH>@
S112 05RXSUrWHWDO

Place de la fulguration 5pFLGLYHVRXVODIRUPHG·XQH791,0GHWUqVKDXWULVTXH

/RUVTXH OD IUDJLOLWp HW OHV FRPRUELGLWpV GX SDWLHQW QH /H SURQRVWLF GH FHV WXPHXUV GRLW IDLUH SURSRVHU OD %&*
SHUPHWWHQW SDV G·HQYLVDJHU XQH 5789 OD IXOJXUDWLRQ WKpUDSLHHWODF\VWHFWRPLHSRXUOHVWUDLWHUDSUqVDYRLUGLVFXWp
SHXWrWUHSURSRVpHFRPPHXQHRSWLRQFKLUXUJLFDOHSRXU GHODPRUELGLWpGHO·LQWHUYHQWLRQDYHFOHSDWLHQW(QHIIHW
OH WUDLWHPHQW GHV UpFLGLYHV SDSLOODLUHV GHV 791,0 GH FHOOHFLGRLWrWUHSURSRVpHLGpDOHPHQWDYDQWODSURJUHVVLRQ
EDV ULVTXH PRLQV GH  WXPHXUV WDLOOH   FP QRQ YHUVXQH79,0>@
V\PSWRPDWLTXHV>@

3ODFHGHO·RSWLPLVDWLRQYLVXHOOH Récidive d’une TVNIM initialement

(OOH Q·HVW SDV UHFRPPDQGpH GH IDoRQ V\VWpPDWLTXH ORUV
GHOD5789GHVUpFLGLYHVGH791,0LQLWLDOHPHQWGHULVTXH
intermédiaire.
La luminofluorescence a amélioré la détection des
OpVLRQV7DDLQVLTXHODVXUYLHVDQVUpFLGLYHGDQVOHJURXSH
GHV791,0 GH EDV ULVTXH$LQVL VRQ XWLOLVDWLRQ HVW UHFRP-
PDQGpHXQLTXHPHQWSRXUOHVUpFLGLYHVGHWDLOOHFPHW
SUpVXPpHVGHVWDGH7DHWGHEDVJUDGH*F\WRORJLHXULQDLUH
classée à haut risque
Principes techniques
3ODFHGHO·RSWLPLVDWLRQYLVXHOOH
/DOXPLQRÁXRUHVFHQFHHVWUHFRPPDQGpHSRXUDPpOLRUHUOD
GpWHFWLRQGHVOpVLRQVSODQHVGH&,6ORUVTXHODF\VWRVFRSLH
HQOXPLqUHEODQFKHQHUpYqOHSDVGHOpVLRQSDSLOODLUH(OOH
QpJDWLYH>@ SHUPHW GH GpWHFWHU  GH OpVLRQV VXSSOpPHQWDLUHV HQ
FRPSDUDLVRQDYHFODOXPLqUHEODQFKHVHXOHHWG·DPpOLRUHU
3ODFHGHO·LQVWLOODWLRQSRVWRSpUDWRLUHSUpFRFH ODVXUYLHVDQVUpFLGLYH(QUHYDQFKHODOXPLQRÁXRUHVFHQFH
GHFKLPLRWKpUDSLH Q·DSDVDPpOLRUpODGpWHFWLRQGHVOpVLRQVSDSLOODLUHVGHKDXW
(OOH Q·HVW SDV UHFRPPDQGpH GH IDoRQ V\VWpPDWLTXH DSUqV ULVTXHHWQ·DSDVUpGXLWOHXUULVTXHGHUpFLGLYH>@
OD 5789 GHV UpFLGLYHV GH 791,0 LQLWLDOHPHQW GH ULVTXH
intermédiaire. ,QVWLOODWLRQSRVWRSpUDWRLUHSUpFRFHGHFKLPLRWKpUDSLH
'·DSUqVODGHUQLqUHPpWDDQDO\VH>@O·,323DXQEpQp- (OOHQ·HVWSDVUHFRPPDQGpHORUVGHOD5789GHVUpFLGLYHVGH
ÀFHHQWHUPHVGHUpGXFWLRQGXULVTXHGHUpFLGLYHXOWpULHXUH 791,0LQLWLDOHPHQWGHKDXWULVTXH>@
XQLTXHPHQWHQFDVGHUpFLGLYH
• XQLTXH Traitement adjuvant à la résection
• WDLOOHFP /H WUDLWHPHQW G·XQH UpFLGLYH G·XQH 791,0 LQLWLDOHPHQW
• VXSSRVpPHQW7D EDV JUDGH RX * F\WRORJLH XULQDLUH FODVVpHFRPPHGHKDXWULVTXHHWWUDLWpHSDU%&*WKpUDSLH
QpJDWLYH DGMXYDQWHGRLWrWUHGLVWLQJXpHQIRQFWLRQGHVDSUpFRFLWpHW
• DSUqV  DQ GH UpPLVVLRQ GpODL VDQV UpFLGLYH VXSpULHXU GXJUDGHKLVWRORJLTXHGHODUpFLGLYH
jDQ
• HWO·DEVHQFHGHFRQWUHLQGLFDWLRQSHUIRUDWLRQYpVLFDOH 5pFLGLYHSUpFRFH”PRLVVRXVODIRUPHGH791,0
KpPDWXULHPDFURVFRSLTXHUpVHFWLRQpWHQGXH
Traitement adjuvant à la résection
/HWUDLWHPHQWDGMXYDQWGpSHQGUDGXVWDGHHWGXJUDGHGH
la récidive.
5pFLGLYHVRXVODIRUPHG·XQH791,0
GHULVTXHLQWHUPpGLDLUH
/HVWUDLWHPHQWVDGMXYDQWVGLVSRQLEOHVVRQW 5pFLGLYHSUpFRFH”PRLVVRXVODIRUPH
• /D FKLPLRWKpUDSLH HQGRYpVLFDOH DYHF WUDLWHPHQW
G·HQWUHWLHQHQO·DEVHQFHGHSUHVFULSWLRQDQWpULHXUH/HV
GHEDVJUDGH
8QHUpFLGLYHGHEDVJUDGHQ·HVWSDVFRQVLGpUpHFRPPHXQ
pFKHF GX %&* 8QH pWXGH UpWURVSHFWLYH D PRQWUp TXH OHV
UpFLGLYHVGHEDVJUDGHjPRLVG·XQWUDLWHPHQWG·LQGXFWLRQ
SDU %&* DYDLHQW XQ ULVTXH IDLEOH GH SURJUHVVLRQ $LQVL
XQ WUDLWHPHQW FRQVHUYDWHXU SHXW rWUH HQYLVDJp SDU XQ
QRXYHDX F\FOH G·LQVWLOODWLRQV HQGRYpVLFDOHV GH %&* RX GH
FKLPLRWKpUDSLH>@
GH791,0GHKDXWJUDGH
6HORQODPrPHpWXGHUpWURVSHFWLYHODUpFLGLYHGHOpVLRQV
PRGDOLWpVLGpDOHVGXWUDLWHPHQWG·HQWUHWLHQQHVRQWSDV
FODLUHPHQWGpÀQLHVPDLVLOVHPEOHTXHODGXUpHQHGRLW
SDVGpSDVVHUDQ>@
• /HVLQVWLOODWLRQVGH%&*DYHFXQWUDLWHPHQWG·HQWUHWLHQ
SHQGDQWDQLQGXFWLRQKHEGRPDGDLUHVHQWUHWLHQ
GHKDXWJUDGHS7DS7jPRLVG·XQWUDLWHPHQWG·LQGXF-
WLRQSDU%&*DYDLWXQULVTXHGHUpFLGLYHHWGHSURJUHVVLRQ
jDQGHHW%LHQTXHFHVGRQQpHVVRLHQWUDS-
SRUWpHV HQ O·DEVHQFH GH WUDLWHPHQW G·HQWUHWLHQ GH %&*
et/ou de 2eF\FOHG·LQGXFWLRQOHWUDLWHPHQWFRQVHUYDWHXU
KHEGRPDGDLUHVjHWPRLV>@ Q·HVWSDVUHFRPPDQGpGDQVOHVUpFLGLYHVSUpFRFHVGHKDXW
JUDGH >@ 'DQV FHV VLWXDWLRQV OD F\VWHFWRPLH WRWDOH
5pFLGLYHVRXVODIRUPHG·XQH791,0GHKDXWULVTXH SHUPHW XQH VXUYLH j  DQV FRPSULVH HQWUH  HW 
(Q O·DEVHQFH GH FULWqUHV G·DJUHVVLYLWp VWDGH S7 GH KDXW /RUVTXHOHWUDLWHPHQWUDGLFDOHVWGpFLGpLOGRLWrWUHUpD-
JUDGH*&,6YDULDQWKLVWRORJLTXHGHPDXYDLVSURQRVWLF OLVpVDQVGpODLDYDQWPRLVFDUOHULVTXHGHSURJUHVVLRQ
SRXYDQW LQGLTXHU XQH F\VWHFWRPLH SUpFRFH OH WUDLWHPHQW GH OD PDODGLH YpVLFDOH HVW LPSRUWDQW /HV WUDLWHPHQWV
SDU LQVWLOODWLRQV HQGRYpVLFDOHV GH %&* HVW UHFRPPDQGp FRQVHUYDWHXUVSDULQVWLOODWLRQVHQGRYpVLFDOHVRXWKHUPR-
 KHEGRPDGDLUHV HW  KHEGRPDGDLUHV j    HW SXLV FKLPLRWKpUDSLHHQGRYpVLFDOHVRQWFRQVLGpUpVFRPPHGHV
WRXVOHVPRLVSHQGDQWDQV>@ DOWHUQDWLYHV SRVVLEOHV HQ FDV GH UHIXV RX G·LQpOLJLELOLWp
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

jODFKLUXUJLHUDGLFDOHPDLVDYHFGHVUpVXOWDWVRQFRORJLTXHV Récidive tardive > 12 mois sous la forme

LQIpULHXUV>@ G·XQH791,0GHKDXWJUDGH
/RUV GX SUHPLHU pSLVRGH GH UpFLGLYH XQH DOWHUQDWLYH
Récidive tardive > 12 mois sous la forme
G·XQH791,0GHEDVJUDGH
8QH UpFLGLYH GH EDV JUDGH WDUGLYH Q·HVW SDV FRQVLGpUpH
FRPPHXQpFKHFGX%&*8QQRXYHDXF\FOHG·LQVWLOODWLRQV
HQGRYpVLFDOHV GH %&* RX GH FKLPLRWKpUDSLH SHXW rWUH
envisagé.
FRQVHUYDWULFH LQVWLOODWLRQV HQGRYpVLFDOHV GH %&* SHXW
rWUH SURSRVpH j FRQGLWLRQ TXH OD 5789 GH VHFRQG ORRN
QH UHWURXYH SDV GH WXPHXU RX XQLTXHPHQW GHV OpVLRQV GH
EDV JUDGH /D F\VWHFWRPLH WRWDOH SHXW rWUH SURSRVpH DX[
SDWLHQWVORUVG·XQHUpFLGLYHGHKDXWJUDGHWDUGLYH7DEOHDXGH
recommandation 10).

7DEOHDXGHUHFRPPDQGDWLRQ
5HFRPPDQGDWLRQVWUDLWHPHQWGHVUpFLGLYHVDSUqV%&*WKpUDSLH 1LYHDX
Délai récidive *UDGHGHOD791,0 Traitements
récidivante
Précoce %DVJUDGH ,QVWLOODWLRQV%&*RXFKLPLRWKpUDSLHHQGRYpVLFDOHV )DLEOH
PRLV
Haut grade &\VWHFWRPLH Fort
Tardive > 12 mois %DVJUDGH ,QVWLOODWLRQV%&*RXFKLPLRWKpUDSLHHQGRYpVLFDOHV )DLEOH
Haut grade 579VHFRQGORRNHWHQO·DEVHQFHGHOpVLRQGHKDXW )DLEOH
JUDGHUpVLGXHOOH,QVWLOODWLRQVHQGRYpVLFDOHV%&*

Cas particulier du CIS isolé Bilan d’imagerie

3ODFHGHODOXPLQRÁXRUHVFHQFH TDM TAP avec temps excrétoire urinaire

/DOXPLQRÁXRUHVFHQFHHVWUHFRPPDQGpHSRXUDPpOLRUHUOD
GpWHFWLRQGHVOpVLRQVGH&,6UpFLGLYDQW/HWDX[GHGpWHFWLRQ • /·XUR7'0DYHFLQMHFWLRQGHSURGXLWGHFRQWUDVWHLRGpHW
GX&,6 vsHWODVXUYLHVDQVUpFLGLYHRQWpWp WHPSVWDUGLIH[FUpWRLUHFRXSOpDXVFDQQHUWKRUDFLTXHHVW
DPpOLRUpVSDUO·XWLOLVDWLRQGHODOXPLqUHEOHXH vs la lumière O·H[DPHQGHUpIpUHQFHGXELODQG·H[WHQVLRQGHV79,0
EODQFKHVHXOH>@ • /·HIÀFDFLWp GH O·XUR7'0 SRXU OD VWDGLÀFDWLRQ ORFDOH
DWWHLQWHGHODJUDLVVHSpULYpVLFDOHHWRXRUJDQHVDGMD-
Traitement du CIS isolé récidivant FHQWVYDULHVHORQOHVpWXGHVHQWUHHW>@
/HWUDLWHPHQWHQGRVFRSLTXHGX&,6GRLWrWUHFRPSOpWpSDUGHV
LQVWLOODWLRQVHQGRYpVLFDOHVGH%&*,OHVWHQVXLWHUHFRPPDQGp
GHIDLUHXQHUppYDOXDWLRQHQGRVFRSLTXHjPRLVDYHFGHV
ELRSVLHVVHQVLELOLVpHVSDUOXPLQRÁXRUHVFHQFH
6LGHV OpVLRQV GH&,6SHUVLVWHQWLO HVWUHFRPPDQGp GH
faire un 2eF\FOHG·LQGXFWLRQGH%&*SXLVXQHQRXYHOOHUppYD-
OXDWLRQHQGRVFRSLTXHjPRLVDYHFGHVELRSVLHVVHQVLELOLVpHV
SDUOXPLQRÁXRUHVFHQFH>@,OHVWUHFRPPDQGpG·pOLPLQHU
XQHOpVLRQGHO·XUqWUHHWRXGXKDXWGHO·DSSDUHLOXULQDLUHj
O·RULJLQHGHODUpFLGLYH>@
/RUVTXHGX&,6HVWSUpVHQWVXUOHVELRSLVHVYpVLFDOHVDSUqV
 F\FOHV G·LQGXFWLRQ LO V·DJLUD G·XQ pFKHF GX %&* HW XQH
F\VWHFWRPLHWRWDOHVHUDLQGLTXpH>@/RUVTXHODF\VWHFWRPLH
• /DVWDGLÀFDWLRQJDQJOLRQQDLUH1SDUO·XUR7'0UHSRVH
XQLTXHPHQWVXUGHVFULWqUHVPRUSKRORJLTXHVQRWDPPHQW
GHSHWLWD[HJDQJOLRQQDLUHHWQHSHUPHWSDVOHGLDJQRVWLF
GHV PLFURPpWDVWDVHV$LQVL OD VHQVLELOLWp GX VFDQQHU
SRXUODGpWHFWLRQGHVHQYDKLVVHPHQWVJDQJOLRQQDLUHVHVW
IDLEOHYDULDQWVHORQOHVpWXGHVHQWUHHWDYHFXQH
VSpFLÀFLWpVHVLWXDQWHQWUHHW>@
IRM de vessie multiparamétrique
• /HVSHUIRUPDQFHVGHO·,50SRXUODVWDGLÀFDWLRQORFDOH7
GH OD WXPHXU YpVLFDOH VRQW QHWWHPHQW VXSpULHXUHV j
HVWGpFLGpHHOOHGRLWrWUHUpDOLVpHVDQVGpODLPRLV(Q
FDVGHUHIXVRXG·LQpOLJLELOLWpjODF\VWHFWRPLHXQQRXYHDX
F\FOHG·LQGXFWLRQGH%&*RXO·LQFOXVLRQGDQVXQHVVDLFOLQLTXH
SHXWrWUHSURSRVp
TVIM
/DSULVHHQFKDUJHGHV79,0HVWUpVXPpHGDQVO·RUJDQLJUDPPH
en Figure 4.
O·XUR7'0 HW SHUPHWWHQW GH IDLUH OD GLIIpUHQFH HQWUH
WXPHXUVVXSHUÀFLHOOHVHWLQÀOWUDQWHVDYHFGHVVHQVLELOLWpV
SRROpHVGHO·RUGUHGHHWGHVVSpFLÀFLWpVSRROpHV
GH O·RUGUH GH  >@ /HV GRQQpHV OHV SOXV
UpFHQWHVFRQFHUQDQWOHVSHUIRUPDQFHVGLDJQRVWLTXHVGH
O·,50GHYHVVLHVRQWUpVXPpHVGDQVO·$QQH[H
• /D UpDOLVDWLRQ G·XQH ,50 YpVLFDOH PXOWLSDUDPpWULTXH
DYDQW UpVHFWLRQ HVW VRXKDLWDEOH SRXU OH ELODQ GH WRXWH
WXPHXUGHYHVVLHVLOHVGpODLVG·REWHQWLRQGHO·H[DPHQ
QHUHWDUGHQWSDVODSULVHHQFKDUJHGXSDWLHQW>@
6 05RXSUrWHWDO

TVIM

Bilan d’extension
TDM TAP +/- IRM de vessie

TVIM localement avancée

TVIM localisée (T4 N0 M0) TVIM métastatique
T2-T3 N0 M0 ou avec atteinte gg M+
(T2-T4 N+ MO)
Tumeur unifocale, T2,
sans Cis, ni hydronéphrose
Patient fit Patient unfit Patient fit Patient unfit Patient fit Patient unfit

Chimiothérapie Chimiothérapie
Traitement Traitement CNA
Chimiothérapie Gemcitabine Chimiothérapie Gemcitabine
standard trimodal + Cystectomie
d’induction + Carbo (sels de platine)* - Carbo*
recommandé cystectomie
OU Gemcitabine OU Gemcitabine
* si patients sans progression après la première
ligne de chimiothérapie (maladie stable ou en réponse),
l’avelumab en entretien a montré un bénéfice en survie
globale (en attente de mise à disposition de la molécule)
Si pT3-T4
Si pT3-T4
et/ou pN+ : Si bonne réponse :
et/ou pN+ :
surveillance ou discuter traitement local
discuter CA Seconde ligne :
essai clinique
Pembrolizumab

Traitement Traitement Chimiothérapie Traitement Essai clinique

Alternatives palliatif palliatif (sels de platine) palliatif
thérapeutiques Essai clinique Traitement
Essai clinique Essai clinique Essai clinique Essai clinique palliatif

Figure 4. Arbre décisionnel de la gestion des TVIM.

Patient ÀWFODLUDQFHGHODFUpDWLQLQH•P/PQHW36
Patient XQÀWFODLUDQFHGHODFUpDWLQLQHP/PQRX36•
1$&= FKLPLRWKpUDSLHQpRDGMXYDQWH$& FKLPLRWKpUDSLHDGMXYDQWH

Scintigraphie osseuse
/DUHFKHUFKHGHORFDOLVDWLRQVVHFRQGDLUHVRVVHXVHVQ·HVWSDV
V\VWpPDWLTXHHWGRLWrWUHUpDOLVpHHQSUpVHQFHGHV\PSW{PHV
FOLQLTXHVpYRFDWHXUV>@
• /HV SHUIRUPDQFHV GH OD 7(3 SRXU OD GpWHFWLRQ GHV
JDQJOLRQVFKH]OHV79,0DYDQWF\VWHFWRPLHVRQWpTXLYD-
OHQWHVjO·LPDJHULHFRQYHQWLRQQHOOHDYHFXQHVHQVLELOLWp
GH O·RUGUH GH  HW XQH VSpFLILFLWp G·HQYLURQ
>@
• &KH]FHUWDLQVSDWLHQWVjULVTXHPpWDVWDWLTXHVLJQLÀFDWLI
OD7(37'0DX)'*SHXWrWUHHQYLVDJpHDSUqVYDOLGDWLRQ
7RPRJUDSKLHSDUpPLVVLRQVGHSRVLWRQV7(3 HQUpXQLRQGHFRQFHUWDWLRQSOXULGLVFLSOLQDLUH5&3DYHF
GDQVXQHPpWDDQDO\VHUpFHQWHGHVVHQVLELOLWpHWVSp-
• ­ O·KHXUH DFWXHOOH LO Q·\ D SDV GH SODFH SRXU OD7(3 FLÀFLWpGHHWSRXUODGpWHFWLRQGHVPpWDVWDVHV
7'0 GDQV OH ELODQ G·H[WHQVLRQ GHV WXPHXUV YpVLFDOHV jGLVWDQFH>@
LQÀOWUDQWHVHQGHKRUVG·pWXGHVFOLQLTXHV>@
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU
Scanner cérébral
• /DUHFKHUFKHGHORFDOLVDWLRQVVHFRQGDLUHVFpUpEUDOHVQ·HVW
SDV V\VWpPDWLTXH HW GRLW rWUH UpDOLVpH HQ SUpVHQFH GH
V\PSW{PHVFOLQLTXHVpYRFDWHXUV>@
• /·,50 FpUpEUDOH HW O·,50 GX FRUSV HQWLHU VRQW GHV
DOWHUQDWLYHVSRVVLEOHVDXVFDQQHUQRWDPPHQWHQFDVGH
6
GH YDOLGHU O·LQGLFDWLRQ GH F\VWHFWRPLH (Q FDV GH
WXPHXU77LOHVWSRVVLEOHGHSURSRVHUXQHpYDOXDWLRQ
WRPRGHQVLWRPpWULTXHDSUqVOHVGHX[SUHPLqUHVFXUHVGH
FKLPLRWKpUDSLH
8QH GL]DLQH G·HVVDLV WKpUDSHXWLTXHV VRQW HQ FRXUV
DÀQ G·pYDOXHU OD SODFH GH O·LPPXQRWKpUDSLH HQ VLWXDWLRQ
QpRDGMXYDQWHVHXOHRXHQFRPELQDLVRQFKH]FHVSDWLHQWV
FRQWUHLQGLFDWLRQ7DEOHDXGHUHFRPPDQGDWLRQ TX·LOV VRLHQW ÀW ou XQÀW DX FLVSODWLQH FOLQLFDOWULDOVJRY
$QQH[H
Tableau de recommandation 11
5HFRPPDQGDWLRQVELODQG·H[WHQVLRQ Niveau 7UDLWHPHQWFKLUXUJLFDOF\VWHFWRPLH
d’une TVIM
Indications et délai
)DLUHXQHXUR7'0DYHFLQMHFWLRQGHSURGXLW Fort • /D F\VWHFWRPLH SUpFpGpH G·XQH FKLPLRWKpUDSLH QpR
GHFRQWUDVWHLRGpHWWHPSVWDUGLIH[FUpWRLUH DGMXYDQWH j EDVH GH VHOV GH SODWLQH HVW OH WUDLWHPHQW
FRXSOpjXQVFDQQHUWKRUDFLTXH FXUDWLIGHUpIpUHQFH>@
)DLUHXQH,50GHYHVVLHPXOWLSDUDPpWULTXH )DLEOH • /D FKLPLRWKpUDSLH QpRDGMXYDQWH RX OD F\VWHFWRPLH
DYDQWUpVHFWLRQVLFHODQHUHWDUGHSDVODSULVH
HQFKDUJHGXSDWLHQW
Prise en charge des TVIM localisées
UDGLFDOHHQO·DEVHQFHGHFKLPLRWKpUDSLHQpRDGMXYDQWH
GRLW rWUH SURSRVpH GDQV XQ GpODL RSWLPDO LQIpULHXU j
VHPDLQHVHWPD[LPDOGHVHPDLQHVDSUqVOHGLDJQRVWLF
GH79,0>@
• /RUVTX·XQH FKLPLRWKpUDSLH QpRDGMXYDQWH D pWp HIIHF-
7710 WXpHODSULVHHQFKDUJHFKLUXUJLFDOHGRLWrWUHUpDOLVpH
GDQV OHV  j  VHPDLQHV DSUqV OD GHUQLqUH FXUH GH
/DSULVHHQFKDUJHGHV79,0ORFDOLVpHVUHSRVHVXUXQWUDLWH FKLPLRWKpUDSLH>@.
PHQW ORFDO LGpDOHPHQW SUpFpGp G·XQH FKLPLRWKpUDSLH
QpRDGMXYDQWH Aspects techniques
3RXUOHVKLVWRORJLHVQRQXURWKpOLDOHVFDUFLQRPHpSLGHU-
PRwGH DGpQRFDUFLQRPH FDUFLQRPH QHXURHQGRFULQH OHV 9RLHG·DERUG
recommandations sont différentes et sont résumées dans • /DF\VWHFWRPLHSHXWrWUHUpDOLVpHSDUYRLHRXYHUWHRXSDU
O·$QQH[H YRLHF±OLRVFRSLTXHVLPSOHRXURERWDVVLVWpH
• /HV YRLHV G·DERUG RXYHUWHV HW PLQLLQYDVLYHV SDU YRLH
F±OLRVFRSLTXHVLPSOHRXURERWDVVLVWpHVRQWpTXLYDOHQWHV
Traitement néo-adjuvant VXUOHSODQRQFRORJLTXH>@
• Pour les tumeurs très volumineuses ou localement avan-
• /DFKLPLRWKpUDSLHQpRDGMXYDQWHDSRXUREMHFWLIV FpHVODYRLHRXYHUWHHVWjSULYLOpJLHU
Ⱦ G·pUDGLTXHUOHVPLFURPpWDVWDVHVHWG·pYLWHUO·LPSODQ- • ,OH[LVWHXQDYDQWDJHjODYRLHPLQLLQYDVLYHHQWHUPHV
tation de cellules tumorales circulantes au moment de GH SHUWHV VDQJXLQHV DYHF XQ WDX[ GH FRPSOLFDWLRQV
ODFKLUXUJLH FRPSDUDEOH>@
Ⱦ de réduire la taille de la tumeur et de faciliter le geste
FKLUXUJLFDO 7HFKQLTXHRSpUDWRLUH
Ⱦ GHSURORQJHUODVXUYLHGXSDWLHQW>@ • 8QHpYDOXDWLRQGHODIRQFWLRQVH[XHOOHGHVSDWLHQWVHVW
• (OOHHVWUHFRPPDQGpHSRXUGHVSDWLHQWVHQFDSDFLWpGH UHFRPPDQGpH DÀQ G·DGDSWHU OD WHFKQLTXH RSpUDWRLUH
UHFHYRLU XQH SRO\FKLPLRWKpUDSLH j EDVH GH FLVSODWLQH ,,()FKH]O·KRPPH)6),FKH]ODIHPPH
F·HVWjGLUH • (Q DXFXQ FDV OD SUpVHUYDWLRQ GH OD VH[XDOLWp QH GRLW
Ⱦ SDWLHQWVDYHFXQHFODLUDQFHGHODFUpDWLQLQHVXSpULHXUH FRPSURPHWWUHODTXDOLWpFDUFLQRORJLTXHGHODFKLUXUJLH
jP/PLQ • Chez l’hommeXQHF\VWRSURVWDWHFWRPLHWRWDOHLQFOXDQW
ET O·H[pUqVHGHODSURVWDWHHWGHVYpVLFXOHVVpPLQDOHVHVW
Ⱦ SDWLHQWV206RX UHFRPPDQGpH 8QH SUpVHUYDWLRQ QHUYHXVH HW JpQLWDOH
• 3RXU GHV SDWLHQWV D\DQW XQH IRQFWLRQ UpQDOH HQWUH  SHXW rWUH UpDOLVpH FKH] GHV SDWLHQWV ELHQ VpOHFWLRQ-
HW  P/PLQ O·LQGLFDWLRQ GH OD FKLPLRWKpUDSLH QpR QpV SDWLHQWV D\DQW XQH PDODGLH ORFDOLVpH >F7@ j
DGMXYDQWHSHXWrWUHGLVFXWpHDXFDVSDUFDVHQ5&3 GLVWDQFH GX FRO YpVLFDO GH OD SURVWDWH RX GH O·XUqWUH
• 'DQVOHFDVGHSDWLHQWVGLWV©XQÀWªSRXUXQHFKLPLR
WKpUDSLH QpRDGMXYDQWH RSWLPDOH VRLW GX IDLW G·XQH
fonction rénale altérée, soit du fait d’un mauvais état
JpQpUDORXG·XQkJHQHSHUPHWWDQWSDVO·XWLOLVDWLRQG·XQ
SURWRFROHRSWLPDOODF\VWHFWRPLHVHXOHHVWLQGLTXpH
• 8QHUppYDOXDWLRQSDU7'07$3HVWUHFRPPDQGpHDSUqV
OD GHUQLqUH FXUH GH FKLPLRWKpUDSLH QpRDGMXYDQWH
SURVWDWLTXH>@
• Chez la femme  XQH SHOYHFWRPLH DQWpULHXUH
HPSRUWDQWODYHVVLHO·XWpUXVHWODIDFHDQWpULHXUHGX
YDJLQ HVW UHFRPPDQGpH 8QH SUpVHUYDWLRQ QHUYHXVH
HW JpQLWDOH SHXW rWUH UpDOLVpH FKH] GHV SDWLHQWHV
ELHQ VpOHFWLRQQpHV SDWLHQWHV D\DQW XQH WXPHXU
ORFDOLVpH>F7@jGLVWDQFHGXFROGXWULJRQHRXGHOD
DILQ GH V·DVVXUHU GH O·DEVHQFH GH SURJUHVVLRQ HW IDFHSRVWpULHXUH>@
S116 05RXSUrWHWDO

([DPHQVH[WHPSRUDQpV Compte-rendu anatomopathologique type

• /·H[DPHQGHVUHFRXSHVXUpWpUDOHVQ·HVWSDVUHFRPPDQGp • /HFRPSWHUHQGXDQDWRPRSDWKRORJLTXHW\SHGRLWFRP-
V\VWpPDWLTXHPHQW ,O GRLW rWUH UpDOLVp HQ FDV G·K\GUR SRUWHUXQHSDUWLHPDFURVFRSLHHWXQHSDUWLHKLVWRORJLH
QpSKURVHGHWXPHXUPXOWLIRFDOHRXGH&,6DVVRFLp>@. • /DSUpVHQFHGHYDULDQWVKLVWRORJLTXHVGRLWrWUHSUpFLVpH
• 8QH[DPHQH[WHPSRUDQpGHODUHFRXSHXUpWUDOHRULHQWpH • /HVFODVVLÀFDWLRQVPROpFXODLUHVVRQWSURPHWWHXVHVHWXQ
SRXUIDFLOLWHUO·DQDO\VHDQDWRPRSDWKRORJLTXHHVWUHFRP-
PDQGpORUVTX·XQHHQWpURF\VWRSODVWLHHVWHQYLVDJpHRXHQ
cas de doute sur l’indication d’urétrectomie.
Urètre
FRQVHQVXVVHPEOHDYRLUpWpWURXYpPDLVHOOHVQHVRQWSDV
HQFRUHDGDSWpHVjODSUDWLTXHFOLQLTXH>@
Optimisation préopératoire et postopératoire
• /·LQFOXVLRQ GH WRXV OHV SDWLHQWV GDQV XQ SURWRFROH GH
• Une urétrectomie est recommandée en cas de marges
XUpWUDOHV SRVLWLYHV HQ FDV G·HQYDKLVVHPHQW PDVVLI GH
O·XUqWUH SURVWDWLTXH FKH] O·KRPPH HQ FDV G·HQYDKLV
sement du col vésical ou de l’urètre chez la femme.
• /·XUpWUHFWRPLHSHXWrWUHUpDOLVpHGDQVOHPrPHWHPSV
RXGHPDQLqUHGLIIpUpH>@.
Curage ganglionnaire
• 8Q FXUDJH JDQJOLRQQDLUH SHOYLHQ pWHQGX LQFOXDQW OHV
UpJLRQVREWXUDWULFHVLOLDTXHVH[WHUQHVLOLDTXHVLQWHUQHV
HW LOLDTXHV SULPLWLYHV GLVWDOHV HQ UHPRQWDQW MXVTX·DX
croisement des uretères, est recommandé au cours de
ODF\VWHFWRPLH>@
• ,O Q·\ D SDV GH EpQpÀFH FDUFLQRORJLTXH j UHPRQWHU OH
UpFXSpUDWLRQDPpOLRUpHDSUqVFKLUXUJLH5$$&HVWUHFRP-
PDQGpHVXLYDQWOHSURWRFROHGHO·$VVRFLDWLRQ)UDQoDLVH
G·8URORJLH>@
• /D5$$&DSRXUREMHFWLIGHUpGXLUHOHWDX[GHFRPSOL-
FDWLRQVSRVWRSpUDWRLUHVHWGHUpGXLUHODGXUpHGHVpMRXU
GHVSDWLHQWV>@
• /·HQVHPEOHGHVPHVXUHVWHFKQLTXHVUHFRPPDQGpHVVRQW
GpWDLOOpHVGDQVOH7DEOHDX
• 3OXVODUJHPHQWO·RSWLPLVDWLRQSpULRSpUDWRLUHQpFHVVLWH
ODPLVHHQSODFHG·XQSDUFRXUVSDWLHQWELHQGpÀQL
• /·pYDOXDWLRQRQFRJpULDWULTXHHVWUHFRPPDQGpHSRXUOHV
SDWLHQWVGRQWOHVFRUH*HVW”>@
FXUDJHMXVTX·jODELIXUFDWLRQDRUWLTXH>@ 7UDLWHPHQWWULPRGDO770

Dérivation urinaire • /H770HVWXQWUDLWHPHQWFXUDWLIGHSUpVHUYDWLRQYpVLFDOH

• /HFKRL[GXPRGHGHGpULYDWLRQXULQDLUHGRLWrWUHSULVHQ TXLSHXWrWUHSURSRVpHQFDVGH
DFFRUGDYHFOHSDWLHQWFRUUHFWHPHQWLQIRUPp(QO·DEVHQFH Ⱦ WXPHXUXQLIRFDOH
GHFRQWUHLQGLFDWLRQO·HQWpURF\VWRSODVWLHGRLWrWUHV\VWp- Ⱦ VWDGH7PD[LPXP
PDWLTXHPHQWSURSRVpHFKH]O·KRPPHHWFKH]ODIHPPH Ⱦ DEVHQFHGH&,6
• /·XUpWpURVWRPLH FXWDQpH WUDQVLOpDOH GH W\SH %ULFNHU Ⱦ DEVHQFHG·K\GURQpSKURVH
HW O·HQWpURF\VWRSODVWLH VRQW OHV GpULYDWLRQV XULQDLUHV j Ⱦ UpVHFWLRQFRPSOqWHSRVVLEOH
SULYLOpJLHU Ⱦ HQO·DEVHQFHG·DOWpUDWLRQIRQFWLRQQHOOHPDMHXUHGHODYHVVLH
• (QFDVG·HQWpURF\VWRSODVWLHODSUpVHUYDWLRQQHUYHXVHHW Ⱦ FKH] XQ SDWLHQW ELHQ LQIRUPp HW FRPSOLDQW VXLYL
JpQLWDOHHVWDVVRFLpHjXQHDPpOLRUDWLRQGHODFRQWLQHQFH ULJRXUHX[>@
FKH]O·KRPPH>@HWFKH]ODIHPPH>@ • /HVUpVXOWDWVFDUFLQRORJLTXHVVRQWLGHQWLTXHVjFHX[GHOD
• /HV FRQWUHLQGLFDWLRQV IRUPHOOHV j OD FRQIHFWLRQ G·XQH F\VWHFWRPLHFKH]OHVSDWLHQWVTXLUpSRQGHQWjFHVFULWqUHV
HQWpURF\VWRSODVWLHVRQW GHVpOHFWLRQ>@
Ⱦ un envahissement de l’urètre (ou du col vésical chez • (QGHKRUVGHFHVLQGLFDWLRQVOH770SHXWrWUHSURSRVp
ODIHPPH HQDOWHUQDWLYHWKpUDSHXWLTXHjODF\VWHFWRPLHWRWDOHFKH]
Ⱦ XQHDOWpUDWLRQGHVIRQFWLRQVFRJQLWLYHVHWGHVWURXEOHV GHVSDWLHQWVLQpOLJLEOHVjODFKLUXUJLHHQUDLVRQGHOHXUV
SV\FKLDWULTXHV FRPRUELGLWpV /HV UpVXOWDWV FDUFLQRORJLTXHV VRQW GDQV
Ⱦ XQHSDWKRORJLHLQÁDPPDWRLUHGHO·LQWHVWLQ FHFDVLQIpULHXUVjFHX[GHODF\VWHFWRPLH>@
Ⱦ GHVDQWpFpGHQWVG·LUUDGLDWLRQSHOYLHQQHjIRUWHGRVH • Le TTM associe :
Ⱦ ODSUpVHQFHG·XQHLQVXIÀVDQFHUpQDOHDYDQFpHP/ Ⱦ XQWUDLWHPHQWORFDOSDUUpVHFWLRQWUDQVXUpWUDOHGHYHVVLH
PLQ DXPLHX[FRPSOqWHVLQRQPD[LPDOLVWH
Ⱦ XQHHVSpUDQFHGHYLHOLPLWpHGXSDWLHQW Ⱦ VXLYL G·XQH UDGLRWKpUDSLH H[WHUQH HQ SULYLOpJLDQW OHV
• ­FHODV·DMRXWHQWGHVFRQWUHLQGLFDWLRQVUHODWLYHV WHFKQLTXHVG·G·Intensity-Modulated Radiotherapy>,057@
Ⱦ âge > 75 ans (en raison des mauvais résultats en termes et d’Image Guided Radiation Therapy>,*57@>@
GHFRQWLQHQFH Ⱦ HWXQHFKLPLRWKpUDSLHUDGLRVHQVLELOLVDQWHFRQFRPLWDQWH
Ⱦ GLIÀFXOWpVSUpYLVLEOHVGHFRPSOLDQFHRXGHJHVWLRQGH GHSRWHQWLDOLVDWLRQjEDVHGHFLVSODWLQHÁXRURXUD-
O·HQWpURF\VWRSODVWLH FLOH0LWRP\FLQH&RXJHPFLWDELQH>@
Ⱦ GLIÀFXOWpVG·RUGUHDQDWRPLTXH • 8QH FKLPLRWKpUDSLH QpRDGMXYDQWH Q·HVW SDV UHFRP
• (QFDVGHFRQWUHLQGLFDWLRQjO·HQWpURF\VWRSODVWLHGXIDLW PDQGpHGHPDQLqUHV\VWpPDWLTXHFKH]GHVSDWLHQWVELHQ
d’un envahissement tumoral de l’urètre, une dérivation VpOHFWLRQQpVPDLVSHXWrWUHSURSRVpHDXFDVSDUFDVHW
H[WHUQH FRQWLQHQWH SRXUUD rWUH GLVFXWpH FKH] XQH VHORQOHVPrPHVPRGDOLWpVTX·DYDQWWUDLWHPHQWORFDOSDU
SDWLHQWHFDSDEOHGHV·DXWRVRQGHU FKLUXUJLH>@
• /·XUpWpURVWRPLH FXWDQpH ELODWpUDOH GRLW rWUH pYLWpH HW • /H VXLYL SRVW770 UHSRVH VXU OD F\WRORJLH XULQDLUH OD
UpVHUYpHDX[F\VWHFWRPLHVSDOOLDWLYHVRXORUVTXHO·pWDW F\VWRVFRSLHOHVFDQQHU7$3WRXVOHVPRLVSHQGDQWDQV
GXSDWLHQWQHSHUPHWSDVXQDXWUHPRGHGHGpULYDWLRQ SXLVWRXVOHVPRLVMXVTX·jDQVSXLVDQQXHOOHjYLH
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

Tableau 7. 3URWRFROHGHUpKDELOLWDWLRQSpULRSpUDWRLUHSRXUXQHUpFXSpUDWLRQDPpOLRUpHDSUqVFKLUXUJLH5$$&

Critères RAAC 6SpFLÀFLWpVSRXUOHVF\VWHFWRPLHV
PRÉOPÉRATOIRE
,QIRUPDWLRQSDWLHQWV $LGHDXVHYUDJHWDEDJLTXH
,QIRUPDWLRQVXUOHVGpULYDWLRQVXULQDLUHVHWOHSDUFRXUVGHVRLQV
2SWLPLVDWLRQPpGLFDOH
HWSUpKDELOLWDWLRQ
eTXLOLEUDWLRQGHVSDWKRORJLHVFKURQLTXHV+E$F%3&2FDUGLRYDVFXODLUH
.LQpVLWKpUDSLHSRXUUHQIRUFHPHQWPXVFXODLUHSUpSDUDWLRQUHVSLUDWRLUHHWSpULQpDOH
VLHQWpURF\VWRSODVWLH
3ULVHHQFKDUJHGHVEHVRLQVSV\FKRVRFLDX[
Traitement des anémies
3UpSDUDWLRQQXWULWLRQQHOOH ,PPXQRQXWULWLRQSUpRSpUDWRLUH2UDO,PSDFW
%LODQQXWULWLRQQHOV\VWpPDWLTXHSHUWHGHSRLGV,0&DOEXPLQHFDOFXOGXJUDGH
nutritionnel)
3UpSDUDWLRQPpFDQLTXH $EVHQFHGHSUpSDUDWLRQGLJHVWLYH
GXF{ORQ
'XUpHGXMH€QHSUpRSpUDWRLUH /LTXLGHVFODLUVMXVTX·jKHXUHVDYDQWO·LQWHUYHQWLRQ
&KDUJHJOXFLGLTXH 50 g le matin, 2 h avant l’intervention
SUpRSpUDWRLUH
7KURPERSURSK\OD[LH %DVGHFRQWHQWLRQ
Prémédication $EVHQFHGHSUpPpGLFDWLRQ
PEROPÉRATOIRE
Chirurgie
Chirurgie mini-invasive eTXLYDOHQFHFDUFLQRORJLTXHGHODYRLHPLQLLQYDVLYHDYHFEpQpÀFHVXUOHVSHUWHV
sanguines
'UDLQDJHSHOYLHQ 'XUpHHWFULWqUHVGHUHWUDLWQRQpWDEOLV
Anesthésie
3UpYHQWLRQGHO·K\SRWKHUPLH 6\VWqPHGHUpFKDXIIHPHQWDFWLI
2SWLPLVDWLRQGHODYROpPLH (QO·DEVHQFHGHWUDQVIXVLRQSHURSpUDWRLUHDSSRUWVOLTXLGLHQVLQWUDYHLQHX[
SHURSpUDWRLUHV”P/NJK
3DVGHGLXUqVHSHURSpUDWRLUH
Anesthésie locorégionale 3pULGXUDOHWKRUDFLTXHRX[\ORFDwQH,9EORFSDULpWDO
Médicaments de l’anesthésie Monitorage de la décurarisation
Prévention des nausées 6FRUHG·$SIHOHWGH[DPpWKDVRQHjO·LQGXFWLRQ
et vomissements
SRVWRSpUDWRLUHV
9HQWLODWLRQDUWLÀFLHOOH 9ROXPHFRXUDQWP/NJGHSRLGVLGpDO
SURWHFWULFH PEEP 6-8 cm d’eau
7KURPERSURSK\OD[LH %DVGHFRQWHQWLRQ
$QWLELRSURSK\OD[LH Protocole SFAR-AFU
POSTOPÉRATOIRE
5HWUDLWSUpFRFHGHODVRQGH 5HWUDLWGHODVRQGHQDVRJDVWULTXHHQSRVWRSpUDWRLUHLPPpGLDWRXHQVDOOHGHUpYHLO
QDVRJDVWULTXH
Prévention de l’iléus &KHZLQJJXP•IRLVMRXUj-MXVTX·jODUHSULVHGXWUDQVLW
5pDOLPHQWDWLRQSUpFRFH %RLVVRQVXFUpHRXQXWULPHQWVOLTXLGHV”-
Drainage urinaire 6RQGDJHXUpWpUDOPRGDOLWpVHWGXUpHQRQpWDEOLHV
6RQGDJHXUpWUDOQpRYHVVLHGXUpHQRQpWDEOLH
Analgésie multimodale •PROpFXOHVQRQPRUSKLQLTXHVGHFODVVHVGLIIpUHQWHV
0RELOLVDWLRQSUpFRFH /HYpHHWPLVHDXIDXWHXLOj-
0DUFKHj-
7KURPERSURSK\OD[LH %DVGHFRQWHQWLRQKpSDULQHVGHEDVSRLGVPROpFXODLUH+%30
S118 05RXSUrWHWDO

• (QFDVGHUpFLGLYHDSUqV770 Tableau de recommandation 13

Ⱦ VXUXQPRGHQRQLQÀOWUDQWXQWUDLWHPHQWFRQVHUYDWHXU
SHXW rWUH SURSRVp VHORQ OHV PrPHV PRGDOLWpV TX·XQH
5HFRPPDQGDWLRQVFKLPLRWKpUDSLH Niveau
791,0G·HPEOpHUpVHFWLRQ²LQVWLOODWLRQV8QHF\V-
périopératoire
WHFWRPLHSHXWDXVVLrWUHGLVFXWpH>@
Ⱦ VXUXQPRGHLQÀOWUDQWXQHF\VWHFWRPLHGHUDWWUDSDJH Situation 36” 09$& Fort
GRLWrWUHSURSRVpH7DEOHDXGHUHFRPPDQGDWLRQ néo- et Clairance RX+'09$&
adjuvante •P/PLQ
RX*& )DLEOH
7DEOHDXGHUHFRPPDQGDWLRQ
5HFRPPDQGDWLRQVWUDLWHPHQW Niveau PS > 1 Pas de Fort
des TVIM localisées ou Clairance FKLPLRWKpUDSLH
P/PLQ QpRDGMXYDQWH
)DLUHXQHF\VWHFWRPLHSUpFpGpH Fort
G·XQHFKLPLRWKpUDSLHQpRDGMXYDQWHjEDVH À discuter )DLEOH
GHFLVSODWLQHWUDLWHPHQWFXUDWLIGHUpIpUHQFH DXFDVSDUFDV
si clairance
)DLUHODF\VWHFWRPLHSDUYRLHRXYHUWHRXSDU Fort entre 50-60 mL/
YRLHF±OLRVFRSLTXHVLPSOHRXURERWDVVLVWpH PLQ&'.(3,
)DLUHXQHpYDOXDWLRQGHODIRQFWLRQVH[XHOOH )DLEOH
Situation 36” 09$&RX*& Fort
FKH]O·KRPPHHWODIHPPHHWSURSRVHU
adjuvante et Clairance
XQHWHFKQLTXHGHSUpVHUYDWLRQVH[XHOOH
(tumeur •P/PLQ
HWJpQLWDOHFKH]OHVSDWLHQWVELHQVpOHFWLRQQpV
pT3-T4
)DLUHXQFXUDJHJDQJOLRQQDLUHSHOYLHQpWHQGX Fort HWRXS1 PS > 1 Pas )DLEOH
TXHOOHTXHVRLWODYRLHG·DERUGDXFRXUV ou Clairance GHFKLPLRWKpUDSLH
GHODF\VWHFWRPLH P/PLQ DGMXYDQWH

)DYRULVHUODPLVHHQSODFHGHSURWRFROHV Fort À discuter )DLEOH

GHUpFXSpUDWLRQDPpOLRUpHDSUqVFKLUXUJLH DXFDVSDUFDV
si clairance
'HPDQGHUXQHpYDOXDWLRQRQFRJpULDWULTXH )DLEOH entre 50-60 mL/
HQFDVGH79,0FKH]XQVXMHWGHSOXV
GHDQVHWRXVLVFRUH*”
3URSRVHUXQWUDLWHPHQWFRQVHUYDWHXUWULPRGDO Fort
DVVRFLDQW5789FRPSOqWHUDGLRWKpUDSLH
HWFKLPLRWKpUDSLHUDGLRVHQVLELOLVDQWHHQFDV
GHWXPHXUXQLIRFDOHGHVWDGH7VDQV&,6
QLK\GURQpSKURVH
Traitements adjuvants
Chimiothérapie adjuvante
/·XWLOLVDWLRQGHODFKLPLRWKpUDSLHSRVWRSpUDWRLUHUHVWHGpEDW-
WXHDXFXQHVVDLQ·D\DQWODSXLVVDQFHQpFHVVDLUHSRXUFRQÀU-
PHUO·LQWpUrWG·XQHFKLPLRWKpUDSLHSRVWRSpUDWRLUH>@
• /D FKLPLRWKpUDSLH DGMXYDQWH SHXW rWUH LQGLTXpH SRXU
XQ SDWLHQW Q·D\DQW SDV UHoX GH FKLPLRWKpUDSLH QpR
DGMXYDQWHHQFDVGHWXPHXUjKDXWULVTXHGHUpFLGLYH
VXU OHV GRQQpHV GH O·DQDO\VH DQDWRPRSDWKRORJLTXH HW
QRWDPPHQWVWDGHS7HWS7VWDWXWJDQJOLRQQDLUH1
PDUJHV FKLUXUJLFDOHV SRVLWLYHV HQ pYDOXDQW OD EDODQFH
EpQpÀFHULVTXHHWVHXOHPHQWVLODIRQFWLRQUpQDOHSHUPHW
O·XWLOLVDWLRQGXFLVSODWLQH>@
• 3RXUGHVSDWLHQWVD\DQWXQHIRQFWLRQUpQDOHHQWUHHW
P/PLQO·LQGLFDWLRQGHODFKLPLRWKpUDSLHDGMXYDQWH
SHXW rWUH GLVFXWpH DX FDV SDU FDV HQ 5&3 7DEOHDXGH
recommandation 13).
PLQ&'.(3,
Alternatives thérapeutiques
Cystectomie partielle
• (OOHSHXWrWUHSURSRVpHHQFDVGH
Ⱦ OpVLRQXQLIRFDOHHWSULPLWLYHG·XQHSRUWLRQPRELOHGHOD
YHVVLHjSOXVGHFPGXFROHWGXWULJRQHDEVHQFHGH
&,6WDLOOH”FPVWDGH7DPD[LPXP
Ⱦ WXPHXULQWUDGLYHUWLFXODLUH>@
Ⱦ DGpQRFDUFLQRPHGHO·RXUDTXH>@
• (OOHGRLWrWUHDVVRFLpHjXQFXUDJHJDQJOLRQQDLUHVHORQOHV
PrPHVPRGDOLWpVTXHORUVG·XQHF\VWHFWRPLHWRWDOH>@
• /D YRLH G·DERUG SHXWrWUH RXYHUWH RX PLQLLQYDVLYH
>@
Radiothérapie seule
• 5DGLRWKpUDSLHVHXOHjYLVpHFXUDWLYH
Ⱦ (IÀFDFLWp OLPLWpH ORUVTX·HOOH Q·HVW SDV DVVRFLpH j XQH
FKLPLRWKpUDSLHVHQVLELOLVDQWHFRQFRPLWDQWH>@
Ⱦ 'LVFXWpH XQLTXHPHQW HQ FDV GH FRQWUHLQGLFDWLRQ
j OD FKLUXUJLH UDGLFDOH HW GH FRQWUHLQGLFDWLRQ j OD
FKLPLRWKpUDSLH
• 5DGLRWKpUDSLHKpPRVWDWLTXHjYLVpHSDOOLDWLYH
Ⱦ %RQQHHIÀFDFLWpLQLWLDOHPDLVPRGHVWHGDQVOHWHPSV
Radiothérapie adjuvante
/DUDGLRWKpUDSLHDGMXYDQWHHVWDFWXHOOHPHQWHQFRXUVG·pYD-
OXDWLRQGDQVOHFDGUHG·HVVDLVFOLQLTXHVFKH]OHVSDWLHQWVS7
7HWRXS1>@
PpGLDQHjPRLV>@
Ⱦ 'LVFXWpHHQFDVGHFRQWUHLQGLFDWLRQjO·DQHVWKpVLHRX
G·pFKHFGHO·KpPRVWDVHHQGRVFRSLTXHHWHQFDVG·HVSp-
rance de vie limitée.
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

Chirurgie palliative • /H FKRL[ WKpUDSHXWLTXH YD WHQLU FRPSWH GHV IDFWHXUV
• /HV 5789 LWpUDWLYHV SHXYHQW rWUH SURSRVpHV FKH] OHV
SDWLHQWVQRQpOLJLEOHVjODF\VWHFWRPLHRXjXQWUDLWHPHQW
WULPRGDODYHFXQHHVSpUDQFHGHYLHFRXUWH
• /D F\VWHFWRPLH SDOOLDWLYH Q·HVW SDV UHFRPPDQGpH GH
SUHPLqUHLQWHQWLRQVDXIHQFDVGHWURXEOHVPLFWLRQQHOV
PDMHXUV RX G·KpPDWXULH GpJOREXOLVDQWH QRQ FRQWU{OpH
F·HVWjGLUHDSUqVpFKHFGHVVWUDWpJLHVKpPRVWDWLTXHV
UpVHFWLRQSDOOLDWLYHUDGLRWKpUDSLHKpPRVWDWLTXHHPER-
SURQRVWLTXHVTXHVRQWO·pWDWJpQpUDODOWpUp36!HWOD
SUpVHQFHGHPpWDVWDVHVYLVFpUDOHV>@
Chimiothérapie de première ligne
• /HSURWRFROHVWDQGDUGLQLWLDOGHWUDLWHPHQWGHSUHPLqUH
OLJQH GDQV OHV WXPHXUV XURWKpOLDOHV PpWDVWDWLTXHV HVW
OLVDWLRQDUWpULHOOH>@ OH PpWKRWUH[DWH YLQEODVWLQH GR[RUXELFLQH FLVSODWLQH
• /DGRXOHXUQ·HVWSDVXQHLQGLFDWLRQGHF\VWHFWRPLHSDO- 09$&OH09$&+'LQWHQVLÀpRXOHJHPFLWDELQH&''3
OLDWLYHHWGRLWrWUHJpUpHSDUXQHDQDOJpVLHPXOWLPRGDOH
DGDSWpH
• /·REVWUXFWLRQ GX KDXW DSSDUHLO XULQDLUH Q·HVW SDV XQH
LQGLFDWLRQGHF\VWHFWRPLHSDOOLDWLYHHWGRLWIDLUHSULYLOp-
JLHUXQHGpULYDWLRQXULQDLUHSDOOLDWLYHVDQVJHVWHYpVLFDO
*&DYHFXQHWR[LFLWpPRLQGUHSRXUXQHVXUYLHJOREDOH
pTXLYDOHQWHSRXUOH*&>@
• 3RXUOHVSDWLHQWVFRQVLGpUpVFRPPHLQpOLJLEOHVXQÀW) au
FLVSODWLQHVRLWGXIDLWG·XQHFODLUDQFHGHODFUpDWLQLQH
 P/PLQ VRLW GX IDLW G·XQH DOWpUDWLRQ GH O·pWDW
QpSKURVWRPLHXUpWpURVWRPLH JpQpUDO36!O·DOWHUQDWLYHHVWOHFDUERSODWLQH
• 3RXUOHVSDWLHQWVQRQpOLJLEOHVjXQHSRO\FKLPLRWKpUDSLH
XQHPRQRFKLPLRWKpUDSLHSDUJHPFLWDELQHDXQHHIÀFDFLWp
Prise en charge des TVIM PRGpUpHjGHUpSRQVHREMHFWLYHVXUYLHJOREDOH
avec envahissement ganglionnaire GHjPRLVDYHFXQHIDLEOHWR[LFLWp>@
7710 • /HVSDWLHQWVD\DQWXQpWDWJpQpUDOWUqVGpJUDGp36RX
Q·RQWDXFXQEpQpÀFHGHODFKLPLRWKpUDSLH
'H QRPEUHX[ HVVDLV VRQW HQ FRXUV j EDVH G·LPPXQR
Chimiothérapie d’induction et réévaluation WKpUDSLH HQ PRQRWKpUDSLH RX HQ DVVRFLDWLRQ SRXU GHV
SDWLHQWVÀW ouXQÀWDXFLVSODWLQH
• /HV SDWLHQWV DYHF DWWHLQWH JDQJOLRQQDLUH LQLWLDOH VXU OH 'DQVO·HVVDL-$9(/,1%ODGGHUO·DYpOXPDEDQWL3'
7'0RQWXQSURQRVWLFEHDXFRXSSOXVUpVHUYpFHG·DXWDQW /HQWUDLWHPHQWG·HQWUHWLHQSRXUGHVSDWLHQWVUpSRQGHXUV
TX·LOV RQW XQH DWWHLQWH UpWURSpULWRQpDOH vs atteinte jXQHSUHPLqUHOLJQHGHFKLPLRWKpUDSLHDSSRUWHXQEpQpÀFH
SHOYLHQQHVHXOH>@ HQ VXUYLH JOREDOH FKH] WRXV OHV SDWLHQWV TXHO TXH VRLW OH
• 8QHDSSURFKHPXOWLPRGDOHSHXWrWUHSURSRVpHDYHFXQH
FKLPLRWKpUDSLHSUHPLqUHDYHFXQHVXUYLHjDQVDOODQW
GHj>@
• /DFKLPLRWKpUDSLHG·LQGXFWLRQQ·HVWSDVXQHFKLPLRWKpUD-
SLHQpRDGMXYDQWHODSULVHHQFKDUJHSRVWFKLPLRWKpUDSLH
VWDWXW3'/PRLV vsPRLV>@'qVODPLVHj
GLVSRVLWLRQGHODPROpFXOHLO\DXUDXQHUHFRPPDQGDWLRQ
SRXUPHWWUHHQSODFHXQWUDLWHPHQWG·HQWUHWLHQDSUqVXQH
SUHPLqUHOLJQHGHFKLPLRWKpUDSLHFKH]WRXVOHVSDWLHQWVpWDQW
VRLWVWDEOHVRLWHQUpSRQVHSDUWLHOOHRXFRPSOqWH7DEOHDXGH
GRLWrWUHGLVFXWpHDXFDVSDUFDVHQIRQFWLRQGHO·H[WHQ- UHFRPPDQGDWLRQ
VLRQWXPRUDOHHWGHODUpSRQVHWKpUDSHXWLTXH

Stratégies de seconde ligne

Place de la chirurgie
• /H SHPEUROL]XPDE DQWL3'/ HVW UHFRPPDQGp HQ
• 8QHF\VWHFWRPLHWRWDOHDYHFFXUDJHGRLWrWUHSURSRVpH GHX[LqPHOLJQHGHWUDLWHPHQWGHVFDUFLQRPHVXURWKpOLDX[
FKH] OHV SDWLHQWV HQ UpSRQVH FRPSOqWH VXU OHV DGpQR DYHF XQ EpQpÀFH HQ VXUYLH JOREDOH vs FKLPLRWKpUDSLH
SDWKLHVSHOYLHQQHVF1VXUOD7'07$3GHUppYDOXDWLRQ (10,3 mois vsPRLV>@
DSUqVFKLPLRWKpUDSLHG·LQGXFWLRQHWFHTXHOOHTXHVRLW • /DYLQÁXQLQHDpWpODSUHPLqUHPROpFXOHTXLDREWHQX
ODPDVVHUpVLGXHOOHDXQLYHDXYpVLFDOH>@ une autorisation de mise sur le marché (AMM) dans
• &KH] OHV SDWLHQWV F1 VXU OD 7'0 GH UppYDOXDWLRQ FHWWHLQGLFDWLRQDYHFXQEpQpÀFHHQVXUYLHJOREDOHVXU
SRVWFKLPLRWKpUDSLHODF\VWHFWRPLHQ·HVWSDVUHFRP-
PDQGpH,OV·DJLWGHSDWLHQWVUpIUDFWDLUHVDX[VHOVGH
SODWLQH/DSULVHHQFKDUJHVHUDFHOOHG·XQHPDODGLH
PpWDVWDWLTXH
Traitement et Suivi des TVIM métastatiques
ODSRSXODWLRQpOLJLEOHPRLV vsPRLV(OOHQ·HVW
DFWXHOOHPHQWSOXVLQVFULWHVXUODOLVWHHQVXVFHTXLQH
SHUPHWSDVVRQXWLOLVDWLRQHQSUDWLTXHFRXUDQWH>@
• 3RXUOHVSDWLHQWVD\DQWHXXQHERQQHUpSRQVHDXFLVSOD-
WLQHHQSUHPLqUHOLJQHDYHFXQLQWHUYDOOHOLEUHGHSOXV
GHPRLVXQHQRXYHOOHVpULHGH09$&+'HVWSRVVLEOH
HQGHX[LqPHOLJQH>@
770 'HQRXYHOOHVYRLHVWKpUDSHXWLTXHVSURPHWWHXVHVVRQWHQ
FRXUV G·H[SORUDWLRQ DYHF OHV DQWL)*)5 FKH] GHV SDWLHQWV
• $X VWDGH PpWDVWDWLTXH OH WUDLWHPHQW UHSRVH VXU OD SUpVpOHFWLRQQpVVXUODSUpVHQFHG·DOWpUDWLRQVGXJqQHSDU
FKLPLRWKpUDSLH j EDVH GH FLVSODWLQH &''3 DYHF XQH VFUHHQLQJPROpFXODLUHHWpJDOHPHQWOHGpYHORSSHPHQWGHV
PpGLDQH GH VXUYLH GH  j  PRLV FKH] OHV SDWLHQWV LPPXQRFRQMXJXpVF\WRWR[LTXHV/·LQFOXVLRQGHVSDWLHQWVGDQV
pOLJLEOHVSRXUFHWWHFKLPLRWKpUDSLH>@ XQHVVDLWKpUDSHXWLTXHGRLWrWUHIDYRULVpH
S120 05RXSUrWHWDO

Tableau de recommandation 14 Surveillance des TVIM

5HFRPPDQGDWLRQVFKLPLRWKpUDSLH Niveau • /·LPDJHULHGHUpIpUHQFHGDQVODVXUYHLOODQFHG·XQH79,0HVW
de première ligne O·XUR7'0FRXSOpHDXVFDQQHUWKRUDFLTXH>@
• (QFDVGHFRQWUHLQGLFDWLRQjODUpDOLVDWLRQGHO·XUR7'0
Patients 36” 09$&RX*& Fort O·XUR,50 FRXSOpH j XQH 7'0 WKRUDFLTXH VDQV LQMHF-
ÀW Clairance WLRQ UHSUpVHQWH XQH H[FHOOHQWH DOWHUQDWLYH SRXU OD
•P/PLQ VXUYHLOODQFH>@
Patients Clairance &DUER Fort • &RPSWHWHQXGHVIDLEOHVQLYHDX[GHSUHXYHOD7(37'0
XQÀW P/PLQ *HPFLWDELQH DX)'*Q·HVWSDVUHFRPPDQGpHSRXUODVXUYHLOODQFH
QLHQFDVGHUpFLGLYH>@
PS > 1 *HPFLWDELQHVHXO )DLEOH • /DVXUYHLOODQFHGHODIRQFWLRQUpQDOHHVWLQGLVSHQVDEOH
ou soins de confort TXHOTXHVRLWOHPRGHGHGpULYDWLRQXULQDLUH>@
• (QFDVGHSUpVHUYDWLRQGHO·XUqWUHLOHVWUHFRPPDQGp
5HFRPPDQGDWLRQVFKLPLRWKpUDSLH Niveau GHOHVXUYHLOOHUSDUÀEURVFRSLH/DIUpTXHQFHGHODVXU-
de deuxième ligne YHLOODQFHHVWjDGDSWHUjO·H[DPHQDQDWRPRSDWKRORJLTXH
GH OD SLqFH GH F\VWHFWRPLH /D VXUYHLOODQFH GRLW rWUH
Patients 36 3HPEUROL]XPDE Fort SOXVIUpTXHQWHHQFDVGHIDFWHXUGHULVTXHGHUpFLGLYH
ÀW HQYDKLVVHPHQW GX VWURPD SURVWDWLTXH PXOWLIRFDOLWp
09$&+' )DLEOH
ORFDOLVDWLRQFHUYLFDOHHWSUpVHQFHGH&,6>@
RXYLQÁXQLQH
• (QFDVGHWUDLWHPHQWFRQVHUYDWHXUXQVXLYLF\VWRVFRSLTXH
Patients PS > 2 Soins de confort )DLEOH UpJXOLHUHVWUHFRPPDQGp>@/DIUpTXHQFHGXVXLYLGRLW
XQÀW rWUHDGDSWpHDXVWDGHLQLWLDOGHODPDODGLH7DEOHDXGH
recommandation 15).

Tableau de recommandation 15
5HFRPPDQGDWLRQVVXUYHLOODQFHGHV79,0 Niveau
([DPHQVUHFRPPDQGpV )UpTXHQFH
$SUqVF\VWHFWRPLH 6LS7 • TDM TAP À 3 et 6 mois, )DLEOH
‡%LRORJLH
SXLVWRXVOHVPRLVSHQGDQWDQV
SXLVWRXVOHVPRLVjYLH
6LS77 • TDM TAP 7RXVOHVjPRLVSHQGDQWDQV )DLEOH
HWRXS1 ‡%LRORJLH
SXLVWRXVOHVPRLVSHQGDQWDQV
SXLVWRXVOHVPRLVjYLH
6LXUqWUHHQSODFH ‡8UpWURVFRSLH DQQXHOOHSHQGDQWDQV )DLEOH
$SUqVWUDLWHPHQW ‡&\VWRVFRSLH 7RXVOHVPRLVSHQGDQWDQV )DLEOH
conservateur trimodal ‡&\WRORJLHXULQDLUH SXLVWRXVOHVPRLVMXVTX·jDQV
• TDM TAP
&UpDWLQpPLHLRQRJUDPPHVDQJXLQ1)6%HWUpVHUYHDOFDOLQH
Déclaration de liens d’intérêts
0RUJDQ 5RXSUrW  KRQRUDLUHV ERDUG$PEX %D\HU -DQVVHQ
5RFKH06')LGLD,SVHQ$VWHOODV$UTXHU&HSKHLG$VWUD
Zeneca, Ferring, Oncodiag.
*pUDOGLQH 3LJQRW  KRQRUDLUHV ERDUG -DQVVHQ %RXFKDUD
5HFRUGDWL %06 5RFKH$UTXHU$VWUD=HQHFD$VWHOODV
%D\HU
$OH[DQGUD0DVVRQ/HFRPWHKRQRUDLUHVERDUG,SVHQ-DQVVHQ
$VWUD=HQHFD$PEX
(YD &RPSpUDW  KRQRUDLUHV ERDUG -DQVVHQ$VWUD=HQHFD
MSD.
)UDQoRLV$XGHQHWKRQRUDLUHVERDUG1XFOHL[FRQIHUHQFHV
)HUULQJ,SVHQ-DQVVHQ
SXLVWRXVOHVPRLVjYLH
0DWKLHX5RXPLJXLpKRQRUDLUHVERDUG-DQVVHQ5RFKH,SVHQ
$VWHOODV$UTXHU$VWUD=HQHFD)HUULQJ2QFRGLDJ3LHUUH)DEUH
1DGLQH+RXpGpKRQRUDLUHVERDUG$VWHOODV$VWUD=HQHFD%D\HU
%06)HUULQJ,SVHQ-DQVVHQ06'1RYDUWLV3À]HU&KXJDL
6WpSKDQH/DUUpKRQRUDLUHVERDUG1XFOHL[6DQRÀ
6HUJH%UXQHOOHDXFXQ
(YDQJXHORV;\OLQDVKRQRUDLUHVERDUG$VWUD=HQHFD)HUULQJ
-DQVVHQ
<DQQ1HX]LOOHWKRQRUDLUHVERDUG$VWHOODV$VWUD=HQHFD%06
%RXFKDUD5HFRUGDWL,SVHQ06'HW6DQRÀ$YHQWLV
$UQDXG 0pMHDQ KRQRUDLUHV %RDUG  3À]HU ,SVHQ$VWHOODV
)HUULQJ-DQVVHQ1RYDUWLV*6.%065RFKH3LHUUH)DEUH
² ,QWpUrWLQVWLWXWLRQQHO $)8&&$)8$3+38QLYHUVLWpGH
Paris, ARTuR.
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

QRQPXVFOH LQYDVLYH EODGGHU FDQFHU DPLQRODHYXOLQLF DFLG

Références ÁXRUHVFHQFHYVKH[\ODPLQROHYXOLQDWHÁXRUHVFHQFHYVQDUURZ
>@ 6LHJHO 5/ 0LOOHU .' -HPDO$ &DQFHU VWDWLVWLFV  &$ EDQGLPDJLQJ%0&&DQFHU
&DQFHU-&OLQ >@ 'DWWD61$OOHQ*0(YDQV59DXJKWRQ.&/XFDV0*8ULQDU\
>@ 5LFKWHUV$$EHQ..+.LHPHQH\/$/07KHJOREDOEXUGHQRI WUDFWXOWUDVRQRJUDSK\LQWKHHYDOXDWLRQRIKDHPDWXULDDUHSRUW
XULQDU\EODGGHUFDQFHUDQXSGDWH:RUOG-8URO RIRYHUFDVHV$QQ5&ROO6XUJ(QJO
V >@ 3DORX - 5RGUtJXH]5XELR ) +XJXHW - 6HJDUUD - 5LEDO 0-
>@ 5RXSUrW 0 1HX]LOOHW < 3LJQRW * &RPSpUDW ($XGHQHW ) $OFDUD]$HWDO0XOWLYDULDWHDQDO\VLVRIFOLQLFDOSDUDPHWHUV
+RXpGp1HWDO5HFRPPDQGDWLRQVIUDQoDLVHVGX&RPLWpGH RIV\QFKURQRXVSULPDU\VXSHUÀFLDOEODGGHUFDQFHUDQGXSSHU
Cancérologie de l’AFU – Actualisation 2018-2020 : tumeurs de XULQDU\WUDFWWXPRU-8URO
ODYHVVLH>)UHQFKFF$)8JXLGHOLQHV²8SGDWH%ODGGHU >@ 5HQDUG3HQQD55RFKHU/5R\&$QGUp0%HOOLQ0)%RXOD\
FDQFHU@3URJ8URO655 ,VDEHOOHHWDO,PDJLQJSURWRFROVIRU&7XURJUDSK\UHVXOWVRID
>@ +DXWH $XWRULWp GH 6DQWp /DEHO ,1&D+$6 ² 6XUYHLOODQFH FRQVHQVXVFRQIHUHQFHIURPWKH)UHQFK6RFLHW\RI*HQLWRXULQDU\
PpGLFRSURIHVVLRQQHOOHGHVWUDYDLOOHXUVH[SRVpVRXD\DQWpWp
H[SRVpVjGHVDJHQWVFDQFpURJqQHVFKLPLTXHVDSSOLFDWLRQDX[
FDQFpURJqQHVSRXUODYHVVLH/D3ODLQH6DLQW'HQLV+$6
>@ %ULHUNH\ *0 :LWWHUNLQG &710 FODVVLÀFDWLRQ RI PDOLJQDQW
WXPRUV8,&&,QWHUQDWLRQDO8QLRQ$JDLQVW&DQFHUthHG1HZ
,PDJLQJ(XU5DGLRO
>@ 5RXYLqUH2&RUQHOLV)%UXQHOOH65R\&$QGUp0%HOOLQ0)
HW DO ,PDJLQJ SURWRFROV IRU UHQDO PXOWLSDUDPHWULF 05,
DQG 05 XURJUDSK\ UHVXOWV RI D FRQVHQVXV FRQIHUHQFH IURP
WKH )UHQFK 6RFLHW\ RI *HQLWRXULQDU\ ,PDJLQJ (XU 5DGLRO
<RUN:LOH\%ODFNZHOODQG8,&& 
>@ <DÀ)$%ULPR)$XJHU0$SULNLDQ$7DQJXD\6.DVVRXI: >@ $EUHX*RPH]-8GDUH$6KDQEKRJXH.36FKLHGD18SGDWH
,V WKH SHUIRUPDQFH RI XULQDU\ F\WRORJ\ DV KLJK DV UHSRUWHG RQ05XURJUDSK\058WHFKQLTXHDQGFOLQLFDODSSOLFDWLRQV
KLVWRULFDOO\"$ FRQWHPSRUDU\ DQDO\VLV LQ WKH GHWHFWLRQ DQG $EGRP5DGLRO1<
VXUYHLOODQFH RI EODGGHU FDQFHU 8URO 2QFRO  >@ =KDL1:DQJ<+=KX/0:DQJ-+6XQ;++X;%HWDO
e1-27.e276. 6HQVLWLYLW\ DQG 6SHFLÀFLW\ RI 'LIIXVLRQ:HLJKWHG 0DJQHWLF
>@ %DUNDQ *$ :RMFLN (0 1D\DU 5 6DYLF3ULQFH 6 4XHN 0/ 5HVRQDQFH,PDJLQJLQ'LDJQRVLVRI%ODGGHU&DQFHUV&OLQ,QYHVW
.XUW\F] '), HW DO7KH 3DULV 6\VWHP IRU 5HSRUWLQJ 8ULQDU\ 0HGHH
&\WRORJ\7KH4XHVWWR'HYHORSD6WDQGDUGL]HG7HUPLQRORJ\ >@ <RVKLGD67DNDKDUD7.ZHH7&:DVHGD<.RED\DVKL6)XMLL<
$FWD&\WRO² ':, DV DQ ,PDJLQJ %LRPDUNHU IRU %ODGGHU &DQFHU$-5$P -
>@ 0EHXWFKD$/XFFD,0DWKLHX5/RWDQ<6KDULDW6)&XUUHQW 5RHQWJHQRO
6WDWXVRI8ULQDU\%LRPDUNHUVIRU'HWHFWLRQDQG6XUYHLOODQFHRI >@ *DQGKL1.ULVKQD6%RRWK&0%UHDX5+)ORRG7$0RUJDQ6&
%ODGGHU&DQFHU8URO&OLQ1RUWK$P² HWDO'LDJQRVWLFDFFXUDF\RIPDJQHWLFUHVRQDQFHLPDJLQJIRU
>@ &RPSpUDW (0 %XUJHU 0 *RQWHUR 3 0RVWDÀG 8+ 3DORX - WXPRXU VWDJLQJ RI EODGGHU FDQFHU V\VWHPDWLF UHYLHZ DQG
5RXSUrW 0 HW DO *UDGLQJ RI 8URWKHOLDO &DUFLQRPD DQG7KH PHWDDQDO\VLV%-8,QW
1HZ©:RUOG+HDOWK2UJDQLVDWLRQ&ODVVLÀFDWLRQRI7XPRXUVRI >@ =KDQJ 1 :DQJ ; :DQJ & &KHQ 6 :X - =KDQJ * HW DO
WKH8ULQDU\6\VWHPDQG0DOH*HQLWDO2UJDQVª(XU8URO 'LDJQRVWLF$FFXUDF\RI0XOWL3DUDPHWULF0DJQHWLF5HVRQDQFH
)RFXV
>@ 9HVNLPlH ( (VSLQRV (/ %UXLQV +0 <XDQ < 6\OYHVWHU 5
.DPDW$0HWDO:KDW,VWKH3URJQRVWLFDQG&OLQLFDO,PSRUWDQFH
RI8URWKHOLDODQG1RQXURWKHOLDO+LVWRORJLFDO9DULDQWVRI%ODGGHU
Cancer in Predicting Oncological Outcomes in Patients with
,PDJLQJIRU7XPRU6WDJLQJRI%ODGGHU&DQFHU0HWD$QDO\VLV
)URQW2QFRO
>@ 3DQHELDQFR 9 1DUXPL<$OWXQ ( %RFKQHU % (IVWDWKLRX -$
+DIHH]6HWDO0XOWLSDUDPHWULF0DJQHWLF5HVRQDQFH,PDJLQJ
IRU%ODGGHU&DQFHU'HYHORSPHQWRI9,5$'69HVLFDO,PDJLQJ
0XVFOHLQYDVLYH DQG 0HWDVWDWLF %ODGGHU &DQFHU"$ (XURSHDQ 5HSRUWLQJ$QG'DWD6\VWHP(XU8URO
$VVRFLDWLRQRI8URORJ\0XVFOH,QYDVLYHDQG0HWDVWDWLF%ODGGHU >@ /XR&+XDQJ%:X<&KHQ-&KHQ/8VHRI9HVLFDO,PDJLQJ
&DQFHU *XLGHOLQHV 3DQHO 6\VWHPDWLF 5HYLHZ (XU 8URO 2QFRO 5HSRUWLQJDQG'DWD6\VWHP9,5$'6IRUGHWHFWLQJWKHPXVFOH
 LQYDVLRQ RI EODGGHU FDQFHU D GLDJQRVWLF PHWDDQDO\VLV (XU
>@ 0DUL$.LPXUD6)RHUVWHU%$EXIDUDM0'·$QGUHD'+DVVOHU0 5DGLRO
HW DO$ V\VWHPDWLF UHYLHZ DQG PHWDDQDO\VLV RI WKH LPSDFW >@ :RR 6 3DQHELDQFR 9 1DUXPL < 'HO *LXGLFH ) 0XJOLD 9)
RI O\PSKRYDVFXODU LQYDVLRQ LQ EODGGHU FDQFHU WUDQVXUHWKUDO 7DNHXFKL0HWDO'LDJQRVWLF3HUIRUPDQFHRI9HVLFDO,PDJLQJ
UHVHFWLRQVSHFLPHQV%-8,QW 5HSRUWLQJDQG'DWD6\VWHPIRUWKH3UHGLFWLRQRI0XVFOHLQYDVLYH
>@ 7DQ7= 5RXDQQH 07DQ .7 +XDQJ 5<7KLHU\ -3 0ROHFXODU %ODGGHU&DQFHU$6\VWHPDWLF5HYLHZDQG0HWDDQDO\VLV(XU
6XEW\SHVRI8URWKHOLDO%ODGGHU&DQFHU5HVXOWVIURPD0HWD 8URO2QFRO
FRKRUW$QDO\VLVRI7XPRUV(XU8URO >@ 3HFRUDUR 07DNHXFKL 0 9DUJDV +$ 0XJOLD 9) &LSROODUL 6
>@ $VVRFLDWLRQIUDQoDLVHG·XURORJLH$)86RFLpWpIUDQoDLVHG·K\- &DWDODQSR & HWDO 2YHUYLHZ RI 9,5$'6 LQ %ODGGHU &DQFHU
JLqQHKRVSLWDOLqUH6)++6RFLpWpGHSDWKRORJLHLQIHFWLHXVH $-5$P-5RHQWJHQRO
GHODQJXHIUDQoDLVH63,/)5pYLVLRQGHVUHFRPPDQGDWLRQVGH >@ 0DUFKLRQL03ULPLFHUL*'HOOL3L]]L$%DVLOLFR5%HUDUGLQHOOL)
ERQQHSUDWLTXHSRXUODSULVHHQFKDUJHHWODSUpYHQWLRQGHV 0LQFX]]L ( HW DO &RXOG %ODGGHU 0XOWLSDUDPHWULF 05, %H
,QIHFWLRQV 8ULQDLUHV$VVRFLpHV DX[ 6RLQV ,8$6 GH O·DGXOWH ,QWURGXFHGLQ5RXWLQH&OLQLFDO3UDFWLFH"5ROHRIWKH1HZ9,5$'6
2015. 6FRUH5HVXOWV)URPD3URVSHFWLYH6WXG\&OLQ*HQLWRXULQ&DQFHU
>@ ;LRQJ</L-0D6*H-=KRX//L'HWDO$PHWDDQDO\VLV 
RI QDUURZ EDQG LPDJLQJ IRU WKH GLDJQRVLV DQG WKHUDSHXWLF >@ 0DUJROLV '-$ +X -& 9\LQJ IRU 6WDQGDUGL]DWLRQ RI %ODGGHU
RXWFRPH RI QRQPXVFOH LQYDVLYH EODGGHU FDQFHU 3/R6 2QH &DQFHU05,,QWHUSUHWDWLRQDQG5HSRUWLQJ9,5$'65DGLRORJ\
HGRLMRXUQDOSRQH 
>@ .DQJ:&XL=&KHQ4=KDQJ'=KDQJ+-LQ;1DUURZEDQG >@ $VVRFLDWLRQIUDQoDLVHG·XURORJLH$)86RFLpWpIUDQoDLVHG·K\-
imaging-assisted transurethral resection reduces the recur- JLqQHKRVSLWDOLqUH6)++6RFLpWpGHSDWKRORJLHLQIHFWLHXVH
UHQFHULVNRIQRQPXVFOHLQYDVLYHEODGGHUFDQFHU$V\VWHPDWLF GHODQJXHIUDQoDLVH63,/)5pYLVLRQGHVUHFRPPDQGDWLRQVGH
UHYLHZDQGPHWDDQDO\VLV2QFRWDUJHW ERQQHSUDWLTXHSRXUODSULVHHQFKDUJHHWODSUpYHQWLRQGHV
>@ /HH -< &KR .6 .DQJ '+ -XQJ +' .ZRQ -. 2K &. HW DO ,QIHFWLRQV8ULQDLUHV$VVRFLpHVDX[6RLQV,8$6GHO·DGXOWH
$ QHWZRUN PHWDDQDO\VLV RI WKHUDSHXWLF RXWFRPHV DIWHU >@ :X <3 /LQ 77 &KHQ 6+ ;X 1 :HL < +XDQJ -% HW DO
QHZ LPDJH WHFKQRORJ\DVVLVWHG WUDQVXUHWKUDO UHVHFWLRQ IRU &RPSDULVRQ RI WKH HIILFDF\ DQG IHDVLELOLW\ RI HQ EORF
S122 05RXSUrWHWDO

WUDQVXUHWKUDOUHVHFWLRQRIEODGGHUWXPRUYHUVXVFRQYHQWLRQDO >@ )HUQDQGH]*RPH]-0DGHUR56ROVRQD(8QGD00DUWLQH]

WUDQVXUHWKUDO UHVHFWLRQ RI EODGGHU WXPRU$ PHWDDQDO\VLV 3LxHLUR / *RQ]DOH] 0 HW DO 3UHGLFWLQJ QRQPXVFOH LQYDVLYH
0HGLFLQH%DOWLPRUHH EODGGHUFDQFHUUHFXUUHQFHDQGSURJUHVVLRQLQSDWLHQWVWUHDWHG
>@ .UDPHU 0:$OWLHUL 9 +XUOH 5 /XVXDUGL / 0HUVHEXUJHU$6 ZLWK EDFLOOXV &DOPHWWH*XHULQ WKH &8(72 VFRULQJ PRGHO -
5DVVZHLOHU-HWDO&XUUHQW(YLGHQFHRI7UDQVXUHWKUDO(QEORF 8URO
5HVHFWLRQRI1RQPXVFOH,QYDVLYH%ODGGHU&DQFHU(XU8URO)RFXV >@ 2GGHQV-%UDXVL06\OYHVWHU5%RQR$YDQGH%HHN&YDQ
 $QGHO* HW DO )LQDOUHVXOWVRIDQ(257&*8 FDQFHUVJURXS
>@ <DQJ + /LQ - *DR 3 +H = .XDQJ ; /L ; HW DO ,V WKH (Q UDQGRPL]HG VWXG\ RI PDLQWHQDQFH EDFLOOXV &DOPHWWH*XpULQ
%ORF7UDQVXUHWKUDO5HVHFWLRQ0RUH(IIHFWLYHWKDQ&RQYHQWLRQDO LQLQWHUPHGLDWHDQGKLJKULVN7D7SDSLOODU\FDUFLQRPDRI
7UDQVXUHWKUDO5HVHFWLRQIRU1RQ0XVFOH,QYDVLYH%ODGGHU&DQFHU" WKHXULQDU\EODGGHURQHWKLUGGRVHYHUVXVIXOOGRVHDQG\HDU
$6\VWHPDWLF5HYLHZDQG0HWD8URO,QW YHUVXV\HDUVRIPDLQWHQDQFH(XU8URO
>@ =KDR&7DQJ.<DQJ+;LD'&KHQ=%LSRODU9HUVXV0RQRSRODU >@ *RQWHUR 3 6\OYHVWHU 5 3LVDQR ) -RQLDX 6 9DQGHU (HFNW .
7UDQVXUHWKUDO5HVHFWLRQRI1RQPXVFOH,QYDVLYH%ODGGHU&DQFHU 6HUUHWWD9HWDO3URJQRVWLFIDFWRUVDQGULVNJURXSVLQ7*
$0HWD$QDO\VLV-(QGRXURO QRQPXVFOHLQYDVLYHEODGGHUFDQFHUSDWLHQWVLQLWLDOO\WUHDWHG
>@ <DQJ+:DQJ1+DQ60DOH0=KDR&<DR'HWDO&RPSDULVRQ ZLWK %DFLOOXV &DOPHWWH*XpULQ UHVXOWV RI D UHWURVSHFWLYH
RIWKHHIÀFDF\DQGIHDVLELOLW\RIODVHUHQXFOHDWLRQRIEODGGHU PXOWLFHQWHUVWXG\RISDWLHQWV(XU8URO
WXPRU YHUVXV WUDQVXUHWKUDO UHVHFWLRQ RI EODGGHU WXPRU D >@ *H3:DQJ//X00DR//L::HQ5HWDO2QFRORJLFDO
PHWDDQDO\VLV/DVHUV0HG6FL 2XWFRPH RI 3ULPDU\ DQG 6HFRQGDU\ 0XVFOH,QYDVLYH %ODGGHU
>@ 6XELHOD-'3DORX-(VTXLQDV&)HUQiQGH]*yPH]-05RGUtJXH] &DQFHU $ 6\VWHPDWLF 5HYLHZ DQG 0HWDDQDO\VLV 6FL 5HS
)DED2&OLQLFDOXVHIXOQHVVRIUDQGRPELRSVLHVLQGLDJQRVLVDQG
WUHDWPHQWRIQRQPXVFOHLQYDVLYHEODGGHUFDQFHU6\VWHPDWLF
UHYLHZ DQG PHWDDQDO\VLV 8WLOLGDG FOtQLFD GH ODV ELRSVLDV
DOHDWRULDVHQHOGLDJQyVWLFR\WUDWDPLHQWRGHOWXPRUYHVLFDO
QRP~VFXORLQYDVLYRUHYLVLyQVLVWHPiWLFD\PHWDDQiOLVLV$FWDV

>@ .RJD + .XURLZD . <DPDJXFKL$ 2VDGD < 7VXQH\RVKL 0
1DLWR 6$ UDQGRPL]HG FRQWUROOHG WULDO RI VKRUWWHUP YHUVXV
ORQJWHUPSURSK\ODFWLFLQWUDYHVLFDOLQVWLOODWLRQFKHPRWKHUDS\
for recurrence after transurethral resection of Ta/T1 transi-
8URO(VS WLRQDOFHOOFDUFLQRPDRIWKHEODGGHU-8URO
>@ =KRX==KDR6/X<:X-/L<*DR=HWDO0HWDDQDO\VLV >@ %DEMXN0%XUJHU0&RPSpUDW(0*RQWHUR30RVWDÀG8+
RIHIÀFDF\DQGVDIHW\RIFRQWLQXRXVVDOLQHEODGGHULUULJDWLRQ 3DORX-HWDO(XURSHDQ$VVRFLDWLRQRI8URORJ\*XLGHOLQHVRQ
FRPSDUHGZLWKLQWUDYHVLFDOFKHPRWKHUDS\DIWHUWUDQVXUHWKUDO 1RQPXVFOHLQYDVLYH%ODGGHU&DQFHU7D7DQG&DUFLQRPD,Q
UHVHFWLRQRIEODGGHUWXPRUV:RUOG-8URO
>@ %XUJHU0*URVVPDQ+%'UROOHU06FKPLGEDXHU-+HUPDQQ*
'UČJRHVFX 2 HW DO 3KRWRG\QDPLF GLDJQRVLV RI QRQPXVFOH
LQYDVLYHEODGGHUFDQFHUZLWKKH[DPLQROHYXOLQDWHF\VWRVFRS\D
PHWDDQDO\VLVRIGHWHFWLRQDQGUHFXUUHQFHEDVHGRQUDZGDWD
6LWX8SGDWH(XU8URO
>@ $UHQGV7- 1DWLY 2 0DIIH]]LQL 0 GH &REHOOL 2 &DQHSD *
9HUZHLM ) HW DO 5HVXOWV RI D 5DQGRPLVHG &RQWUROOHG 7ULDO
&RPSDULQJ,QWUDYHVLFDO&KHPRK\SHUWKHUPLDZLWK0LWRP\FLQ&
9HUVXV %DFLOOXV &DOPHWWH*XpULQ IRU$GMXYDQW7UHDWPHQW RI
(XU8URO 3DWLHQWVZLWK,QWHUPHGLDWHDQG+LJKULVN1RQ0XVFOHLQYDVLYH
>@ 5RXSUrW 0 0DODYDXG % 0ROLQLHU / /HOHX + %ODFKLHU 0 %ODGGHU&DQFHU(XU8URO
0DUWHDX)&R€WHIÀFDFLWpGHODUpVHFWLRQWUDQVXUpWUDOHGHYHV- >@ 7DQ:63DQFKDO$%XFNOH\/'HYDOO$-/RXELqUH/63DSH$0
VLHHQOXPLqUHEOHXHFKH]OHVSDWLHQWVDWWHLQWVG·XQFDQFHUGH HW DO 5DGLRIUHTXHQF\LQGXFHG 7KHUPRFKHPRWKHUDS\
ODYHVVLHQRQLQÀOWUDQWHQ)UDQFH3URJ8URO (IIHFW 9HUVXV D 6HFRQG &RXUVH RI %DFLOOXV &DOPHWWH*XpULQ
>@ .DQJ:&XL=&KHQ4=KDQJ'=KDQJ+-LQ;1DUURZEDQG RU ,QVWLWXWLRQDO 6WDQGDUG LQ 3DWLHQWV ZLWK 5HFXUUHQFH RI
imaging-assisted transurethral resection reduces the recur- 1RQPXVFOHLQYDVLYH %ODGGHU &DQFHU )ROORZLQJ ,QGXFWLRQ RU
UHQFHULVNRIQRQPXVFOHLQYDVLYHEODGGHUFDQFHU$V\VWHPDWLF 0DLQWHQDQFH %DFLOOXV &DOPHWWH*XpULQ 7KHUDS\ +<01$
UHYLHZDQGPHWDDQDO\VLV2QFRWDUJHW 3KDVH,,,2SHQODEHO5DQGRPLVHG&RQWUROOHG7ULDO(XU8URO
>@ 5RXSUrW01HX]LOOHW</DUUp63LJQRW*&RORE\35pELOODUG; 
et al. Recommandations du comité de cancérologie de l’Asso- >@ GH-RQJ--+HQGULFNVHQ.5RVLHU00RVWDÀG+%RRUPDQV-/
FLDWLRQIUDQoDLVHG·XURORJLH&&$)8SRXUODERQQHSUDWLTXH +\SHUWKHUPLF,QWUDYHVLFDO&KHPRWKHUDS\IRU%&*8QUHVSRQVLYH
GHV LQVWLOODWLRQV HQGRYpVLFDOHV GH %&* HW GH P\WRP\FLQH & 1RQ0XVFOH,QYDVLYH%ODGGHU&DQFHU3DWLHQWV%ODGGHU&DQFHU
GDQVOHWUDLWHPHQWGHVWXPHXUVGHODYHVVLHQ·HQYDKLVVDQWSDV 
OHPXVFOH791,0>*XLGHOLQHVIRUJRRGSUDFWLFHRILQWUDYHVLFDO >@ 3ROHWDMHZ 6 =DSDãD 3 5DG]LV]HZVNL 3 6DIHW\ DQG (IÀFDF\
LQVWLOODWLRQVRI%&*DQGPLWRP\FLQ&IURPWKH)UHQFKQDWLRQDO RI ,QWUDYHVLFDO %DFLOOXV &DOPHWWH*XpULQ ,PPXQRWKHUDS\ LQ
FDQFHUFRPPLWWHH&&$)8IRUQRQPXVFOHLQYDVLYHEODGGHU 3DWLHQWVZLWK1RQ0XVFOH,QYDVLYH%ODGGHU&DQFHU3UHVHQWLQJ
FDQFHU@3URJ8URO ZLWK$V\PSWRPDWLF%DFWHULXULD$6\VWHPDWLF5HYLHZ8URO,QW
>@ 6\OYHVWHU5-2RVWHUOLQFN:+ROPDQJ66\GHV05%LUWOH$
*XGMRQVVRQ 6 HW DO 6\VWHPDWLF 5HYLHZ DQG ,QGLYLGXDO
3DWLHQW 'DWD 0HWDDQDO\VLV RI 5DQGRPL]HG7ULDOV &RPSDULQJ
D 6LQJOH ,PPHGLDWH ,QVWLOODWLRQ RI &KHPRWKHUDS\ $IWHU
Transurethral Resection with Transurethral Resection Alone

>@ 1HX]LOOHW<5RXSUrW0:DOOHUDQG+3LJQRW*/DUUp6,UDQL-
HWDO'LDJQRVWLFHWSULVHHQFKDUJHGHVpYpQHPHQWVLQGpVL-
UDEOHV VXUYHQDQW DX GpFRXUV GHV LQVWLOODWLRQV HQGRYpVLFDOHV
GH%&*SRXUOHWUDLWHPHQWGHVWXPHXUVGHYHVVLHQ·LQÀOWUDQW
LQ 3DWLHQWV ZLWK 6WDJH S7DS7 8URWKHOLDO &DUFLQRPD RI WKH SDVOHPXVFOH791,0UHYXHGXFRPLWpGHFDQFpURORJLHGH
%ODGGHU:KLFK3DWLHQWV%HQHÀWIURPWKH,QVWLOODWLRQ"(XU8URO l’Association française d’urologie [Diagnosis and management
 RIDGYHUVHHYHQWVRFFXULQJGXULQJ%&*WKHUDS\IRUQRQPXVFOH
>@ 1DVHOOL$+XUOH53DSDUHOOD6%XIÀ10/XJKH]]DQL*/LVWD* LQYDVLYH EODGGHU FDQFHU 10,%& UHYLHZ RI WKH &DQFHU
HWDO5ROHRI5HVWDJLQJ7UDQVXUHWKUDO5HVHFWLRQIRU71RQ &RPPLWWHHRIWKH)UHQFK$VVRFLDWLRQRI8URORJ\@3URJ8URO
PXVFOH LQYDVLYH %ODGGHU &DQFHU$ 6\VWHPDWLF 5HYLHZ DQG 
0HWDDQDO\VLV(XU8URO)RFXV >@ 5LHNHQ06KDULDW6).OXWK/.OXWK/&ULYHOOL--$EXIDUDM0
>@ 6\OYHVWHU5-YDQGHU0HLMGHQ$302RVWHUOLQFN::LWMHV-$ HWDO&RPSDULVRQRIWKH(257&WDEOHVDQGWKH($8FDWHJRULHV
%RXIÀRX[&'HQLV/HWDO3UHGLFWLQJUHFXUUHQFHDQGSURJUHVVLRQ IRU ULVN VWUDWLÀFDWLRQ RI SDWLHQWV ZLWK QRQPXVFOHLQYDVLYH
LQLQGLYLGXDOSDWLHQWVZLWKVWDJH7D7EODGGHUFDQFHUXVLQJ EODGGHUFDQFHU8URO2QFROHH
(257&ULVNWDEOHVDFRPELQHGDQDO\VLVRISDWLHQWVIURP >@ /RWDQ<%LYDODFTXD7-'RZQV7+XDQJ:-RQHV-.DPDW$0
VHYHQ(257&WULDOV(XU8UROGLVFXVVLRQ HWDO%OXHOLJKWÁH[LEOHF\VWRVFRS\ZLWKKH[DPLQROHYXOLQDWH
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

LQQRQPXVFOHLQYDVLYHEODGGHUFDQFHUUHYLHZRIWKHFOLQLFDO >@ 2] ,,$OWLQEDV 1. 6HULIRJOX , 2] (%<DJFL &7KH UROH RI
HYLGHQFHDQGFRQVHQVXVVWDWHPHQWRQRSWLPDOXVHLQWKH86$ FRPSXWHUL]HG WRPRJUDSK\ LQ WKH DVVHVVPHQW RI SHULYHVLFDO
²XSGDWH1DW5HY8URO LQYDVLRQLQEODGGHUFDQFHU3RO-5DGLRO
>@ 3LFR]]L65LFFL&*DHWD05DWWL'0DFFKL$&DVHOODWR6HWDO >@ .LP -. 3DUN 6<$KQ +- .LP &6 &KR .6 %ODGGHU FDQFHU
8SSHUXULQDU\WUDFWUHFXUUHQFHIROORZLQJUDGLFDOF\VWHFWRP\ DQDO\VLVRIPXOWLGHWHFWRUURZKHOLFDO&7HQKDQFHPHQWSDWWHUQ
IRUEODGGHUFDQFHUDPHWDDQDO\VLVRQSDWLHQWV-8URO DQG DFFXUDF\ LQ WXPRU GHWHFWLRQ DQG SHULYHVLFDO VWDJLQJ
 5DGLRORJ\
>@ +HUQiQGH] 9 /ORUHQWH & GH OD 3HxD ( 3pUH])HUQiQGH] ( >@ .LP%6HPHOND5&$VFKHU60&KDOSLQ'%&DUUROO35+ULFDN+
*XLMDUUR$6ROD,/RQJWHUPRQFRORJLFDORXWFRPHVRIDQDFWLYH %ODGGHUWXPRUVWDJLQJFRPSDULVRQRIFRQWUDVWHQKDQFHG&77
VXUYHLOODQFHSURJUDPLQUHFXUUHQWORZJUDGH7DEODGGHUFDQFHU ²DQG7ZHLJKWHG05LPDJLQJG\QDPLFJDGROLQLXPHQKDQFHG
8URO2QFROH²H LPDJLQJ DQG ODWH JDGROLQLXPHQKDQFHG LPDJLQJ 5DGLRORJ\
>@ +XUOH5/D]]HUL09DQQL(/XJKH]]DQL*%XIÀ1&DVDOH3 
HW DO$FWLYH 6XUYHLOODQFH IRU /RZ 5LVN 1RQPXVFOH ,QYDVLYH >@ +XVEDQG-(2OOLII-):LOOLDPV03+HURQ&:&KHUU\PDQ*5
%ODGGHU &DQFHU$ &RQÀUPDWRU\ DQG 5HVRXUFH &RQVXPSWLRQ %ODGGHU FDQFHU VWDJLQJ ZLWK &7 DQG 05 LPDJLQJ 5DGLRORJ\
6WXG\IURPWKH%,$63URMHFW-8URO 
>@ +XUOH 5 &RORPER 3 /D]]HUL 0 /XJKH]]DQL * %XIIL 10 >@ %DOWDFL65HVRUOX%<DJFL&7XUNROPH].*RJXV&%HGXN<
Saita A, et al. Pathological Outcomes for Patients Who Failed &RPSXWHUL]HGWRPRJUDSK\IRUGHWHFWLQJSHULYHVLFDOLQÀOWUDWLRQ
7R5HPDLQ8QGHU$FWLYH6XUYHLOODQFHIRU/RZULVN1RQPXVFOH DQGO\PSKQRGHPHWDVWDVLVLQLQYDVLYHEODGGHUFDUFLQRPD8URO
LQYDVLYH%ODGGHU&DQFHU8SGDWHDQG5HVXOWVIURPWKH%ODGGHU ,QW
&DQFHU ,WDOLDQ$FWLYH 6XUYHLOODQFH 3URMHFW (XU 8URO 2QFRO >@ /RGGH0/DFRPEH/)ULHGH-0RULQ)6DRXULQH$)UDGHW<
 (YDOXDWLRQRIÁXRURGHR[\JOXFRVHSRVLWURQHPLVVLRQWRPRJUDSK\
>@ +HUU +: 'RQDW 60 5HXWHU 9( 0DQDJHPHQW RI ORZ JUDGH ZLWKFRPSXWHGWRPRJUDSK\IRUVWDJLQJRIXURWKHOLDOFDUFLQRPD
SDSLOODU\EODGGHUWXPRUV-8URO3W %-8,QW
>@ 3ODQHOOHV*yPH]-2OPRV6iQFKH]/&DUGRVD%HQHW--0DUWtQH] >@ 3LFFKLR07UHLEHU8%HHU$-0HW]6%|VVQHU3YDQ5DQGHQERUJK
/ySH] ( 9LGDO 0RUHQR -) +ROPLXP<$* 3KRWRFRDJXODWLRQ +HWDO9DOXHRI&FKROLQH3(7DQGFRQWUDVWHQKDQFHG&7
Safe and Economical Alternative to Transurethral Resection IRUVWDJLQJRIEODGGHUFDQFHUFRUUHODWLRQZLWKKLVWRSDWKRORJLF
LQ 6PDOO 1RQPXVFOH,QYDVLYH %ODGGHU 7XPRUV - (QGRXURO ÀQGLQJV-1XFO0HG
 >@ +RUQ7 =DKHO7$GW 1 6FKPLG 6& +HFN 007KDOJRWW 0.
>@ 5LYHUR *XHUUD É )HUQiQGH]$SDULFLR7 %DUFHOy %D\RQDV , HW DO (YDOXDWLRQ RI FRPSXWHG WRPRJUDSK\ IRU O\PSK QRGH
0DUWtQH] $3 *XLOOHUPR 90 3HUDOWD '- HW DO 2XWSDWLHQW VWDJLQJLQEODGGHUFDQFHUSULRUWRUDGLFDOF\VWHFWRP\8URO,QW
+ROPLXPODVHUIXOJXUDWLRQ$VDIHSURFHGXUHIRUWUHDWPHQWRI 
UHFXUUHQFHRIQRQPXVFOHLQYDVLYHEODGGHUFDQFHU)XOJXUDFLyQ >@ *DQGKL1.ULVKQD6%RRWK&0%UHDX5+)ORRG7$0RUJDQ6&
DPEXODWRULDFRQOiVHU+ROPLXP8QSURFHGLPLHQWRVHJXURSDUD HWDO'LDJQRVWLFDFFXUDF\RIPDJQHWLFUHVRQDQFHLPDJLQJIRU
el tratamiento de la recidiva del carcinoma vesical no músculo WXPRXU VWDJLQJ RI EODGGHU FDQFHU V\VWHPDWLF UHYLHZ DQG
LQÀOWUDQWH$FWDV8URO(VS PHWDDQDO\VLV%-8,QW
>@ 0PHMH&2*XR&&6KDK-%1DYDL1*URVVPDQ+%'LQQH\&3 >@ =KDQJ 1 :DQJ ; :DQJ & &KHQ 6 :X - =KDQJ * HW DO
HWDO3DSLOODU\5HFXUUHQFHRI%ODGGHU&DQFHUDW)LUVW(YDOXDWLRQ 'LDJQRVWLF$FFXUDF\RI0XOWL3DUDPHWULF0DJQHWLF5HVRQDQFH
DIWHU,QGXFWLRQ%DFLOOXV&DOPHWWH*XpULQ7KHUDS\,PSOLFDWLRQ ,PDJLQJIRU7XPRU6WDJLQJRI%ODGGHU&DQFHU0HWD$QDO\VLV
IRU&OLQLFDO7ULDO'HVLJQ(XU8URO )URQW2QFRO
>@ 7DQ:63DQFKDO$%XFNOH\/'HYDOO$-/RXELqUH/63RSH$0 >@ +XDQJ/.RQJ4/LX=:DQJ-.DQJ==KX<7KH'LDJQRVWLF
HW DO 5DGLRIUHTXHQF\LQGXFHG 7KHUPRFKHPRWKHUDS\ 9DOXH RI 05 ,PDJLQJ LQ 'LIIHUHQWLDWLQJ7 6WDJLQJ RI %ODGGHU
(IIHFW 9HUVXV D 6HFRQG &RXUVH RI %DFLOOXV &DOPHWWH*XpULQ &DQFHU$0HWD$QDO\VLV5DGLRORJ\
RU ,QVWLWXWLRQDO 6WDQGDUG LQ 3DWLHQWV ZLWK 5HFXUUHQFH RI >@ :RR 6 6XK &+ .LP 6< &KR -< .LP 6+ 'LDJQRVWLF SHUIRU-
1RQPXVFOHLQYDVLYH %ODGGHU &DQFHU )ROORZLQJ ,QGXFWLRQ RU PDQFHRI05,IRUSUHGLFWLRQRIPXVFOHLQYDVLYHQHVVRIEODGGHU
0DLQWHQDQFH %DFLOOXV &DOPHWWH*XpULQ 7KHUDS\ +<01$ FDQFHU$V\VWHPDWLFUHYLHZDQGPHWDDQDO\VLV(XU-5DGLRO
3KDVH,,,2SHQODEHO5DQGRPLVHG&RQWUROOHG7ULDO(XU8URO 
 >@ /XR&+XDQJ%:X<&KHQ-&KHQ/8VHRI9HVLFDO,PDJLQJ
>@ /DPP '/ %OXPHQVWHLQ %$ &ULVVPDQ -' 0RQWLH -( 5HSRUWLQJDQG'DWD6\VWHP9,5$'6IRUGHWHFWLQJWKHPXVFOH
*RWWHVPDQ-(/RZH%$HWDO0DLQWHQDQFHEDFLOOXV&DOPHWWH LQYDVLRQ RI EODGGHU FDQFHU D GLDJQRVWLF PHWDDQDO\VLV (XU
*XpULQLPPXQRWKHUDS\IRUUHFXUUHQW7$7DQGFDUFLQRPDLQ 5DGLRO
VLWXWUDQVLWLRQDOFHOOFDUFLQRPDRIWKHEODGGHUDUDQGRPL]HG >@ :RR 6 3DQHELDQFR 9 1DUXPL < 'HO *LXGLFH ) 0XJOLD 9)
6RXWKZHVW2QFRORJ\*URXS6WXG\-8URO 7DNHXFKL0HWDO'LDJQRVWLF3HUIRUPDQFHRI9HVLFDO,PDJLQJ
>@ *LDQQDULQL*%LUNKlXVHU)'5HFNHU)7KDOPDQQ*16WXGHU8( 5HSRUWLQJDQG'DWD6\VWHPIRUWKH3UHGLFWLRQRI0XVFOHLQYDVLYH
%DFLOOXV&DOPHWWH*XpULQIDLOXUHLQSDWLHQWVZLWKQRQPXVFOH %ODGGHU&DQFHU$6\VWHPDWLF5HYLHZDQG0HWDDQDO\VLV(XU
LQYDVLYHXURWKHOLDOFDUFLQRPDRIWKHEODGGHUPD\EHGXHWR 8URO2QFROSLL6
the urologist’s failure to detect urothelial carcinoma of the >@ 3HFRUDUR 07DNHXFKL 0 9DUJDV +$ 0XJOLD 9) &LSROODUL 6
XSSHUXULQDU\WUDFWDQGXUHWKUD(XU8URO &DWDODQR&HWDO2YHUYLHZRI9,5$'6LQ%ODGGHU&DQFHU$-5
>@ &DVH\5*&DWWR-:&KHQJ/&RRNVRQ06+HUU+6KDULDW6 $P-5RHQWJHQRO
et al. Diagnosis and management of urothelial carcinoma in >@ 0DUFKLRQL03ULPLFHUL*'HOOL3L]]L$%DVLOLFR5%HUDUGLQHOOL)
VLWXRIWKHORZHUXULQDU\WUDFWDV\VWHPDWLFUHYLHZ(XU8URO 0LQFX]]L ( HW DO &RXOG %ODGGHU 0XOWLSDUDPHWULF 05, %H
 ,QWURGXFHGLQ5RXWLQH&OLQLFDO3UDFWLFH"5ROHRIWKH1HZ9,5$'6
>@ .XQGUD 9 6LOYHUPDQ 30 ,PDJLQJ LQ RQFRORJ\ IURP WKH 6FRUH5HVXOWV)URPD3URVSHFWLYH6WXG\&OLQ*HQLWRXULQ&DQFHU
8QLYHUVLW\RI7H[DV0'$QGHUVRQ&DQFHU&HQWHU,PDJLQJLQ SLL6
WKHGLDJQRVLVVWDJLQJDQGIROORZXSRIFDQFHURIWKHXULQDU\ >@ 0DUJROLV '-$ +X -& 9\LQJ IRU 6WDQGDUGL]DWLRQ RI %ODGGHU
EODGGHU$-5$P-5RHQWJHQRO &DQFHU05,,QWHUSUHWDWLRQDQG5HSRUWLQJ9,5$'65DGLRORJ\
>@ 9LNUDP56DQGOHU&01J&6,PDJLQJDQGVWDJLQJRIWUDQVL- .RJD):KDWDUHUROHVRIPXOWLSDUDPHWULF
WLRQDOFHOOFDUFLQRPD3DUW/RZHUXULQDU\WUDFW$-5$P- PDJQHWLFUHVRQDQFHLPDJLQJSULRUWRWUDQVXUHWKUDOUHVHFWLRQRI
5RHQWJHQRO EODGGHUWXPRU"7UDQVO$QGURO8URO
6 05RXSUrWHWDO

>@ %UDHQGHQJHQ0:LQGHUHQ0)RVVD6'&OLQLFDOVLJQLÀFDQFHRI &RQWUROOHG7KUHHDUP7ULDORI2SHQ5RERWLFDQG/DSDURVFRSLF

URXWLQHSUHF\VWHFWRP\ERQHVFDQVLQSDWLHQWVZLWKPXVFOH 5DGLFDO&\VWHFWRP\&25$/(XU8URO
LQYDVLYHEODGGHUFDQFHU%U-8URO >@%RFKQHU%+6MREHUJ''/DXGRQH930HPRULDO6ORDQ.HWWHULQJ
>@ +HLGHQUHLFK$$OEHUV3&ODVVHQ-*UDHIHQ0*VFKZHQG- &DQFHU&HQWHU%ODGGHU&DQFHU6XUJLFDO7ULDOV*URXS$UDQGR-
.RW]HUNH-HWDO,PDJLQJVWXGLHVLQPHWDVWDWLFXURJHQLWDOFDQ- PL]HGWULDORIURERWDVVLVWHGODSDURVFRSLFUDGLFDOF\VWHFWRP\
FHUSDWLHQWVXQGHUJRLQJV\VWHPLFWKHUDS\5HFRPPHQGDWLRQV 1(QJO-0HG
RIDPXOWLGLVFLSOLQDU\FRQVHQVXVPHHWLQJRIWKH$VVRFLDWLRQRI >@5D]D 6- :LOVRQ 7 3HDERG\ -2 :LNOXQG 3 6FKHUU '6
8URORJLFDO 2QFRORJ\ RI WKH *HUPDQ &DQFHU 6RFLHW\ 8URO ,QW Al-Daghmin A, et al. Long-term oncologic outcomes following
 URERWDVVLVWHGUDGLFDOF\VWHFWRP\UHVXOWVIURPWKH,QWHUQDWLRQDO
>@ 'DVRQ6:RQJ1&'RQDKXH7)0HLHU$=KHQJ-0DQQHOOL/ 5RERWLF&\VWHFWRP\&RQVRUWLXP(XU8URO
HWDO8WLOLW\RIURXWLQHSUHRSHUDWLYH)ÁXRURGHR[\JOXFRVH >@5DL%3%RQGDG-9DVGHY1$GVKHDG-/DQH7$KPHG.HWDO
SRVLWURQHPLVVLRQWRPRJUDSK\FRPSXWHGWRPRJUDSK\))'* 5RERWLF9HUVXV2SHQ5DGLFDO&\VWHFWRP\IRU%ODGGHU&DQFHU
3(7&7LQLGHQWLI\LQJSDWKRORJLFO\PSKQRGHPHWDVWDVHVDW LQ$GXOWV&RFKUDQH'DWDEDVH6\VW5HY&'
UDGLFDOF\VWHFWRP\-8URO >@%RFKQHU %+ 'DOEDJQL * 6MREHUJ '' 6LOEHUVWHLQ - .HUHQ
>@ $OWXQ(05,PDJLQJRIWKH8ULQDU\%ODGGHU$GGHG9DOXHRI 3D]*('RQDW60HWDO&RPSDULQJ2SHQ5DGLFDO&\VWHFWRP\
3(705,PDJLQJ0DJQ5HVRQ,PDJLQJ&OLQ1$P DQG 5RERWDVVLVWHG /DSDURVFRSLF 5DGLFDO &\VWHFWRP\ $
>@ (XOLWW 3-$OWXQ ( 6KHLNK$ :RQJ7= :RRGV 0( 5RVH7/ 5DQGRPL]HG&OLQLFDO7ULDO(XU8URO
HW DO 3LORW 6WXG\ RI >)@ )OXRURGHR[\JOXFRVH 3RVLWURQ >@1RYDUD * &DWWR -:) :LOVRQ 7 $QQHUVWHGW 0 &KDQ .
(PLVVLRQ 7RPRJUDSK\ )'*3(70DJQHWLF 5HVRQDQFH 0XUSK\'*HWDO6\VWHPDWLFUHYLHZDQGFXPXODWLYHDQDO\VLVRI
,PDJLQJ05,IRU6WDJLQJRI0XVFOHLQYDVLYH%ODGGHU&DQFHU SHULRSHUDWLYHRXWFRPHVDQGFRPSOLFDWLRQVDIWHUURERWDVVLVWHG
0,%& &OLQ *HQLWRXULQ &DQFHU  SLL UDGLFDOF\VWHFWRP\(XU8URO
6
>@ 6RXEUD$+D\ZDUG''DKP3*ROGIDUE5)URHKOLFK--KD*
HWDO7KHGLDJQRVWLFDFFXUDF\RI)ÁXRURGHR[\JOXFRVHSRVL-
WURQHPLVVLRQWRPRJUDSK\DQGFRPSXWHGWRPRJUDSK\LQVWDJLQJ
EODGGHU FDQFHU D VLQJOHLQVWLWXWLRQ VWXG\ DQG D V\VWHPDWLF
UHYLHZZLWKPHWDDQDO\VLV:RUOG-8URO
>@ &UR]LHU-3DSD13HUHUD01JR%%ROWRQ'6HQJXSWD6HWDO
&RPSDUDWLYHVHQVLWLYLW\DQGVSHFLÀFLW\RILPDJLQJPRGDOLWLHVLQ
>@5R]HW)/HVXU*&DWKHOLQHDX;%DUUHW(6P\WK*6RRQ6
HWDO2QFRORJLFDOHYDOXDWLRQRISURVWDWHVSDULQJF\VWHFWRP\
WKH 0RQWVRXULV ORQJWHUP UHVXOWV - 8URO 
GLVFXVVLRQ
>@$OL(O'HLQ%$EGHO/DWLI00RVEDK$(UDN\,6KDDEDQ$$
7DKD 10 HW DO 6HFRQGDU\ PDOLJQDQW LQYROYHPHQW RI J\QH-
FRORJLF RUJDQV LQ UDGLFDO F\VWHFWRP\ VSHFLPHQV LQ ZRPHQ
LV LW PDQGDWRU\ WR UHPRYH WKHVH RUJDQV URXWLQHO\" - 8URO
VWDJLQJEODGGHUFDQFHUSULRUWRUDGLFDOF\VWHFWRP\DV\VWHPD- 
WLFUHYLHZDQGPHWDDQDO\VLV:RUOG-8URO >@*DNLV * 6FKLOOLQJ ' 3HUQHU 6 6FKZHQWQHU & 6LHYHUW .'
>@ /X<< &KHQ -+ /LDQJ -$ :DQJ +< /LQ && /LQ :< HW DO 6WHQ]O$6HTXHQWLDO5HVHFWLRQRI0DOLJQDQW8UHWHUDO0DUJLQV
&OLQLFDO YDOXH RI )'* 3(7 RU 3(7 &7 LQ XULQDU\ EODGGHU DW5DGLFDO&\VWHFWRP\$&ULWLFDO$VVHVVPHQWRIWKH9DOXHRI
FDQFHU D V\VWHPLF UHYLHZ DQG PHWDDQDO\VLV (XU - 5DGLRO )UR]HQ6HFWLRQ$QDO\VLV:RUOG-8URO
<LQ 0 -RVKL 0 0HLMHU 53 *ODQW] 0 >@0DVVRQ/HFRPWH$)UDQFRLV79RUGRV'&RUGRQQLHU&$OORU\<
+ROGHU 6 +DUYH\ +$ HW DO 1HRDGMXYDQW &KHPRWKHUDS\ IRU 'HVJUDQGFKDPSV)HWDO3UHGLFWLYH)DFWRUVIRU)LQDO3DWKRORJLF
0XVFOH,QYDVLYH %ODGGHU &DQFHU$ 6\VWHPDWLF 5HYLHZ DQG 8UHWHUDO 6HFWLRQV RQ  5DGLFDO &\VWHFWRP\ 6SHFLPHQV
7ZR6WHS0HWD$QDO\VLV2QFRORJLVW ,PSOLFDWLRQVIRU,QWUDRSHUDWLYH)UR]HQ6HFWLRQ'HFLVLRQ0DNLQJ
>@ :LWMHV-$%UXLQV+0&DWKRPDV5&RPSpUDW(0&RZDQ1& 8URO2QFROHH
*DNLV * HW DO (XURSHDQ$VVRFLDWLRQ RI 8URORJ\ *XLGHOLQHV >@6SLHVV3(.DVVRXI:%URZQ*+LJKVKDZ5:DQJ;'R.$
RQ 0XVFOHLQYDVLYH DQG 0HWDVWDWLF %ODGGHU &DQFHU HWDO,PPHGLDWH9HUVXV6WDJHG8UHWKUHFWRP\LQ3DWLHQWVDW
6XPPDU\ RI WKH  *XLGHOLQHV (XU 8URO  SLL +LJK5LVNRI8UHWKUDO5HFXUUHQFH,V7KHUHD%HQHÀWWR(LWKHU
6;>(SXEDKHDGRISULQW@5HYLHZ $SSURDFK"8URORJ\
>@6DQFKH]2UWL] 5) +XDQJ :& 0LFN 5 9DQ $UVGDOHQ .1 >@/DUUp64XLQWHQV++RXpGp1&RPSHUDW(5R\&3LJQRW*
:HLQ$- 0DONRZLF] 6%$Q LQWHUYDO ORQJHU WKDQ  ZHHNV HWDO,QWpUrWGXFXUDJHJDQJOLRQQDLUHGDQVOHVWXPHXUVXURWKp-
EHWZHHQWKHGLDJQRVLVRIPXVFOHLQYDVLRQDQGF\VWHFWRP\LV OLDOHVLQÀOWUDQWHVGHODYHVVLH79,0HWGHODYRLHH[FUpWULFH
DVVRFLDWHGZLWKZRUVHRXWFRPHLQEODGGHUFDUFLQRPD-8URO VXSpULHXUH79(6DUWLFOHGHUHYXHGX&RPLWpGHFDQFpURORJLH
GLVFXVVLRQ GHO·$VVRFLDWLRQIUDQoDLVHG·XURORJLH3URJ8URO
>@$XGHQHW)6IDNLDQRV-3:DLQJDQNDU15XHO1+*DOVN\0' >@%UXLQV+09HVNLPlH(+HUQiQGH]9,PDPXUD01HXEHUJHU00
<XK%(HWDO$'HOD\•:HHNVWR1HRDGMXYDQW&KHPRWKHUDS\ 'DKP 3 HW DO7KH LPSDFW RI WKH H[WHQW RI O\PSKDGHQHF-
%HIRUH 5DGLFDO &\VWHFWRP\ ,QFUHDVHV WKH 5LVN RI 8SVWDJLQJ WRP\ RQ RQFRORJLF RXWFRPHV LQ SDWLHQWV XQGHUJRLQJ UDGLFDO
8URO2QFRO F\VWHFWRP\IRUEODGGHUFDQFHUDV\VWHPDWLFUHYLHZ(XU8URO
>@0PHMH&2%HQVRQ&51RJXHUDV*RQ]iOH]*0-D\DUDWQD,6 
*DR-6LHINHU5DGWNH$2HWDO'HWHUPLQLQJWKHRSWLPDOWLPH >@*VFKZHQG -( +HFN 00 /HKPDQQ - 5EEHQ +$OEHUV 3
IRUUDGLFDOF\VWHFWRP\DIWHUQHRDGMXYDQWFKHPRWKHUDS\%-8 :ROII-0HWDO([WHQGHG9HUVXV/LPLWHG/\PSK1RGH'LVVHFWLRQ
,QW LQ %ODGGHU &DQFHU 3DWLHQWV 8QGHUJRLQJ 5DGLFDO &\VWHFWRP\
>@%RHUL / 6ROLJR 0 )UDQN , %RRUMLDQ 6$ 7KRPSVRQ 5+ 6XUYLYDO 5HVXOWV )URP D 3URVSHFWLYH 5DQGRPL]HG7ULDO (XU
7ROOHIVRQ 0 HW DO 'HOD\LQJ 5DGLFDO &\VWHFWRP\ $IWHU 8URO
1HRDGMXYDQW&KHPRWKHUDS\IRU0XVFOHLQYDVLYH%ODGGHU&DQFHU >@-DFREV %/ 'DLJQDXOW 6 /HH &7 +DIH] .6 0RQWJRPHU\ -6
,V$VVRFLDWHG:LWK$GYHUVH6XUYLYDO2XWFRPHV(XU8URO2QFRO 0RQWLH -( HW DO 3URVWDWH &DSVXOH 6SDULQJ 9HUVXV 1HUYH
 6SDULQJ5DGLFDO&\VWHFWRP\IRU%ODGGHU&DQFHU5HVXOWVRID
>@9HQNDWUDPDQL95HLV,0&DVWOH(3*RQ]DOJR0/:RRGV0( 5DQGRPL]HG&RQWUROOHG7ULDO-8URO
6YDWHN56HWDO3UHGLFWRUVRI5HFXUUHQFHDQG3URJUHVVLRQ)UHH >@9HVNLPlH(1HX]LOOHW<5RXDQQH00DF/HQQDQ6/DP7%/
DQG 2YHUDOO 6XUYLYDO )ROORZLQJ 2SHQ 9HUVXV 5RERWLF 5DGLFDO <XDQ < HW DO 6\VWHPDWLF 5HYLHZ RI WKH 2QFRORJLFDO DQG
&\VWHFWRP\$QDO\VLV )URP WKH 5$=25 7ULDO :LWK D <HDU Functional Outcomes of Pelvic Organ-Preserving Radical
)ROORZXS-8URO &\VWHFWRP\ 5& &RPSDUHG :LWK 6WDQGDUG 5& LQ :RPHQ
>@.KDQ062PDU.$KPHG.*DQ&9DQ+HPHOULMFN01DLU5HWDO :KR 8QGHUJR &XUDWLYH 6XUJHU\ DQG 2UWKRWRSLF 1HREODGGHU
/RQJWHUP2QFRORJLFDO2XWFRPHV)URPDQ(DUO\3KDVH5DQGRPLVHG 6XEVWLWXWLRQIRU%ODGGHU&DQFHU%-8,QW
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

>@.DPRXQ$GH5H\QLqV$$OORU\<6M|GDKO*5REHUWVRQ$* >@.UDXVH )6 :DOWHU % 2WW 2- +lEHUOH / :HLVV & 5|GHO &
6HLOHU5HWDO$&RQVHQVXV0ROHFXODU&ODVVLÀFDWLRQRI0XVFOH HWDO\HDUVXUYLYDOUDWHVDIWHUWUDQVXUHWKUDOUHVHFWLRQDQG
LQYDVLYH%ODGGHU&DQFHU(XU8URO UDGLRFKHPRWKHUDS\RUUDGLDWLRQLQEODGGHUFDQFHUWUHDWPHQW
>@3RLQDV*%ODFKH-/.DVVDE&KDKPL'(YUDUG3/$UWXV30 $QWLFDQFHU5HV
$OIRQVL 3 HW DO 9HUVLRQ FRXUWH GHV UHFRPPDQGDWLRQV GH OD >@-DPHV1'+XVVDLQ6$+DOO(-HQNLQV37UHPOHWW-5DZOLQJV&
UpFXSpUDWLRQ DPHOLRUpH DSUqV FKLUXUJLH 5$$& SRXU OD F\V- HWDO5DGLRWKHUDS\ZLWKRUZLWKRXWFKHPRWKHUDS\LQPXVFOH
WHFWRPLHPHVXUHVWHFKQLTXHV3URJ8URO LQYDVLYHEODGGHUFDQFHU1(QJO-0HG
>@.DUO$%XFKQHU$%HFNHU$6WDHKOHU06HLW]0.KRGHU:HWDO >@&RHQ -- =KDQJ 3 6D\ORU 3- /HH &7 :X &/ 3DUNHU :
$1HZ&RQFHSWIRU(DUO\5HFRYHU\$IWHU6XUJHU\IRU3DWLHQWV HWDO%ODGGHU3UHVHUYDWLRQ:LWK7ZLFHD'D\5DGLDWLRQ3OXV
8QGHUJRLQJ5DGLFDO&\VWHFWRP\IRU%ODGGHU&DQFHU5HVXOWVRI )OXRURXUDFLO&LVSODWLQRU2QFH'DLO\5DGLDWLRQ3OXV*HPFLWDELQH
D3URVSHFWLYH5DQGRPL]HG6WXG\-8URO IRU 0XVFOH,QYDVLYH %ODGGHU &DQFHU 15*572* $
>@7DQ:67DQ0</DPE%:6ULGKDU$0RKDPPHG$%DNHU+ 5DQGRPL]HG3KDVH,,7ULDO-&OLQ2QFRO
HW DO ,QWUDFRUSRUHDO 5RERW$VVLVWHG 5DGLFDO &\VWHFWRP\ >@&DIIR 27KRPSVRQ & 'H 6DQWLV 0 .UDJHOL % +DPVWUD '$
7RJHWKHU :LWK DQ (QKDQFHG 5HFRYHU\ 3URJUDPPH ,PSURYHV $]ULD'HWDO&RQFXUUHQW*HPFLWDELQHDQG5DGLRWKHUDS\IRU
3RVWRSHUDWLYH2XWFRPHVE\$JJUHJDWLQJ0DUJLQDO*DLQV%-8 WKH7UHDWPHQW RI 0XVFOH,QYDVLYH %ODGGHU &DQFHU$ 3RROHG
,QW ,QGLYLGXDO 'DWD$QDO\VLV RI (LJKW 3KDVH ,,,7ULDOV 5DGLRWKHU
>@6RXEH\UDQ3%HOOHUD&*R\DUG-+HLW]'&XUp+5RXVVHORW+ 2QFRO
HWDO6FUHHQLQJIRUYXOQHUDELOLW\LQROGHUFDQFHUSDWLHQWVWKH >@-LDQJ '0 -LDQJ + &KXQJ 3:0 =ORWWD $5 )OHVKQHU 1(
21&2'$*( 3URVSHFWLYH 0XOWLFHQWHU &RKRUW 6WXG\ 3/R6 2QH %ULVWRZ5*HWDO1HRDGMXYDQW&KHPRWKHUDS\%HIRUH%ODGGHU
H 6SDULQJ &KHPRUDGLRWKHUDS\ LQ 3DWLHQWV :LWK 1RQPHWDVWDWLF
>@(IVWDWKLRX-$6SLHJHO'<6KLSOH\:8+HQH\10.DXIPDQ'6 0XVFOH,QYDVLYH %ODGGHU &DQFHU &OLQ *HQLWRXULQ &DQFHU
1LHPLHUNR$HWDO/RQJWHUPRXWFRPHVRIVHOHFWLYHEODGGHU 
SUHVHUYDWLRQE\FRPELQHGPRGDOLW\WKHUDS\IRULQYDVLYHEODG- >@&RJQHWWL)5XJJHUL(0)HOLFL$*DOOXFFL00XWR*3ROOHUD&)
GHUFDQFHUWKH0*+H[SHULHQFH(XU8URO HWDO$GMXYDQWFKHPRWKHUDS\ZLWKFLVSODWLQDQGJHPFLWDELQH
>@5|GHO&:HLVV&2UJDQVSDULQJPXOWLPRGDOLW\WUHDWPHQWIRU YHUVXV FKHPRWKHUDS\ DW UHODSVH LQ SDWLHQWV ZLWK PXVFOH
PXVFOHLQYDVLYHEODGGHUFDQFHUFDQZHFRQWLQXHWRLJQRUHWKH LQYDVLYHEODGGHUFDQFHUVXEPLWWHGWRUDGLFDOF\VWHFWRP\DQ
HYLGHQFH"-&OLQ2QFRO ,WDOLDQ PXOWLFHQWHU UDQGRPL]HG SKDVH ,,, WULDO$QQ 2QFRO
>@3ORXVVDUG*'DQHVKPDQG6(IVWDWKLRX-$+HUU+:-DPHV1' 
5|GHO&0HWDO&ULWLFDODQDO\VLVRIEODGGHUVSDULQJZLWKWUL- >@6WHUQEHUJ &1 6NRQHF]QD , .HUVW -0 $OEHUV 3 )RVVn 6'
PRGDOWKHUDS\LQPXVFOHLQYDVLYHEODGGHUFDQFHUDV\VWHPDWLF $JHUE N0HWDO,PPHGLDWHYHUVXVGHIHUUHGFKHPRWKHUDS\
UHYLHZ(XU8URO DIWHU UDGLFDO F\VWHFWRP\ LQ SDWLHQWV ZLWK S7 ² S7 RU 1
>@)DKP\2.KDLUXO$VUL0*6FKXEHUW75HQQLQJHU00DOHN5 0 XURWKHOLDO FDUFLQRPD RI WKH EODGGHU (257&  DQ
.EOHU + HW DO$ V\VWHPDWLF UHYLHZ DQG PHWDDQDO\VLV RQ LQWHUJURXSRSHQODEHOUDQGRPLVHGSKDVHWULDO/DQFHW2QFRO
WKH RQFRORJLFDO ORQJWHUP RXWFRPHV DIWHU WULPRGDOLW\ WKH- 
UDS\ DQG UDGLFDO F\VWHFWRP\ ZLWK RU ZLWKRXW QHRDGMXYDQW >@*DOVN\0'6WHQVODQG.'0RVKLHU(6IDNLDQRV-30F%ULGH5%
FKHPRWKHUDS\IRUPXVFOHLQYDVLYHEODGGHUFDQFHU8URO2QFRO 7VDR &. HW DO (IIHFWLYHQHVV RI $GMXYDQW &KHPRWKHUDS\
 IRU /RFDOO\ $GYDQFHG %ODGGHU &DQFHU - &OLQ 2QFRO
>@0DN 5+ +XQW ' 6KLSOH\ :8 (IVWDWKLRX -$ 7HVWHU :-
+DJDQ03HWDO/RQJWHUPRXWFRPHVLQSDWLHQWVZLWKPXVFOH
LQYDVLYH EODGGHU FDQFHU DIWHU VHOHFWLYH EODGGHUSUHVHUYLQJ
FRPELQHGPRGDOLW\ WKHUDS\ D SRROHG DQDO\VLV RI 5DGLDWLRQ
7KHUDS\ 2QFRORJ\ *URXS SURWRFROV    

>@=DJKORXO06&KULVWRGRXOHDV-36PLWK$$EGDOODK$:LOOLDP+
.KDOHG +0 HW DO$GMXYDQW 6DQGZLFK &KHPRWKHUDS\ 3OXV
5DGLRWKHUDS\ YV$GMXYDQW &KHPRWKHUDS\$ORQH IRU /RFDOO\
$GYDQFHG %ODGGHU &DQFHU $IWHU 5DGLFDO &\VWHFWRP\ $
DQG-&OLQ2QFRO 5DQGRPL]HG3KDVH7ULDO-$0$6XUJH
>@*DUFL3HUGRPR +$ 0RQWHV&DUGRQD &( *XDFKHWD 0 >@%D\RXPL<+HLNDO7'DUZHLVK+6XUYLYDO%HQHÀWRI$GMXYDQW
&DVWLOOR ') 5HLV /2 0XVFOHLQYDVLYH %ODGGHU &DQFHU 2UJDQ 5DGLRWKHUDS\LQ6WDJH,,,DQG,9%ODGGHU&DQFHU5HVXOWVRI
3UHVHUYLQJ7KHUDS\ 6\VWHPDWLF 5HYLHZ DQG 0HWD$QDO\VLV 3DWLHQWV&DQFHU0DQDJH5HV
:RUOG-8URO >@9RVNXLOHQ&66HLOHU55LQN03R\HW&1RRQ$35RJKPDQQ)
>@6HLVHQ76XQ0/LSVLW]65$EGROODK)/HRZ-/0HQRQ0HWDO HWDO8URWKHOLDO&DUFLQRPDLQ%ODGGHU'LYHUWLFXOD$0XOWLFHQWHU
&RPSDUDWLYH(IIHFWLYHQHVVRI7ULPRGDO7KHUDS\9HUVXV5DGLFDO $QDO\VLV RI &KDUDFWHULVWLFV DQG &OLQLFDO 2XWFRPHV (XU 8URO
&\VWHFWRP\IRU/RFDOL]HG0XVFOHLQYDVLYH8URWKHOLDO&DUFLQRPD )RFXV6
RIWKH%ODGGHU(XU8URO >@6LHINHU5DGWNH$8UDFKDODGHQRFDUFLQRPDDFOLQLFLDQ·VJXLGH
>@5LWFK &5 %DOLVH 5 3UDNDVK 16 $ORQ]R ' $OPHQJR . IRUWUHDWPHQW6HPLQ2QFRO
$ODPHGGLQH0HWDO3URSHQVLW\0DWFKHG&RPSDUDWLYH$QDO\VLV >@0LVWUHWWD)$&\U6-/X]]DJR60D]]RQH(.QLSSHU63DOXPER&
RI6XUYLYDO)ROORZLQJ&KHPRUDGLDWLRQRU5DGLFDO&\VWHFWRP\IRU HWDO3DUWLDO&\VWHFWRP\:LWK3HOYLF/\PSK1RGH'LVVHFWLRQIRU
0XVFOH,QYDVLYH%ODGGHU&DQFHU%-8,QW 3DWLHQWV:LWK1RQPHWDVWDWLF6WDJHS778URWKHOLDO&DUFLQRPD
>@&DKQ'%+DQGRUI($*KLUDOGL(05LVWDX%7*H\QLVPDQ'0 RI8ULQDU\%ODGGHU7HPSRUDO7UHQGVDQG6XUYLYDO2XWFRPHV&OLQ
&KXULOOD 70 HW DO &RQWHPSRUDU\ 8VH 7UHQGV DQG 6XUYLYDO *HQLWRXULQ&DQFHUH
2XWFRPHV LQ 3DWLHQWV 8QGHUJRLQJ 5DGLFDO &\VWHFWRP\ RU >@*RORPERV '0 2·0DOOH\ 3 /HZLFNL 3 6WRQH %9 6FKHUU '6
%ODGGHU3UHVHUYDWLRQ 7KHUDS\ IRU 0XVFOH,QYDVLYH %ODGGHU 5RERWDVVLVWHG SDUWLDO F\VWHFWRP\ SHULRSHUDWLYH RXWFRPHV
&DQFHU&DQFHU DQGHDUO\RQFRORJLFDOHIÀFDF\%-8,QW
>@:KDOOH\'&DLQH+0F&ORXG3*XR/.QHHERQH$(DGH7 >@2Z\RQJ 0 .RUX6HQJXO 7 0LDR ) 5D]GDQ 6 0RRUH .-
3URPLVLQJ 5HVXOWV :LWK ,PDJH *XLGHG ,QWHQVLW\ 0RGXODWHG $ODPHGGLQH0HWDO,PSDFWRI6XUJLFDO7HFKQLTXHRQ6XUJLFDO
5DGLRWKHUDS\IRU0XVFOH,QYDVLYH%ODGGHU&DQFHU5DGLDW2QFRO 0DUJLQ 6WDWXV )ROORZLQJ 3DUWLDO &\VWHFWRP\ 8URO 2QFRO
 
>@.KDOLID - 3LJQRW * &XOLQH 6 %HOKRPPH 6 &UHKDQJH * >@/DFDUULqUH(6PDDOL&%HQ\RXFHI$3ÀVWHU&*ULVH37KH
5RXSUHW0HWDO*(78*$)8UHFRPPHQGDWLRQVIRUSODQQLQJ HIILFDF\ RI KHPRVWDWLF UDGLRWKHUDS\ IRU EODGGHU FDQFHU
DQGGHOLYHU\RIUDGLFDOUDGLRWKHUDS\IRUORFDOL]HGXURWKHOLDO UHODWHGKHPDWXULDLQSDWLHQWVXQÀWIRUVXUJHU\,QW%UD]-8URO
FDUFLQRPDRIWKHEODGGHULQSUHVV 
S126 05RXSUrWHWDO

>@$EW'%\ZDWHU0(QJHOHU'66FKPLG+37KHUDSHXWLFRSWLRQV >@YRQGHU0DDVH+*HPFLWDELQHLQWUDQVLWLRQDOFHOOFDUFLQRPD
IRULQWUDFWDEOHKHPDWXULDLQDGYDQFHGEODGGHUFDQFHU,QW- RIWKHXURWKHOLXP([SHUW5HY$QWLFDQFHU7KHU
8URO >@%HOOPXQW-GH:LW59DXJKQ'-)UDGHW</HH-/)RQJ/HWDO
>@'H%HUDUGLQLV(9LFLQL36DOYDWRUL)6FLDUUD$*HQWLOH9'L 3HPEUROL]XPDEDVVHFRQGOLQHWKHUDS\IRUDGYDQFHGXURWKHOLDO
6LOYHULR)6XSHUVHOHFWLYHHPEROL]DWLRQRIEODGGHUDUWHULHVLQ FDUFLQRPD1(QJO-0HG
WKHWUHDWPHQWRILQWUDFWDEOHEODGGHUKDHPRUUKDJH,QW-8URO >@%HOOPXQW - )RXJHUD\ 5 5RVHQEHUJ -( YRQ GHU 0DDVH +
 6FKXW] )$ 6DOKL < HW DO /RQJWHUP VXUYLYDO UHVXOWV RI D
>@*KDKHVWDQL606KDNKVVDOLP13DOOLDWLYHWUHDWPHQWRILQWUDF- UDQGRPL]HGSKDVH,,,WULDORIYLQÁXQLQHSOXVEHVWVXSSRUWLYH
WDEOH KHPDWXULD LQ FRQWH[W RI DGYDQFHG EODGGHU FDQFHU  D FDUHYHUVXVEHVWVXSSRUWLYHFDUHDORQHLQDGYDQFHGXURWKHOLDO
V\VWHPLFUHYLHZ8URO- FDUFLQRPDSDWLHQWVDIWHUIDLOXUHRISODWLQXPEDVHGFKHPRWKH-
>@*URVVPDQ+%1DWDOH5%7DQJHQ&06SHLJKWV929RJHO]DQJ1- UDS\$QQ2QFRO
7UXPS'/HWDO1HRDGMXYDQWFKHPRWKHUDS\SOXVF\VWHFWRP\ >@(GHOLQH-/RULRW<&XOLQH60DVVDUG&$OELJqV/%OHVLXV$
FRPSDUHGZLWKF\VWHFWRP\DORQHIRUORFDOO\DGYDQFHGEODGGHU HW DO $FFHOHUDWHG 09$& FKHPRWKHUDS\ LQ SDWLHQWV ZLWK
FDQFHU1(QJO-0HG DGYDQFHGEODGGHUFDQFHUSUHYLRXVO\WUHDWHGZLWKDSODWLQXP
>@Al-Alao O, Mueller-Leonhard C, Kim SP, Amin A, Tucci C, Kott O, JHPFLWDELQHUHJLPHQ(XU-&DQFHU
HWDO&OLQLFDOO\1RGH3RVLWLYHF18URWKHOLDO&DUFLQRPDRIWKH >@&ROLQ31HX]LOOHW<3LJQRW*5RXSUrW0&RPSHUDW(/DUUp6
%ODGGHU7UHDWHG:LWK&KHPRWKHUDS\DQG5DGLFDO&\VWHFWRP\ HW DO 6XUYHLOODQFH GHV FDUFLQRPHV XURWKpOLDX[  UHYXH GX
&OLQLFDO2XWFRPHVDQG'HYHORSPHQWRID3RVWRSHUDWLYH5LVN Comité de cancérologie de l’Association française d’urologie.
6WUDWLÀFDWLRQ0RGHO8URO2QFROHH 3URJ8URO
>@%DH:./HH+/3DUN6+.LP-+.LP+-0DHQJ&+HWDO >@Carando R, Shariat SF, Moschini M, D’Andrea D. Ureteral and
&RPSDUDWLYH(IIHFWLYHQHVVRI3DOOLDWLYH&KHPRWKHUDS\9HUVXV XUHWKUDO UHFXUUHQFH DIWHU UDGLFDO F\VWHFWRP\ D V\VWHPDWLF
1HRDGMXYDQW&KHPRWKHUDS\)ROORZHGE\5DGLFDO&\VWHFWRP\ UHYLHZ&XUU2SLQ8URO
9HUVXV &\VWHFWRP\ )ROORZHG E\ $GMXYDQW &KHPRWKHUDS\ >@5RXYLqUH2&RUQHOLV)%UXQHOOH65R\&$QGUp0%HOOLQ0)
9HUVXV &\VWHFWRP\ IRU 5HJLRQDO 1RGH3RVLWLYH %ODGGHU HW DO ,PDJLQJ SURWRFROV IRU UHQDO PXOWLSDUDPHWULF 05,
&DQFHU$5HWURVSHFWLYH$QDO\VLV.&6**8&DQFHU0HG DQG 05 XURJUDSK\ UHVXOWV RI D FRQVHQVXV FRQIHUHQFH IURP
 WKH )UHQFK 6RFLHW\ RI *HQLWRXULQDU\ ,PDJLQJ (XU 5DGLRO
>@YRQGHU0DDVH+6HQJHO¡Y/5REHUWV-75LFFL6'RJOLRWWL/ 
Oliver T, et al. Long-term survival results of a randomized >@(LVHQEHUJ 06 7KRPSVRQ 5+ )UDQN , .LP 63 &RWWHU .-
WULDOFRPSDULQJJHPFLWDELQHSOXVFLVSODWLQZLWKPHWKRWUH[DWH Tollefson MK, et al. Long-term Renal Function Outcomes After
YLQEODVWLQHGR[RUXELFLQSOXVFLVSODWLQLQSDWLHQWVZLWKEODGGHU 5DGLFDO&\VWHFWRP\-8URO
FDQFHU-&OLQ2QFRO >@%RRUMLDQ6$.LP63:HLJKW&-&KHYLOOH-&7KDSD3)UDQN,
>@%DMRULQ')'RGG300D]XPGDU0)D]]DUL00F&DIIUH\-$ 5LVN IDFWRUV DQG RXWFRPHV RI XUHWKUDO UHFXUUHQFH IROORZLQJ
6FKHU+,HWDO/RQJWHUPVXUYLYDOLQPHWDVWDWLFWUDQVLWLRQDO UDGLFDOF\VWHFWRP\(XU8URO
FHOOFDUFLQRPDDQGSURJQRVWLFIDFWRUVSUHGLFWLQJRXWFRPHRI >@3RZOHV 7 3DUN 6+ 9RRJ ( &DVHUWD & 9DOGHUUDPD %3
WKHUDS\-&OLQ2QFRO *XUQH\ + .DORIRQRV + 5DGXORYLĄ 6 'HPH\ : 8OOpQ$
>@6RQSDYGH**DOVN\0'%HOOPXQW-$QHZDSSURDFKWRVHFRQG /RULRW < 6ULGKDU 66 7VXFKL\D 1 .RS\OWVRY ( 6WHUQEHUJ
OLQHWKHUDS\IRUXURWKHOLDOFDQFHU"/DQFHW2QFRO &1%HOOPXQW-$UDJRQ&KLQJ-%3HWU\ODN'3/DOLEHUWH5
>@6WHUQEHUJ &1 GH 0XOGHU 3 6FKRUQDJHO -+ 7KHRGRUH & :DQJ-+XDQJ%'DYLV&)RZVW&&RVWD1%ODNH+DVNLQV
)RVVn 6' YDQ 2RVWHURP$7 HW DO 6HYHQ \HDU XSGDWH RI DQ -$ GL 3LHWUR$ *ULYDV 3$YHOXPDE 0DLQWHQDQFH 7KHUDS\
(257&SKDVH,,,WULDORIKLJKGRVHLQWHQVLW\09$&FKHPRWKH- IRU$GYDQFHG RU 0HWDVWDWLF 8URWKHOLDO &DUFLQRPD 1 (QJO
UDS\ DQG *&6) YHUVXV FODVVLF 09$& LQ DGYDQFHG XURWKHOLDO - 0HG  6HS  GRL 
WUDFWWXPRXUV(XU-&DQFHU 1(-0RD
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

Annexe 1. /HGLVSRVLWLIG·pFKDXIIHPHQWYpVLFDOSDUUDGLRIUpTXHQFH
W\SH PLFURRQGHV GpOLYUp DX PR\HQ GX FDWKpWHU YpVLFDO
TV Argumentaires 6\QHUJRŠ$PVWHOYHHQ7KH1HWKHUODQGVDGpPRQWUpXQH
HIÀFDFLWpVXSpULHXUHjOD00&VHXOHDYHFXQHGLPLQXWLRQGH
complémentaires GXULVTXHGHUpFLGLYHHWXQHHIÀFDFLWppTXLYDOHQWHDX
%&*DVVRFLpHjXQHPRUELGLWpVXSpULHXUHDX%&*GDQVXQH
pWXGHUDQGRPLVpHGHSKDVH,,,LQFOXDQWGHV791,0GHULVTXHV
LQWHUPpGLDLUH HW pOHYp HQ DQDO\VH HQ LQWHQWLRQ GH WUDLWHU
Principes techniques et critères (QSHUSURWRFROHSDWLHQWVD\DQWUHoX a minima un traitement
qualitatifs de la RTUV
7URLV PpWDDQDO\VHV RQW pYDOXp O·LQWpUrW GH OD UpVHFWLRQ
PRQREORFRXHQEORF/DSUHPLqUHSRUWDQWVXUpWXGHVGRQW
SURVSHFWLYHHWUDQGRPLVpHDPRQWUpXQHUpGXFWLRQGHOD
GXUpH GH VRQGDJH HW G·KRVSLWDOLVDWLRQ DLQVL TX·XQH UpGXF-
WLRQGXULVTXHGHUpFLGLYHjDQVDVVRFLpHVjODUpVHFWLRQ
PRQREORF>@/DGHX[LqPHPpWDDQDO\VHLQFOXDQWpWXGHV
G·LQFXWLRQGHLQVWLOODWLRQVFRPSOHWODWKHUPRFKLPLRWKpUDSLH
SDUUDGLRIUpTXHQFHDGpPRQWUpXQEpQpÀFHVXUODVXUYHQXH
GHUpFLGLYHV>@(QpFKHFGH%&*PDOJUpGHVGRQQpHVUpWUR
VSHFWLYHVSURPHWWHXVHVFHGLVSRVLWLIQ·DSDVGpPRQWUpGHVXSp-
ULRULWpHQFRPSDUDLVRQjODFKLPLRWKpUDSLHRXjXQHQRXYHOOH
%&*WKpUDSLHGDQVXQHpWXGHSURVSHFWLYHUDQGRPLVpH>@
/H GLVSRVLWLI G·pFKDXIIHPHQW H[WUDYpVLFDO HW GH FLU-
FXODWLRQ HQ FLUFXLW IHUPp GH OD VROXWLRQ GH 00& +,9(&Š,
GRQWSURVSHFWLYHVHWUDQGRPLVpHVDPRQWUpTXHSRXUGHV :KHDWKDPSVWHDG8QLWHG.LQJGRPDGpPRQWUpXQHHIÀFD-
WXPHXUV”FPODUpVHFWLRQPRQREORFDPpOLRUDLWODTXDOLWp FLWpGDQVXQHpWXGHSURVSHFWLYHQRQUDQGRPLVpHGHSKDVH,,
GXSUpOqYHPHQWFKLUXUJLFDOH[DPHQDQDWRPRSDWKRORJLTXH
HWSRXUUDLWDPpOLRUHUO·H[KDXVWLYLWpGHODUpVHFWLRQVDQVHQ
PRGLÀHUODPRUELGLWp>@/DWURLVLqPHSOXVUpFHQWHLQFOXDQW
pWXGHVGRQWSURVSHFWLYHHWUDQGRPLVpHDERXWLWDX[PrPHV
FRQFOXVLRQV>@/HEpQpÀFHDWWHQGXVXUODUpGXFWLRQGXULVTXH
GHUpFLGLYHWXPRUDOHQ·DSDVSXrWUHGpPRQWUpDXWUDYHUVGHV
UpVXOWDWVGLVSRQLEOHVGDQVFHVGHX[GHUQLqUHVPpWDDQDO\VHV
/XPLQRÁXRUHVFHQFHYpVLFDOH
'HX[PpWDDQDO\VHVGHVGRQQpHVJOREDOHVGHUHVSHFWLYHPHQW
HVVDLVGHSKDVH,,,HWHVVDLVGHSKDVH,,,HWXQHpWXGH
UpWURVSHFWLYHRQWpWpUDSSRUWpVSDU&KRXHWDO>@HW*DNLV
HWDO>@(OOHVRQWpWpSRROpHVSDU7UDQHWDOSRXUOHVDXWRULWpV
GHVDQWpFDQDGLHQQHV>@(OOHVPRQWUHQWXQHUpGXFWLRQVLJQL-
ÀFDWLYHGHHWGXULVTXHGHUpFLGLYHjPRLVHW
DXGHOjGHPRLVUHVSHFWLYHPHQWDYHFO·KH[DPLQROpYXOLQDWH
/HQLYHDXGHSUHXYHpWDLWIDLEOHHQUDLVRQGHVELDLVLQKpUHQWV
DX[pWXGHV8QHUpGXFWLRQGHGXULVTXHGHSURJUHVVLRQYHUV
XQH79,0DpWpUDSSRUWpHDYHFXQQLYHDXGHSUHXYHPRGpUp
LQFOXDQW GHV791,0 GH ULVTXH LQWHUPpGLDLUH &HV GRQQpHV
PpULWHQWG·rWUHFRQÀUPpHVSDUXQHpWXGHUDQGRPLVpH>@
Cystoscopie et biopsies
8QH pWXGH GH SKDVH  SRUWDQW VXU  SDWLHQWV D pYDOXp
OHJDLQGLDJQRVWLFDVVRFLpjO·XWLOLVDWLRQGHODÁXRUHVFHQFH
YpVLFDOHHQOXPLqUHEOHXHDSUqVLQVWLOODWLRQG·KH[DPLQROpYX-
OLQDWH>@PRQWUDQWXQJDLQGHGLDJQRVWLFFKH]GHV
SDWLHQWVGRQWXQHGpWHFWLRQGH&,6GDQVGHVFDV/HWDX[
GH IDX[ SRVLWLI UDSSRUWp j O·XWLOLVDWLRQ GH OD ÁXRUHVFHQFH
YpVLFDOHHQOXPLqUHEOHXHDpWpGHHWpWDLWFRPSDUDEOH
jFHOXLUDSSRUWpjODOXPLqUHEODQFKH/DPRUELGLWpDVVRFLpH
jO·XWLOLVDWLRQGHODÁXRUHVFHQFHYpVLFDOHHQOXPLqUHEOHXHD
pWpGHFRQVLVWDQWHQGHVG\VXULHVHWGRXOHXUVXUpWUDOHV
GHJUDGHV&HWWHpWXGHLVROpHQHSHUPHWSDVGHUHFRP-
PDQGHUO·XWLOLVDWLRQGHODÁXRUHVFHQFHYpVLFDOHHQOXPLqUH
EOHXHSRXUODÀEURVFRSLHGHVXLYLGHVSDWLHQWVDWWHLQWVGH
791,0niveau de preuve 3).
(QLYHDXGHSUHXYH&HVPpWDDQDO\VHVQHSHUPHWWDLHQWSDV
GHGpÀQLUOHVFDUDFWpULVWLTXHVGHVWXPHXUVGHVSDWLHQWVFKH] Place de la surveillance active
TXLO·KH[DPLQROpYXOLQDWHDDSSRUWpXQHUpGXFWLRQGHODVXUYLH
VDQVUpFLGLYHHWRXVDQVSURJUHVVLRQ /D VXUYHLOODQFH DFWLYH G·XQH UpFLGLYH G·XQH791,0 LQLWLD-
/D PpWDDQDO\VH GHV GRQQpHV EUXWHV GH  pWXGHV VXU OHPHQW FODVVpH FRPPH GH IDLEOH ULVTXH RX LQWHUPpGLDLUH
O·XWLOLVDWLRQ GH OD ÁXRUHVFHQFH YpVLFDOH HQ OXPLqUH EOHXH DpWppYDOXpHGDQVOHFDGUHGHGHX[pWXGHVSURVSHFWLYHV
DSUqV LQVWLOODWLRQ SUpRSpUDWRLUH G·KH[DPLQROpYXOLQDWH D /HVFULWqUHVG·LQFOXVLRQVHWGHPDLQWLHQGDQVOHSURWRFROHGH
PRQWUpXQEpQpÀFHSRXU>@ VXUYHLOODQFHpWDLHQWXQQRPEUHPD[LPDOGHWXPHXUVHWXQH
• ODGpWHFWLRQGHVOpVLRQVWXPRUDOHVS7DS7ORUVGHVWRXWHV WDLOOHWXPRUDOHPD[LPXPGHFPDVVRFLpjXQHF\WRORJLH
SUHPLqUHV5789VDXIHQFDVGHWXPHXUXQLIRFDOHFP XULQDLUHQpJDWLYHSRXUXQFDUFLQRPHXURWKpOLDOGHKDXWJUDGH
DYHFF\WRORJLHXULQDLUHQRUPDOHQLYHDXGHSUHXYH /DVXUYHLOODQFHFRQVLVWDLWHQXQHF\WRORJLHXULQDLUHHWXQH
• OD GpWHFWLRQ GHV OpVLRQV GH &,6 QRWDPPHQW ORUVTXH OD F\VWRVFRSLHWULPHVWULHOOHODSUHPLqUHDQQpHSXLVVHPHVWULHOOH
F\WRORJLHXULQDLUHHVWVXVSHFWHGHSUpVHQFHG·XQHWXPHXU HQVXLWH/D5789DpWppYLWpHGDQVO·DQQpHVXLYDQWO·LQFOXVLRQ
GHKDXWJUDGHHWODF\VWRVFRSLHHQOXPLqUHEODQFKHQH FKH]HWGHVSDWLHQWVUHVSHFWLYHPHQWGDQVO·pWXGH
UpYqOHSDVGHOpVLRQSDSLOODLUHQLYHDXGHSUHXYH).
Thermochimiothérapie
/DSpQpWUDWLRQ HWO·HIÀFDFLWpGHOD00&HQHVWDPpOLRUpH
DYHF XQH WROpUDQFH VDWLVIDLVDQWH 'HX[ GLVSRVLWLIV VRQW
commercialisés.
HVSDJQROH>@HWLWDOLHQQH>@VDQVFRPSURPHWWUHOHSUR-
QRVWLFFDUFLQRORJLTXHGHVSDWLHQWVVXUYHLOOpV>@(XpJDUG
jFHVGRQQpHVODVXUYHLOODQFHDFWLYHSHXWrWUHSURSRVpHHQ
RSWLRQDX[SDWLHQWVUpSRQGDQWSUpVHQWDQWXQHUpFLGLYHDSUqV
SOXVG·XQDQGHVXLYLG·XQH791,0S7DGHEDVJUDGHG·DX
PD[LPXPWXPHXUVGHWDLOOH”FPD\DQWXQHF\WRORJLH
XULQDLUHQRUPDOHHWDFFHSWDQWODVXUYHLOODQFHSOXVUDSSURFKpH
(niveau de preuve 3).
S128 05RXSUrWHWDO

>@ :X<3/LQ77&KHQ6+;X1:HL<+XDQJ-%HWDO&RPSDULVRQ
Place de la fulguration RIWKHHIÀFDF\DQGIHDVLELOLW\RIHQEORFWUDQVXUHWKUDOUHVHFWLRQ
RIEODGGHUWXPRUYHUVXVFRQYHQWLRQDOWUDQVXUHWKUDOUHVHFWLRQ
/H WUDLWHPHQW FKLUXUJLFDO GH UpIpUHQFH HVW OD 5789 (OOH RI EODGGHU WXPRU $ PHWDDQDO\VLV 0HGLFLQH %DOWLPRUH
GRLW rWUH DVVRFLpH j XQ second look en cas de résection HGRL0'
LQFRPSOqWH G·DEVHQFH GH PXVFOH VDXI7D EDV JUDGH RX >@ .UDPHU 0:$OWLHUL 9 +XUOH 5 /XVXDUGL / 0HUVHEXUJHU$6
*GHS7(QO·DEVHQFHG·HVVDLFRQWU{OpUDQGRPLVpOD 5DVVZHLOHU-HWDO&XUUHQW(YLGHQFHRI7UDQVXUHWKUDO(QEORF
IXOJXUDWLRQSHXWrWUHSURSRVpHFRPPHXQHRSWLRQFKLUXU- 5HVHFWLRQRI1RQPXVFOH,QYDVLYH%ODGGHU&DQFHU(XU8URO)RFXV
JLFDOH SRXU OH WUDLWHPHQW GHV UpFLGLYHV SDSLOODLUHV GHV GRLMHXI
791,0GHEDVULVTXHPRLQVGHWXPHXUVWDLOOHFP >@ <DQJ + /LQ - *DR 3 +H = .XDQJ ; /L ; HW DO ,V WKH (Q
%ORF7UDQVXUHWKUDO5HVHFWLRQ0RUH(IIHFWLYHWKDQ&RQYHQWLRQDO
SHUPHWWDQWGHGLPLQXHUOHVULVTXHVSpULRSpUDWRLUHVniveau
7UDQVXUHWKUDO5HVHFWLRQIRU1RQ0XVFOH,QYDVLYH%ODGGHU&DQFHU"
de preuve 3>@
'DQVO·pWXGHSURVSHFWLYHGH3ODQHOOHV*RPHV-HWDO
SDWLHQWVRQWpWpWUDLWpVHQWUHIpYULHUHWIpYULHU
SDUODYDSRULVDWLRQDXODVHU+ROPLXP<$*GHUpFLGLYHV791,0
$6\VWHPDWLF5HYLHZDQG0HWD$QDO\VLV>SXEOLVKHGRQOLQHDKHDG
RISULQW-DQ@8URO,QWGRL
>@ &KRX56HOSK6%XFNOH\',)X5*ULIÀQ-&*UXVLQJ6HWDO
&RPSDUDWLYH(IIHFWLYHQHVVRI)OXRUHVFHQW9HUVXV:KLWH/LJKW
GHULVTXHIDLEOHn RXLQWHUPpGLDLUHn RXGH &\VWRVFRS\IRU,QLWLDO'LDJQRVLVRU6XUYHLOODQFHRI%ODGGHU&DQFHU
791,0GHKDXWULVTXHFKH]GHVSDWLHQWV$6$n >@ RQ&OLQLFDO2XWFRPHV6\VWHPDWLF5HYLHZDQG0HWD$QDO\VLV-
/HWDX[GHUpFLGLYHFRQVWDWpjODreÀEURVFRSLHPRLVD 8UROGRLMMXUR
pWp GH  ­  PRLV  GHV SDWLHQWV  ²  GHV >@ *DNLV * )DKP\ 2 6\VWHPDWLF 5HYLHZ DQG 0HWD$QDO\VLV
IDLEOHVULVTXHV²GHVULVTXHVLQWHUPpGLDLUHVHW RQ WKH ,PSDFW RI +H[DPLQROHYXOLQDWH 9HUVXV :KLWH/LJKW
²GHVKDXWVULVTXHV *XLGHG7UDQVXUHWKUDO%ODGGHU7XPRU5HVHFWLRQRQ3URJUHVVLRQ
LQ 1RQ0XVFOH ,QYDVLYH %ODGGHU &DQFHU %ODGGHU &DQFHU
'DQV O·pWXGH SURVSHFWLYH GH 5LYHUR *XHUUD $
GRL%/&
HW DO  SDWLHQWV RQW pWp WUDLWpV HQWUH MDQYLHU  HW
>@ 7UDQ . 6HYHUQ 0 %OXH /LJKW &\VWRVFRS\ LQ 3DWLHQWV ZLWK
GpFHPEUH  SDU OD YDSRULVDWLRQ DX ODVHU +ROPLXP<$* 6XVSHFWHG1RQ0XVFOH,QYDVLYH%ODGGHU&DUFLQRPD$5HYLHZ
GHUpFLGLYHVSDSLOODLUHVPD[OpVLRQVPPF\WRORJLH RI&OLQLFDO8WLOLW\2WWDZD21&DQDGLDQ$JHQF\IRU'UXJVDQG
XULQDLUHQpJDWLYHGH791,0GHULVTXHIDLEOH>@/HWDX[
GHUpFLGLYHDpWpGHjPRLV/DVXUYLHVDQVUpFLGLYHV
DSUqVWUDLWHPHQWVGHVresUpFLGLYHVGH791,0DpWpVXSpULHXUH
jFHOOHDSUqVWUDLWHPHQWVGHUpFLGLYHVLWpUDWLYHVGH791,0
'DQV O·pWXGH SURVSHFWLYH GH :RQJ .$ HW DO
SDWLHQWVkJpVRXIUDJLOHVRQWpWpWUDLWpVHQWUHPDUV
HWMXLOOHWSDUODYDSRULVDWLRQDXODVHU+ROPLXP<$*GH
UpFLGLYHVGH791,0GHWRXVJURXSHVGHULVTXHHW79,0GH
7HFKQRORJLHVLQ+HDOWK
>@ %XUJHU0*URVVPDQ+%'UROOHU06FKPLGEDXHU-+HUPDQQ*
'UČJRHVFX 2 HW DO 3KRWRG\QDPLF GLDJQRVLV RI QRQPXVFOH
LQYDVLYHEODGGHUFDQFHUZLWKKH[DPLQROHYXOLQDWHF\VWRVFRS\D
PHWDDQDO\VLVRIGHWHFWLRQDQGUHFXUUHQFHEDVHGRQUDZGDWD
(XU8UROGRLMHXUXUR
>@ $UHQGV7-1DWLY20DIIH]]LQL0&REHOOL2&DQHSD*9HUZHLM)
HW DO 5HVXOWV RI D 5DQGRPLVHG &RQWUROOHG 7ULDO &RPSDULQJ
,QWUDYHVLFDO &KHPRK\SHUWKHUPLD ZLWK 0LWRP\FLQ & 9HUVXV
IDLEOHYROXPHFP>@6RL[DQWHTXDWRU]HSURFpGXUHV
%DFLOOXV&DOPHWWH*XpULQIRU$GMXYDQW7UHDWPHQWRI3DWLHQWVZLWK
RQWpWpIDLWHVGRQWDYHFOXPLQRÁXRUHVFHQFH/HWDX[GH ,QWHUPHGLDWHDQG+LJKULVN1RQ0XVFOHLQYDVLYH%ODGGHU&DQFHU
UpFLGLYHjDQDpWpGHHWSRXUOHVSDWLHQWV (XU8UROGRLMHXUXUR
WUDLWpVVDQVHWDYHFOXPLQRÁXURUHVFHQFHUHVSHFWLYHPHQW >@ 7DQ:63DQFKDO$%XFNOH\/'HYDOO$-/RXELqUH/63RSH$0
,QFOXDQWXQHSRSXODWLRQDWWHLQWHGHWXPHXUVSOXVKpWpUR HW DO 5DGLRIUHTXHQF\LQGXFHG 7KHUPRFKHPRWKHUDS\
gènes et traitée avec une méthode non recommandée (IIHFW 9HUVXV D 6HFRQG &RXUVH RI %DFLOOXV &DOPHWWH*XpULQ
ÀEURVFRSLH DYHF OXPLQRÁXRUHVFHQFH OHV UpVXOWDWV GH RU ,QVWLWXWLRQDO 6WDQGDUG LQ 3DWLHQWV ZLWK 5HFXUUHQFH RI
FHWWH pWXGH IRQW O·REMHW GH UpVHUYHV GDQV O·pODERUDWLRQ 1RQPXVFOHLQYDVLYH %ODGGHU &DQFHU )ROORZLQJ ,QGXFWLRQ RU
de recommandations. 0DLQWHQDQFH %DFLOOXV &DOPHWWH*XpULQ 7KHUDS\ +<01$
3KDVH,,,2SHQODEHO5DQGRPLVHG&RQWUROOHG7ULDO(XU8URO
GRLMHXUXUR
>@ GH-RQJ--+HQGULFNVHQ.5RVLHU00RVWDÀG+%RRUPDQV-/
Traitement du CIS isolé récidivant +\SHUWKHUPLF,QWUDYHVLFDO&KHPRWKHUDS\IRU%&*8QUHVSRQVLYH
1RQ0XVFOH,QYDVLYH%ODGGHU&DQFHU3DWLHQWV%ODGGHU&DQFHU
/·pWXGH GX 6:2*  D PRQWUp TXH OH WDX[ GH UpSRQVH GRL%/&
FRPSOqWHjPRLVpWDLWPHLOOHXUTX·jPRLV%&*WUDLWHPHQW >@ 'DQHVKPDQG63DWHO6/RWDQ<3RKDU.7UDEXOVL(:RRGV0
G·LQGXFWLRQYV%&*WUDLWHPHQW,QGXFWLRQHQWUHWLHQ HWDO(IÀFDF\DQG6DIHW\RI%OXH/LJKW)OH[LEOH&\VWRVFRS\ZLWK
YV>@ +H[DPLQROHYXOLQDWHLQWKH6XUYHLOODQFHRI%ODGGHU&DQFHU$
/DUpSRQVHDX[LQVWLOODWLRQVHQGRYpVLFDOHVGH%&*HVWXQ 3KDVH,,,&RPSDUDWLYH0XOWLFHQWHU6WXG\>SXEOLVKHGFRUUHFWLRQ
IDFWHXUSURQRVWLFLPSRUWDQWGHVSDWLHQWVUpSRQGHXUV DSSHDUVLQ-8URO@-8URO
DX%&*DXURQWXQHSURJUHVVLRQYHUVOD79,0FRQWUHHQYLURQ GRLMMXUR
GHVSDWLHQWVQRQUpSRQGHXUVQLYHDXGHSUHXYH>@ >@ +HUQiQGH] 9 /ORUHQWH & GH OD 3HxD ( 3pUH])HUQiQGH] (
8QHUpFLGLYHDSUqVXQDQGHUpPLVVLRQHVWXQIDFWHXUSUpGLFWLI *XLMDUUR$6ROD,/RQJWHUPRQFRORJLFDORXWFRPHVRIDQDFWLYH
VXUYHLOODQFHSURJUDPLQUHFXUUHQWORZJUDGH7DEODGGHUFDQFHU
LQGpSHQGDQWGHPHLOOHXUHUpSRQVHDXWUDLWHPHQW
8URO2QFROHH(GRLM
8QHpWXGHUpWURVSHFWLYHUDSSRUWDLWSOXVGHGHOpVLRQV
urolonc.2015.11.005.
XUpWpUDOHV RX XUpWUDOHV DVVRFLpHV DX[ UpFLGLYHV GH791,0 >@ +XUOH5/D]]HUL09DQQL(/XJKH]]DQL*%XIÀ10&DVDOH3
DSUqV%&*niveau de preuve 4>@ HW DO$FWLYH 6XUYHLOODQFH IRU /RZ 5LVN 1RQPXVFOH ,QYDVLYH
/DF\VWHFWRPLHSRXU&,6UpVLVWDQWDX[WUDLWHPHQWVFRQVHU- %ODGGHU &DQFHU$ &RQÀUPDWRU\ DQG 5HVRXUFH &RQVXPSWLRQ
YDWHXUVSHUPHWXQHVXUYLHJOREDOHjDQVFRPSULVHHQWUH 6WXG\ IURP WKH %,$6 3URMHFW - 8URO 
HW>@ GRLMMXUR
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

>@ +XUOH 5 &RORPER 3 /D]]HUL 0 /XJKH]]DQL * %XIIL 10 FDQFHU LV LW VDIH WROHUDEOH DQG FRVWHIIHFWLYH" %-8 ,QW
Saita A, et al. Pathological Outcomes for Patients Who Failed GRLEMX
7R5HPDLQ8QGHU$FWLYH6XUYHLOODQFHIRU/RZULVN1RQPXVFOH >@ /DPP '/ %OXPHQVWHLQ %$ &ULVVPDQ -' 0RQWLH -(
LQYDVLYH%ODGGHU&DQFHU8SGDWHDQG5HVXOWVIURPWKH%ODGGHU *RWWHVPDQ -( /RZH %$ HW DO 0DLQWHQDQFH EDFLOOXV
&DQFHU ,WDOLDQ$FWLYH 6XUYHLOODQFH 3URMHFW (XU 8URO 2QFRO &DOPHWWH*XHULQ LPPXQRWKHUDS\ IRU UHFXUUHQW 7$ 7
GRLMHXR and carcinoma in situ transitional cell carcinoma of the
>@ +HUU +: 'RQDW 60 5HXWHU 9( 0DQDJHPHQW RI ORZ JUDGH EODGGHUDUDQGRPL]HG6RXWKZHVW2QFRORJ\*URXS6WXG\-
SDSLOODU\ EODGGHU WXPRUV - 8URO  3W 
GRLMMXUR
>@ 3ODQHOOHV*yPH]-2OPRV6iQFKH]/&DUGRVD%HQHW--0DUWtQH]
/ySH] ( 9LGDO 0RUHQR -) +ROPLXP<$* 3KRWRFRDJXODWLRQ
Safe and Economical Alternative to Transurethral Resection
8URO
>@ 5RXSUrW 0 1HX]LOOHW< 3LJQRW * HW DO 5HFRPPDQGDWLRQV
françaises du Comité de Cancérologie de l’AFU – Actualisation
2018-2020 : tumeurs de la vessie [French ccAFU guide-
OLQHV ² 8SGDWH ² %ODGGHU FDQFHU@ 3URJ 8URO
LQ 6PDOO 1RQPXVFOH,QYDVLYH %ODGGHU 7XPRUV - (QGRXURO 655GRLMSXURO
GRLHQG >@ *LDQQDULQL*%LUNKlXVHU)'5HFNHU)7KDOPDQQ*16WXGHU8(
>@ 5LYHUR *XHUUD É )HUQiQGH] $SDULFLR 7 %DUFHOy %D\RQDV , %DFLOOXV&DOPHWWH*XpULQIDLOXUHLQSDWLHQWVZLWKQRQPXVFOH
0DUWtQH]$3*XLOOHUPR903HUDOWD'-HWDO2XWSDWLHQW+ROPLXP LQYDVLYHXURWKHOLDOFDUFLQRPDRIWKHEODGGHUPD\EHGXHWR
ODVHUIXOJXUDWLRQ$VDIHSURFHGXUHIRUWUHDWPHQWRIUHFXUUHQFH the urologist’s failure to detect urothelial carcinoma of the
RIQRQPXVFOHLQYDVLYHEODGGHUFDQFHU)XOJXUDFLyQDPEXODWRULD XSSHUXULQDU\WUDFWDQGXUHWKUD(XU8URO
FRQOiVHU+ROPLXP8QSURFHGLPLHQWRVHJXURSDUDHOWUDWDPLHQWR GRLMHXUXUR
GHODUHFLGLYDGHOFDUFLQRPDYHVLFDOQRP~VFXORLQÀOWUDQWH$FWDV >@ &DVH\5*&DWWR-:&KHQJ/&RRNVRQ06+HUU+6KDULDW6
8URO(VSGRLMDFXUR et al. Diagnosis and management of urothelial carcinoma in
>@ :RQJ .$ =LVHQJZH *$WKDQDVLRX7 2·%ULHQ77KRPDV . VLWXRIWKHORZHUXULQDU\WUDFWDV\VWHPDWLFUHYLHZ(XU8URO
2XWSDWLHQW ODVHU DEODWLRQ RI QRQPXVFOHLQYDVLYH EODGGHU GRLMHXUXUR
S130 05RXSUrWHWDO

$QQH[H3ODFHGHO·,50 >@ 3DQHELDQFR91DUXPL<$OWXQ(%RFKQHU%+(IVWDWKLRX-$

+DIHH]6HWDO0XOWLSDUDPHWULF0DJQHWLF5HVRQDQFH,PDJLQJ

de vessie dans la prise

IRU%ODGGHU&DQFHU'HYHORSPHQWRI9,5$'69HVLFDO,PDJLQJ
5HSRUWLQJ$QG'DWD6\VWHP(XU8URO
>@ :DQJ=6KDQJ</XDQ7'XDQ<:DQJ-:DQJ+HWDO(YDOXDWLRQ
en charge des TVIM RIWKHYDOXHRIWKH9,5$'6VFRULQJV\VWHPLQDVVHVVLQJPXVFOH
LQÀOWUDWLRQE\EODGGHUFDQFHU&DQFHU,PDJLQJ
>@ .LP6+9DOLGDWLRQRIYHVLFDOLPDJLQJUHSRUWLQJDQGGDWDV\VWHP
/HVSHUIRUPDQFHVGHO·,50SRXUODVWDGLÀFDWLRQORFDOH7GHOD IRUDVVHVVLQJPXVFOHLQYDVLRQLQEODGGHUWXPRU$EGRP5DGLRO
1<
WXPHXUYpVLFDOHVRQWQHWWHPHQWVXSpULHXUHVjO·XURVFDQQHU
>@ 'HO*LXGLFH)%DUFKHWWL*'H%HUDUGLQLV(3HFRUDUR0>@
HWSHUPHWWHQWGHIDLUHODGLIIpUHQFHHQWUHWXPHXUVVXSHU- 6DOYR 9 6LPRQH * HW DO 3URVSHFWLYH$VVHVVPHQW RI 9HVLFDO
ÀFLHOOHVHWLQÀOWUDQWHVDYHFGHVVHQVLELOLWpVSRROpHVGHO·RUGUH
GHHWVSpFLÀFLWpVSRROpHVGHO·RUGUHGH>@
Des recommandations concernant la réalisation, l’inter-
SUpWDWLRQ HW OD VWDQGDUGLVDWLRQ GHV FRPSWHVUHQGXV G·,50
YpVLFDOH RQW pWp SXEOLpHV HQ  VRXV OD GpQRPLQDWLRQ
,PDJLQJ5HSRUWLQJDQG'DWD6\VWHP9,5$'6DQG,WV&OLQLFDO
,PSDFWRQWKH0DQDJHPHQWRI+LJKULVN1RQPXVFOHLQYDVLYH
%ODGGHU&DQFHU3DWLHQWV&DQGLGDWHIRU5HSHDWHG7UDQVXUHWKUDO
5HVHFWLRQ(XU8URO
>@ :DQJ+/XR&=KDQJ)*XDQ-/L6<DR+HWDO0XOWLSDUDPHWULF
Vesical Imaging-Reporting and Data System 9,5$'6 >@
/HV pWXGHV GH YDOLGDWLRQ GX 9,5$'6 VRQW HQFRXUDJHDQWHV
jODIRLVHQWHUPHVGHUHSURGXFWLELOLWpLQWHUOHFWHXUVHWGH
SHUIRUPDQFHVGLDJQRVWLTXHV>@
En attendant les résultats des études en cours, la réali-
VDWLRQG·XQH,50YpVLFDOHPXOWLSDUDPpWULTXHDYDQWUpVHFWLRQ
HVWVRXKDLWDEOHSRXUOHELODQGHWRXWHWXPHXUGHYHVVLHVLOHV
GpODLVG·REWHQWLRQGHO·H[DPHQQHUHWDUGHQWSDVODSULVHHQ
FKDUJHGXSDWLHQW>@niveau de preuve faible).
/·,50 DPpOLRUH OD VWDGLILFDWLRQ JDQJOLRQQDLUH GH OD
PDODGLH SDU UDSSRUW DX VFDQQHU >@ 'HX[ PpWDDQDO\VHV
UpFHQWHV UHWURXYHQW XQH 6HQVLELOLWp HQWUH  HW  HW
XQH 6SpFLÀFLWp HQWUH  HW  WUDGXLVDQW OHV GLIÀFXOWpV
SHUVLVWDQWHV GH O·LPDJHULH j GLDJQRVWLTXHU OHV PpWDVWDVHV
GDQVGHVJDQJOLRQVGHSHWLWHWDLOOH>@3OXVLHXUVpWXGHV
05,IRU%ODGGHU&DQFHU9DOLGDWLRQRI9,5$'6IRUWKH'HWHFWLRQ
RI'HWUXVRU0XVFOH,QYDVLRQ5DGLRORJ\
>@ 8HQR < 7DNHXFKL 0 7DPDGD 7 6RIXH . 7DNDKDVKL 6
.DPLVKLPD< HW DO 'LDJQRVWLF$FFXUDF\ DQG ,QWHUREVHUYHU
$JUHHPHQWIRUWKH9HVLFDO,PDJLQJ5HSRUWLQJDQG'DWD6\VWHP
IRU0XVFOHLQYDVLYH%ODGGHU&DQFHU$0XOWLUHDGHU9DOLGDWLRQ
6WXG\(XU8URO
>@ +RQJ6%/HH1..LP66RQ,:+D+..X-<HWDO9HVLFDO
,PDJLQJ5HSRUWLQJDQG'DWD6\VWHPIRU0XOWLSDUDPHWULF05,WR
3UHGLFWWKH3UHVHQFHRI0XVFOH,QYDVLRQIRU%ODGGHU&DQFHU-
0DJQ5HVRQ,PDJLQJ
>@ 9D] $ =DSDUROOL 0 'LDJQRVWLF DFFXUDF\ RI UHWURVSHFWLYH
DSSOLFDWLRQRIWKH9HVLFDO,PDJLQJ5HSRUWLQJDQG'DWD6\VWHP
SUHOLPLQDU\UHVXOWV5DGLRO%UDV
>@ 0DNERXO 0 )DUJKDO\ 6$EGHONDZL ,) 0XOWLSDUDPHWULF 05,
LQ GLIIHUHQWLDWLRQ EHWZHHQ PXVFOH LQYDVLYH DQG QRQPXVFOH
LQYDVLYH XULQDU\ EODGGHU FDQFHU ZLWK YHVLFDO LPDJLQJ UHSRU-
pYRTXHQWXQHDPpOLRUDWLRQGHODVWDGLÀFDWLRQJDQJOLRQQDLUH WLQJ DQG GDWD V\VWHP 9,5$'6 DSSOLFDWLRQ %U - 5DGLRO
HWQRWDPPHQWGHODVHQVLELOLWpGHO·H[DPHQSDUO·XWLOLVDWLRQ 
GHVVpTXHQFHVGHGLIIXVLRQ':,>@ >@ /XR&+XDQJ%:X<&KHQ-&KHQ/8VHRI9HVLFDO,PDJLQJ
/·,50 YpVLFDOH LQLWLDOH SRXUUDLW pJDOHPHQW SHUPHWWUH
G·HVWLPHU OH SURQRVWLF GH OD WXPHXU >@ OH JUDGH
FHOOXODLUH GH OD OpVLRQ >@ RX OD VHQVLELOLWp j OD
UDGLRFKLPLRWKpUDSLH>@PDLVFHVGRQQpHVVRQWHQFRUH
SUpOLPLQDLUHV
$SUqVFKLPLRWKpUDSLHQpRDGMXYDQWHO·,50SHXWpJDOH-
PHQWVHUYLUjODUppYDOXDWLRQGHODWXPHXUYpVLFDOH>@
HWGDQVOHELODQSUpFKLUXUJLFDOSRXUpYDOXHUQRWDPPHQWOHV
SRVVLELOLWpV GH SUpVHUYDWLRQ JpQLWDOH niveau de preuve
5HSRUWLQJDQG'DWD6\VWHP9,5$'6IRUGHWHFWLQJWKHPXVFOH
LQYDVLRQ RI EODGGHU FDQFHU D GLDJQRVWLF PHWDDQDO\VLV (XU
5DGLRO
>@ :RR 6 3DQHELDQFR 9 1DUXPL < 'HO *LXGLFH ) 0XJOLD 9)
7DNHXFKL0HWDO'LDJQRVWLF3HUIRUPDQFHRI9HVLFDO,PDJLQJ
5HSRUWLQJDQG'DWD6\VWHPIRUWKH3UHGLFWLRQRI0XVFOHLQYDVLYH
%ODGGHU&DQFHU$6\VWHPDWLF5HYLHZDQG0HWDDQDO\VLV(XU
8URO2QFRO
>@ 3HFRUDUR 07DNHXFKL 0 9DUJDV +$ 0XJOLD 9) &LSROODUL 6
&DWDODQR & HW DO 2YHUYLHZ RI 9,5$'6 LQ %ODGGHU &DQFHU
faible­O·KHXUHDFWXHOOHO·,50YpVLFDOHSHQGDQWRXDSUqV
FKLPLRWKpUDSLH QpRDGMXYDQWH SHXW rWUH SURSRVpH GDQV OH
FDGUHG·pWXGHVVFLHQWLÀTXHV>@
>@ *DQGKL1.ULVKQD6%RRWK&0%UHDX5+)ORRG7$0RUJDQ6&
HWDO'LDJQRVWLFDFFXUDF\RIPDJQHWLFUHVRQDQFHLPDJLQJIRU
WXPRXU VWDJLQJ RI EODGGHU FDQFHU V\VWHPDWLF UHYLHZ DQG
PHWDDQDO\VLV%-8,QW
>@ =KDQJ 1 :DQJ ; :DQJ & &KHQ 6 :X - =KDQJ * HW DO
'LDJQRVWLF$FFXUDF\RI0XOWL3DUDPHWULF0DJQHWLF5HVRQDQFH
,PDJLQJIRU7XPRU6WDJLQJRI%ODGGHU&DQFHU0HWD$QDO\VLV
)URQW2QFRO
>@ +XDQJ/.RQJ4/LX=:DQJ-.DQJ==KX<7KH'LDJQRVWLF
9DOXH RI 05 ,PDJLQJ LQ 'LIIHUHQWLDWLQJ7 6WDJLQJ RI %ODGGHU
&DQFHU$0HWD$QDO\VLV5DGLRORJ\
>@ :RR 6 6XK &+ .LP 6< &KR -< .LP 6+ 'LDJQRVWLF SHUIRU-
PDQFHRI05,IRUSUHGLFWLRQRIPXVFOHLQYDVLYHQHVVRIEODGGHU
FDQFHU$V\VWHPDWLFUHYLHZDQGPHWDDQDO\VLV(XU-5DGLRO

$-5$P-5RHQWJHQRO>(SXEDKHDGRISULQW@
>@ 0DUFKLRQL03ULPLFHUL*'HOOL3L]]L$%DVLOLFR5%HUDUGLQHOOL)
0LQFX]]L ( HW DO &RXOG %ODGGHU 0XOWLSDUDPHWULF 05, %H
,QWURGXFHGLQ5RXWLQH&OLQLFDO3UDFWLFH"5ROHRIWKH1HZ9,5$'6
6FRUH5HVXOWV)URPD3URVSHFWLYH6WXG\&OLQ*HQLWRXULQ&DQFHU
H>(SXEDKHDGRISULQW@
>@ 0DUJROLV '-$ +X -& 9\LQJ IRU 6WDQGDUGL]DWLRQ RI %ODGGHU
&DQFHU05,,QWHUSUHWDWLRQDQG5HSRUWLQJ9,5$'65DGLRORJ\

>@ .RJD):KDWDUHUROHVRIPXOWLSDUDPHWULFPDJQHWLFUHVRQDQFH
LPDJLQJ SULRU WR WUDQVXUHWKUDO UHVHFWLRQ RI EODGGHU WXPRU"
7UDQVO$QGURO8URO
>@ &UR]LHU-3DSD13HUHUD01JR%%ROWRQ'6HQJXSWD6HWDO
&RPSDUDWLYHVHQVLWLYLW\DQGVSHFLÀFLW\RILPDJLQJPRGDOLWLHV
LQVWDJLQJEODGGHUFDQFHUSULRUWRUDGLFDOF\VWHFWRP\DV\VWH-
PDWLFUHYLHZDQGPHWDDQDO\VLV:RUOG-8URO
>@ :RR66XK&+.LP6<&KR-<.LP6+7KHGLDJQRVWLFSHUIRU-
PDQFHRI05,IRUGHWHFWLRQRIO\PSKQRGHPHWDVWDVLVLQEODGGHU
DQGSURVWDWHFDQFHUDQXSGDWHGV\VWHPDWLFUHYLHZDQGGLDJQRV-
WLFPHWDDQDO\VLV$-5$P-5RHQWJHQRO::
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU
>@ 3DSDOLD 5 6LPRQH * *UDVVR 5 $XJHOOL 5 )DLHOOD (
*XDJOLDQRQH6HWDO'LIIXVLRQZHLJKWHGPDJQHWLFUHVRQDQFH
LPDJLQJLQSDWLHQWVVHOHFWHGIRUUDGLFDOF\VWHFWRP\GHWHFWLRQ
UDWHRISHOYLFO\PSKQRGHPHWDVWDVHV%-8,QW
>@ 7KRHQ\+&)URHKOLFK-07ULDQWDI\OORX0+XHVOHU-%DLQV/-
9HUPDWKHQ3HWDO0HWDVWDVHVLQQRUPDOVL]HGSHOYLFO\PSK
QRGHV GHWHFWLRQ ZLWK GLIIXVLRQZHLJKWHG 05 ,PDJLQJ
6
>@ .RED\DVKL 6 .RJD ) .DMLQR .<RVKLWD 6 ,VKLL &7DQDND +
HW DO$SSDUHQW GLIIXVLRQ FRHIÀFLHQW YDOXH UHÁHFWV LQYDVLYH
DQGSUROLIHUDWLYHSRWHQWLDORIEODGGHUFDQFHU-0DJQ5HVRQ
,PDJLQJ
>@ 0RWWHUOH *$QGUHZV -5 0RUODFFR$ .DUQHV 5- 3UHGLFWLQJ
5HVSRQVH WR 1HRDGMXYDQW &KHPRWKHUDS\ LQ %ODGGHU &DQFHU
(XU8URO)RFXV
5DGLRORJ\
>@ :DQJ+-3XL0+*XR<<DQJ'3DQ%7=KRX;+'LIIXVLRQ
ZHLJKWHG 05, LQ EODGGHU FDUFLQRPD WKH GLIIHUHQWLDWLRQ
EHWZHHQWXPRUUHFXUUHQFHDQGEHQLJQFKDQJHVDIWHUUHVHFWLRQ
$EGRP,PDJLQJ
>@ =KRX 0 /X % /Y * HW DO 'LIIHUHQWLDO GLDJQRVLV EHWZHHQ
PHWDVWDWLFDQGQRQPHWDVWDWLFO\PSKQRGHVXVLQJ':05,D
PHWDDQDO\VLVRIGLDJQRVWLFDFFXUDF\VWXGLHV-&DQFHU5HV&OLQ
2QFRO
>@ )XQDWVX+,PDPXUD$7DNDQR+8HGD78QR7&DQSUHWUHDW-
PHQW$'&YDOXHVSUHGLFWUHFXUUHQFHRIEODGGHUFDQFHUDIWHU
WUDQVXUHWKUDOUHVHFWLRQ"(XU-5DGLRO
>@ <DMLPD6<RVKLGD67DNDKDUD7$ULWD<7DQDND+:DVHGD<
HWDO8VHIXOQHVVRIWKHLQFKZRUPVLJQRQ':,IRUSUHGLFWLQJ
S7EODGGHUFDQFHUSURJUHVVLRQ(XU5DGLRO
>@ +DVVDQLHQ2$$ERXHONKHLU57$ERX(O*KDU0,%DGDZ\0((O
>@ 1JX\HQ+70RUWD]DYL$3RKDU.6=\QJHU'/:HL/6KDK=.
HW DO 4XDQWLWDWLYH$VVHVVPHQW RI +HWHURJHQHLW\ LQ %ODGGHU
7XPRU 05, 'LIIXVLYLW\ &DQ 5HVSRQVH EH 3UHGLFWHG 3ULRU WR
1HRDGMXYDQW&KHPRWKHUDS\"%ODGGHU&DQFHU
>@ 6HLOHU 5 $VKDE +$' (UKR 1 YDQ 5KLMQ %:* :LQWHUV %
'RXJODV - HW DO ,PSDFW RI 0ROHFXODU 6XEW\SHV LQ 0XVFOH
LQYDVLYH%ODGGHU&DQFHURQ3UHGLFWLQJ5HVSRQVHDQG6XUYLYDO
DIWHU1HRDGMXYDQW&KHPRWKHUDS\(XU8URO
>@ <RVKLGD6.RJD).RED\DVKL6,VKLL&7DQDND+7DQDND+
et al. Role of diffusion-weighted magnetic resonance
LPDJLQJ LQ SUHGLFWLQJ VHQVLWLYLW\ WR FKHPRUDGLRWKHUDS\ LQ
PXVFOHLQYDVLYHEODGGHUFDQFHU,QW-5DGLDW2QFRO%LRO3K\V
H
>@ 1JX\HQ+7-LD*6KDK=.3RKDU.0RUWD]DYL$=\QJHU'/
HW DO 3UHGLFWLRQ RI FKHPRWKHUDSHXWLF UHVSRQVH LQ EODGGHU
FDQFHUXVLQJ.PHDQVFOXVWHULQJRIG\QDPLFFRQWUDVWHQKDQFHG
*DPDO6$(O+DPLG0$'\QDPLF&RQWUDVW(QKDQFHG0DJQHWLF
5HVRQDQFH,PDJLQJDVD'LDJQRVWLF7RROLQWKH$VVHVVPHQWRI
7XPRXU$QJLRJHQHVLV LQ 8ULQDU\ %ODGGHU &DQFHU &DQ$VVRF
5DGLRO-
>@ =KRX*&KHQ;=KDQJ-=KX-=RQJ*:DQJ=&RQWUDVW
HQKDQFHG G\QDPLF DQG GLIIXVLRQZHLJKWHG 05 LPDJLQJ DW
7WRDVVHVVDJJUHVVLYHQHVVRIEODGGHUFDQFHU(XU-5DGLRO

>@ /L+/LX/'LQJ/=KDQJ==KDQJ04XDQWLWDWLYH$VVHVVPHQW
RI%ODGGHU&DQFHU5HÁHFWV*UDGHDQG5HFXUUHQFH&RPSDULQJ
RI7KUHH 0HWKRGV RI 3RVLWLRQLQJ 5HJLRQ RI ,QWHUHVW IRU$'&
0HDVXUHPHQWVDW'LIIXVLRQZHLJKWHG05,PDJLQJ$FDG5DGLRO

>@ 1LVKL]DZD7<RVKLGD6.RJD)7DQDND+.DJD0:DWDQDEH.
HW DO 6WDQGDUGL]DWLRQ RI WKH DSSDUHQW GLIIXVLRQ FRHIÀFLHQW
YDOXHRIEODGGHUFDQFHUDFURVVGLIIHUHQWFHQWHUV$SSOLFDELOLW\
LQSUHGLFWLQJDJJUHVVLYHSDWKRORJLFSKHQRW\SHV&OLQ,PDJLQJ

>@ :DQJ</L=0HQJ;+X;6KHQ<0RUHOOL-HWDO1RQPXVFOH
LQYDVLYH DQG 0XVFOHLQYDVLYH 8ULQDU\ %ODGGHU &DQFHU ,PDJH
4XDOLW\ DQG &OLQLFDO 9DOXH RI 5HGXFHG )LHOGRIYLHZ 9HUVXV
&RQYHQWLRQDO6LQJOHVKRW(FKRSODQDU,PDJLQJ':,0HGLFLQH
'&(05,SKDUPDFRNLQHWLFSDUDPHWHUV-0DJQ5HVRQ,PDJLQJ

>@ 6FKULHU %3 3HWHUV 0 %DUHQWV] -2 :LWMHV -$ (YDOXDWLRQ RI
FKHPRWKHUDS\ ZLWK PDJQHWLF UHVRQDQFH LPDJLQJ LQ SDWLHQWV
ZLWK UHJLRQDOO\ PHWDVWDWLF RU XQUHVHFWDEOH EODGGHU FDQFHU
(XU8URO
>@ &KDNLED & &RUQHOLV ) 'HVFDW ( *URVV*RXSLO 0 6DUJRV 3
5RXEDXG * HW DO '\QDPLF FRQWUDVW HQKDQFHG 05,GHULYHG
SDUDPHWHUVDUHSRWHQWLDOELRPDUNHUVRIWKHUDSHXWLFUHVSRQVH
LQEODGGHUFDUFLQRPD(XU-5DGLRO
>@ 1HFFKL$%DQGLQL0&DODUHVR*5DJJL'3HGHU]ROL))DUq(
HW DO 0XOWLSDUDPHWULF 0DJQHWLF 5HVRQDQFH ,PDJLQJ DV D
1RQLQYDVLYH$VVHVVPHQW RI7XPRU 5HVSRQVH WR 1HRDGMXYDQW
3HPEUROL]XPDELQ0XVFOHLQYDVLYH%ODGGHU&DQFHU3UHOLPLQDU\
)LQGLQJVIURPWKH385(6WXG\(XU8URO
>@ )XNXL7 0DWVXL< 8PHRND 6 ,QRXH7 .DPED77RJDVKL .
HW DO 3UHGLFWLYH YDOXH RI UDGLRORJLFDO UHVSRQVH UDWH IRU
SDWKRORJLFDO UHVSRQVH WR QHRDGMXYDQW FKHPRWKHUDS\ DQG
SRVWF\VWHFWRP\ VXUYLYDO RI EODGGHU XURWKHOLDO FDQFHU -SQ
-&OLQ2QFRO
>@ 0DUWLQL $ -LD 5 )HUNHW %6 :DLQJDQNDU 1 3OLPDFN (5
%DOWLPRUHH
>@ $YFX6.RVHRJOX01&H\ODQ.%XOXW0'8QDO27KHYDOXH
RIGLIIXVLRQZHLJKWHG05,LQWKHGLDJQRVLVRIPDOLJQDQWDQG
EHQLJQXULQDU\EODGGHUOHVLRQV%U-5DGLRO
>@ .RED\DVKL6.RJD)<RVKLGD60DVXGD+,VKLL&7DQDND+
HWDO'LDJQRVWLFSHUIRUPDQFHRIGLIIXVLRQZHLJKWHGPDJQHWLF
UHVRQDQFH LPDJLQJ LQ EODGGHU FDQFHU SRWHQWLDO XWLOLW\ RI
DSSDUHQWGLIIXVLRQFRHIÀFLHQWYDOXHVDVDELRPDUNHUWRSUHGLFW
FOLQLFDODJJUHVVLYHQHVV(XU5DGLRO
>@ 7DNHXFKL06DVDNL6,WR02NDGD67DNDKDVKL6.DZDL7HWDO
8ULQDU\EODGGHUFDQFHUGLIIXVLRQZHLJKWHG05LPDJLQJ²DFFX-
UDF\IRUGLDJQRVLQJ7VWDJHDQGHVWLPDWLQJKLVWRORJLFJUDGH
5DGLRORJ\²GRLUDGLRO
>@ 6HYFHQFR 6 3RQKROG / +HLQ]3HHU * )DMNRYLF + +DLWHO$
6XVDQL0HWDO3URVSHFWLYHHYDOXDWLRQRIGLIIXVLRQZHLJKWHG
05,RIWKHEODGGHUDVDELRPDUNHUIRUSUHGLFWLRQRIEODGGHU
FDQFHUDJJUHVVLYHQHVV8URO2QFRO
&UDEE6-HWDO7XPRUGRZQVWDJLQJDVDQLQWHUPHGLDWHHQG-
SRLQWWRDVVHVVWKHDFWLYLW\RIQHRDGMXYDQWV\VWHPLFWKHUDS\
LQ SDWLHQWV ZLWK PXVFOHLQYDVLYH EODGGHU FDQFHU &DQFHU

>@ *XUUDP60XWKLJL$(JDQ-6WDPDWDNLV/,PDJLQJLQ/RFDOL]HG
%ODGGHU &DQFHU &DQ &XUUHQW 'LDJQRVWLF 0RGDOLWLHV 3URYLGH
$FFXUDWH/RFDO7XPRU6WDJLQJ"&XUU8URO5HS
>@ 'RQDOGVRQ6%%RQLQJWRQ6&.HUVKDZ/(&RZDQ5/\RQV-
(OOLRWW7HWDO'\QDPLFFRQWUDVWHQKDQFHG05,LQSDWLHQWVZLWK
PXVFOHLQYDVLYHWUDQVLWLRQDOFHOOFDUFLQRPDRIWKHEODGGHUFDQ
GLVWLQJXLVK EHWZHHQ UHVLGXDO WXPRU DQG SRVWFKHPRWKHUDS\
HIIHFW(XU-5DGLRO
>@ &KRXHLUL 7. -DFREXV 6 %HOOPXQW - 4X $ $SSOHPDQ /-
7UHWWHU&HWDO1HRDGMXYDQWGRVHGHQVHPHWKRWUH[DWHYLQ-
EODVWLQHGR[RUXELFLQDQGFLVSODWLQZLWKSHJÀOJUDVWLPVXSSRUW
in muscle-invasive urothelial cancer: Pathologic, radiologic,
DQGELRPDUNHUFRUUHODWHV-&OLQ2QFRO
S132 05RXSUrWHWDO

Annexe 3. Carcinome neuro-endocrine

Prise en charge • 8Q3(7VFDQQHUDX)'*jODUHFKHUFKHGHORFDOLVDWLRQVj
distance est recommandé.
des carcinomes • 8QHH[SORUDWLRQFpUpEUDOH7'0RX,50HVWpJDOHPHQW
UHFRPPDQGpHHQUDLVRQGHODIUpTXHQFHGHVPpWDVWDVHV
non urothéliaux •
jFHQLYHDX
8Q GRVDJH GHV PDUTXHXUV QHXURHQGRFULQHV
&KURPRJUDQLQH$HW16(HVWUHFRPPDQGpDXGLDJQRVWLF
HWDXFRXUVGXVXLYLSRVWWKpUDSHXWLTXH
• )DLEOHQLYHDXGHSUHXYHpWXGHVUpWURVSHFWLYHVDYHFGH • 3RXU OHV IRUPHV ORFDOLVpHV XQH FKLPLRWKpUDSLH SDU
SHWLWVHIIHFWLIV²$YLVG·H[SHUWV FLVSODWLQHpWRSRVLGH93HVWUHFRPPDQGpHHQSUHPLqUH
• &H SDUDJUDSKH QH FRQFHUQH SDV OHV KLVWRORJLHV PL[WHV intention, suivie d’un traitement local de consolidation
FDUFLQRPHVXURWKpOLDX[DYHFGLIIpUHQWLDWLRQRXFRQWLQ- SDUF\VWHFWRPLHWRWDOHRXUDGLRWKpUDSLHH[WHUQH>@
JHQW QRQ XURWKpOLDO PLQRULWDLUH DVVRFLp GH SURQRVWLF • 3RXUOHVIRUPHVPpWDVWDWLTXHVXQHFKLPLRWKpUDSLHSDU
DVVLPLODEOHDX[IRUPHVXURWKpOLDOHVSXUHVHWTXLGRLYHQW
rWUHWUDLWpVGHODPrPHIDoRQ>@
• Les tumeurs de vessie non urothéliales de stade T1 doivent
rWUHSULVHVHQFKDUJHFRPPHGHVWXPHXUVLQÀOWUDQWHV
Carcinome épidermoïde
• (Q UDLVRQ GH VRQ HIÀFDFLWp PRLQGUH SDU UDSSRUW DX[
WXPHXUVXURWKpOLDOHV>@ODFKLPLRWKpUDSLHQpRDGMX-
YDQWHQ·HVWSDVUHFRPPDQGpHHWXQHF\VWHFWRPLHDYHF
FLVSODWLQHpWRSRVLGH93HVWUHFRPPDQGpH>@
>@ /LQ-:KDOHQ0+ROGHU'+UXE\*'HFDVWUR*-0F.LHUQDQ-
1HRDGMXYDQW FKHPRWKHUDS\ LQ WKH WUHDWPHQW RI PXVFOH
LQYDVLYH EODGGHU FDQFHU ZLWK PL[HG KLVWRORJ\ &DQ - 8URO

>@ %DQGLQL 0 3HGHU]ROL ) 0DGLVRQ 5 %ULJDQWL $ 5RVV -6
1LHJLVFK * HW DO 8QIDYRUDEOH &DQFHUVSHFLILF 6XUYLYDO
$IWHU 1HRDGMXYDQW &KHPRWKHUDS\ DQG 5DGLFDO &\VWHFWRP\
LQ 3DWLHQWV :LWK %ODGGHU &DQFHU DQG 6TXDPRXV &HOO
9DULDQW$ 0XOWLLQVWLWXWLRQDO 6WXG\ &OLQ *HQLWRXULQ &DQFHU
FXUDJHGRLWrWUHUpDOLVpHHQSUHPLqUHLQWHQWLRQVLWXPHXU
H[WLUSDEOH
Ⱦ (QFDVGHWXPHXUF7F7SULYLOpJLHUXQHF\VWHFWRPLH
VDQVFKLPLRWKpUDSLHQpRDGMXYDQWH
Ⱦ (QFDVGHWXPHXUF7HWRXQRQH[WLUSDEOHHQPDUJHV
VDLQHV SULYLOpJLHU XQH FKLPLRWKpUDSLH SUHPLqUH j
HHSLL6
>@ =DUJDU6KRVKWDUL.6YHUULVVRQ()6KDUPD3*XSWD63RFK0$
3RZ6DQJ -0 HW DO &OLQLFDO 2XWFRPHV$IWHU 1HRDGMXYDQW
&KHPRWKHUDS\ DQG 5DGLFDO &\VWHFWRP\ LQ WKH 3UHVHQFH
RI 8URWKHOLDO &DUFLQRPD RI WKH %ODGGHU :LWK 6TXDPRXV RU
*ODQGXODU'LIIHUHQWLDWLRQ&OLQ*HQLWRXULQ&DQFHU
EDVHGHFLVSODWLQHVXLYLHVLSRVVLEOHG·XQWUDLWHPHQW >@ 9HWWHUOHLQ 0: :DQNRZLF] 6$0 6HLVHQ 7 /DQGHU 5
/|SSHQEHUJ % &KXQ ). HW DO 1HRDGMXYDQW FKHPRWKHUDS\
ORFRUpJLRQDODGDSWpjODUpSRQVHWKpUDSHXWLTXH
SULRUWRUDGLFDOF\VWHFWRP\IRUPXVFOHLQYDVLYHEODGGHUFDQFHU
• /D FKLPLR DGMXYDQWH Q·HVW SDV UHFRPPDQGpH FDU VRQ
HIÀFDFLWpQ·DSDVpWpGpPRQWUpH>@
Adénocarcinome
• 8QH WXPHXU GX G{PH DYHF XQH KLVWRORJLH G·DGpQR-
FDUFLQRPH GRLW rWUH FRQVLGpUpH FRPPH XQ FDQFHU GH
O·RXUDTXH
ZLWKYDULDQWKLVWRORJ\&DQFHU
>@ %HUJ 6 '·$QGUHD ' 9HWWHUOHLQ 0: &ROH$3 )OHWFKHU 6$
.ULPSKRYH 0- HW DO ,PSDFW RI DGMXYDQW FKHPRWKHUDS\ LQ
SDWLHQWVZLWKDGYHUVHIHDWXUHVDQGYDULDQWKLVWRORJ\DWUDGLFDO
F\VWHFWRP\IRUPXVFOHLQYDVLYHFDUFLQRPDRIWKHEODGGHU'RHV
KLVWRORJLFVXEW\SHPDWWHU"&DQFHU
>@ 6LHINHU5DGWNH$8UDFKDODGHQRFDUFLQRPDDFOLQLFLDQ·VJXLGH
IRUWUHDWPHQW6HPLQ2QFRO
>@ 0DLVK:11JX\HQ/.1JX&%HQQHWW*3UDQDYDQ*0HWDVWDWLF
8UDFKXV1HRSODVLD$&DVH5HSRUWDQG5HYLHZRIWKH&XUUHQW
• 8QH H[SORUDWLRQ GLJHVWLYH FRORVFRSLH HW JDVWURVFRSLH
HVWUHFRPPDQGpHSRXUpOLPLQHUXQHRULJLQHGLJHVWLYH
• /DFKLPLRWKpUDSLHQpRDGMXYDQWHQ·DSDVIDLWODSUHXYH
GHVRQHIÀFDFLWp>@
• (QFDVGHFDQFHUGHO·RXUDTXHXQHF\VWHFWRPLHSDUWLHOOH
DYHFUpVHFWLRQPRQREORFGHO·RXUDTXHHPSRUWDQWO·RPEL-
OLFHWFXUDJHJDQJOLRQQDLUHDVVRFLpSHXWrWUHSURSRVpHVL
/LWHUDWXUH&OLQ*HQLWRXULQ&DQFHUHH
>@ &ODSV06WHOODWR0=DWWDULQ(0HQQLWWR$6HSH3*XDGDOXSL9
et al. Current Understanding of Urachal Adenocarcinoma and
0DQDJHPHQW6WUDWHJ\&XUU2QFRO5HS
>@ /DPEHUWL*%UL]]L033XVFHGGX6*HOVRPLQR)'L0HJOLR*
0DVVDUL ) HW DO 3HULRSHUDWLYH &KHPRWKHUDS\ LQ 3RRUO\
'LIIHUHQWLDWHG 1HXURHQGRFULQH 1HRSODVLD RI WKH %ODGGHU$
OHELODQG·H[WHQVLRQHVWQpJDWLIHWVLODWXPHXUHVWELHQ 0XOWLFHQWHU$QDO\VLV-&OLQ0HGSLL(
OLPLWpHDXG{PHFP>@
• 3RXU OHV DGpQRFDUFLQRPHV QRQ RXUDTXLHQV GH VWDGH
ORFDOLVpXQHF\VWHFWRPLHWRWDOHHVWUHFRPPDQGpH
• 8QHFKLPLRWKpUDSLHDGMXYDQWHDGDSWpHjODFRPSRVDQWH
>@ 1LX4/X<;X66KL4*XR%*XR=HWDO&OLQLFRSDWKRORJLFDO
FKDUDFWHULVWLFVDQGVXUYLYDORXWFRPHVRIEODGGHUQHXURHQGR-
FULQHFDUFLQRPDVDSRSXODWLRQEDVHGVWXG\&DQFHU0DQDJ5HV

>@ /RKULVFK&0XUUD\13LFNOHV76XOOLYDQ/6PDOOFHOOFDUFLQRPD
DGpQRFDUFLQRPDWHXVH GH W\SH WXPHXUV FRORUHFWDOHV
SHXWrWUHSURSRVpHVL1RX5
• 3RXU OHV IRUPHV PpWDVWDWLTXHV XQH FKLPLRWKpUD-
SLH HVW UHFRPPDQGpH j EDVH GH FLVSODWLQH RX GH
ÁXRURXUDFLOH>@
RIWKHEODGGHUORQJWHUPRXWFRPHZLWKLQWHJUDWHGFKHPRUD-
GLDWLRQ&DQFHU
>@ /X]]DJR 6 3DOXPER & 5RVLHOOR * .QLSSHU 6 3HFRUDUR$
1D]]DQL6HWDO6XUYLYDORI&RQWHPSRUDU\3DWLHQWV:LWK1RQ
PHWDVWDWLF6PDOOFHOO&DUFLQRPDRI8ULQDU\%ODGGHU$FFRUGLQJ
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

WR$OWHUQDWLYH7UHDWPHQW0RGDOLWLHV&OLQ*HQLWRXULQ&DQFHU >@ 0LWU\(%DXGLQ('XFUHX[06DERXULQ-&5XÀH3$SDULFLR7

HHSLL6;
>@ 0RHUWHO &* .YROV /. 2·&RQQHOO 0- 5XELQ -7UHDWPHQW RI
QHXURHQGRFULQHFDUFLQRPDVZLWKFRPELQHGHWRSRVLGHDQGFLV-
SODWLQ(YLGHQFHRIPDMRUWKHUDSHXWLFDFWLYLW\LQWKHDQDSODVWLF
YDULDQWVRIWKHVHQHRSODVPV&DQFHU
HW DO 7UHDWPHQW RI SRRUO\ GLIIHUHQWLDWHG QHXURHQGR-
FULQH WXPRXUV ZLWK HWRSRVLGH DQG FLVSODWLQ %U - &DQFHU

6 05RXSUrWHWDO

Annexe 4. ,QVWLWXWH RI &DQDGD &OLQLFDO 7ULDOV *URXS )LQQEODGGHU

1RUZHJLDQ%ODGGHU&DQFHU6WXG\*URXSHWDO,QWHUQDWLRQDO

Chimiothérapie
3KDVH,,,7ULDO$VVHVVLQJ1HRDGMXYDQW&LVSODWLQ0HWKRWUH[DWH
DQG 9LQEODVWLQH &KHPRWKHUDS\ IRU 0XVFOH,QYDVLYH %ODGGHU
&DQFHU/RQJ7HUP5HVXOWVRIWKH%$7ULDO-&OLQ2QFRO
néoadjuvante >@

$GYDQFHG%ODGGHU&DQFHU$%&0HWDDQDO\VLV&ROODERUDWLRQ
1HRDGMXYDQWFKHPRWKHUDS\LQLQYDVLYHEODGGHUFDQFHUXSGDWH
/DGHUQLqUHPpWDDQDO\VHSXEOLpHSRUWDQWVXUSDWLHQWV RIDV\VWHPDWLFUHYLHZDQGPHWDDQDO\VLVRILQGLYLGXDOSDWLHQW
GDQV  pWXGHV UDQGRPLVpHV FRQILUPH O·LQWpUrW G·XQH
FKLPLRWKpUDSLH QpRDGMXYDQWH j EDVH GH FLVSODWLQH DYHF
>@
XQH DPpOLRUDWLRQ GH OD VXUYLH JOREDOH GH O·RUGUH GH  j
DQVTXHOTXHVRLWOHVWDGHLQLWLDOGHOD79,0>@niveau
GDWDDGYDQFHGEODGGHUFDQFHU$%&PHWDDQDO\VLVFROODERUD-
WLRQ(XU8UROGLVFXVVLRQ
*URVVPDQ+%1DWDOH5%7DQJHQ&06SHLJKWV929RJHO]DQJ1-
7UXPS'/HWDO1HRDGMXYDQW&KHPRWKHUDS\SOXV&\VWHFWRP\
&RPSDUHGZLWK&\VWHFWRP\$ORQHIRU/RFDOO\$GYDQFHG%ODGGHU
de preuve 1/HPpWKRWUH[DWHYLQEODVWLQHGR[RUXELFLQH &DQFHU1(QJO-0HG
FLVSODWLQH 09$& RX OH 09$& KDXWH GRVH +' LQWHQVLÀp >@ 3ÀVWHU&+DUWHU9$OORU\<5DGYDQ\L)&XOLQH69(63(57ULDO
VRQWOHVGHX[SURWRFROHVUpIpUHQFpVGDQVFHWWHLQGLFDWLRQ ,QYHVWLJDWRUV 'HVLJQ RI D 5DQGRPL]HG &RQWUROOHG 3KDVH ,,,
/HQRPEUHRSWLPDOGHF\FOHVGHFKLPLRWKpUDSLHQ·DMDPDLV 6WXG\RI'RVH'HQVH0HWKRWUH[DWH9LQEODVWLQH'R[RUXELFLQ
pWpGpWHUPLQpSUpFLVpPHQWHWYDULHGHjF\FOHVSRXU
OHSURWRFROH09$&+'HWGHjF\FOHVSRXUOH09$&/H
SURWRFROH JHPFLWDELQHFLVSODWLQH Q·D MDPDLV pWp YDOLGp
GDQV OH FDGUH G·XQ HVVDL SURVSHFWLI ,O HVW DFWXHOOHPHQW j
O·pWXGHGDQVOHSURWRFROHQDWLRQDO9(63(5&OLQLFDO7ULDOVJRY
>@
DQG &LVSODWLQ GG09$& RU *HPFLWDELQH DQG &LVSODWLQ *&
DV 3HUL2SHUDWLYH &KHPRWKHUDS\ IRU 3DWLHQWV :LWK /RFDOO\
$GYDQFHG7UDQVLWLRQDO&HOO&DQFHURIWKH%ODGGHU7KH)UHQFK
*(78*$)899(63(57ULDO&RQWHPS&OLQ7ULDOV&RPPXQ

/DYHU\ +- 6WHQVODQG .' 1LHJLVFK *$OEHUV 3 'UROOHU 0-
,GHQWLÀHU1&7TXLFRPSDUHF\FOHVGHFLVSODWLQH 3DWKRORJLFDO 7 IROORZLQJ UDGLFDO F\VWHFWRP\ ZLWK RU ZLW-
JHPFLWDELQHjF\FOHVGH09$&+'/HVSUHPLHUVUpVXOWDWV KRXW QHRDGMXYDQW FKHPRWKHUDS\ D XVHIXO VXUURJDWH - 8URO
FRPPXQLTXpV j l’American Society of Clinical Oncology- 
Genitourinary $6&2*8  UHWURXYHQW XQH UpSRQVH
KLVWRORJLTXHVLJQLÀFDWLYHPHQWSOXVLPSRUWDQWHGDQVOHEUDV
09$& +' OD VXUYLH VDQV SURJUHVVLRQ HW OD VXUYLH JOREDOH
QHVRQWSDVDWWHQGXHVDYDQW>@/HFDUERSODWLQHQ·D
MDPDLVIDLWODSUHXYHGHVRQLQWpUrWRXGHVRQpTXLYDOHQFH
DXFLVSODWLQHGDQVFHWWHLQGLFDWLRQ
$SUqVFKLPLRWKpUDSLHQpRDGMXYDQWHGHVSDWLHQWV
>@ =DUJDU+(VSLULWX31)DLUH\$60HUWHQV/6'LQQH\&30LU0&
HWDO0XOWLFHQWHUDVVHVVPHQWRIQHRDGMXYDQWFKHPRWKHUDS\
IRUPXVFOHLQYDVLYHEODGGHUFDQFHU(XU8URO
>@ 9DQ$OOHQ(00RXZ.:.LP3,\HU*:DJOH1$O$KPDGLH+
HWDO6RPDWLF(5&&PXWDWLRQVFRUUHODWHZLWKFLVSODWLQVHQVL-
WLYLW\LQPXVFOHLQYDVLYHXURWKHOLDOFDUFLQRPD&DQFHU'LVFRY

>@ 3OLPDFN(5'XQEUDFN5/%UHQQDQ7$$QGUDNH0'=KRX<
RQWXQHUpSRQVHFRPSOqWHS7FHTXLHVWDVVRFLpjXQH
DPpOLRUDWLRQ GH OD VXUYLH JOREDOH >@ 3OXVLHXUV ELRPDU-
TXHXUV GH UpSRQVH j OD FKLPLRWKpUDSLH VRQW DFWXHOOHPHQW
HQFRXUVG·pYDOXDWLRQLQFOXDQWFHUWDLQHVPXWDWLRQV>@
RXOHVVRXVW\SHVPROpFXODLUHV>@
>@ <LQ 0 -RVKL 0 0HLMHU 53 *ODQW] 0 +ROGHU 6 +DUYH\ +$
HWDO1HRDGMXYDQW&KHPRWKHUDS\IRU0XVFOH,QYDVLYH%ODGGHU
&DQFHU$ 6\VWHPDWLF 5HYLHZ DQG 7ZR6WHS 0HWD$QDO\VLV
2QFRORJLVW
>@ ,QWHUQDWLRQDO &ROODERUDWLRQ RI 7ULDOLVWV 0HGLFDO 5HVHDUFK
&RXQFLO$GYDQFHG %ODGGHU &DQFHU :RUNLQJ 3DUW\ QRZ WKH
1DWLRQDO &DQFHU 5HVHDUFK ,QVWLWXWH %ODGGHU &DQFHU &OLQLFDO
6HUHEULLVNLL ,* HW DO 'HIHFWV LQ '1$ 5HSDLU *HQHV 3UHGLFW
5HVSRQVH WR 1HRDGMXYDQW &LVSODWLQEDVHG &KHPRWKHUDS\ LQ
0XVFOHLQYDVLYH%ODGGHU&DQFHU(XU8URO
>@ *URHQHQGLMN )+ GH -RQJ - )UDQVHQ YDQ GH 3XWWH ((
0LFKDXW 0 6FKOLFNHU$ 3HWHUV ' HW DO (5%% 0XWDWLRQV
&KDUDFWHUL]HD6XEJURXSRI0XVFOHLQYDVLYH%ODGGHU&DQFHUV
ZLWK([FHOOHQW5HVSRQVHWR1HRDGMXYDQW&KHPRWKHUDS\(XU
8URO
>@ ,\HU * %DODU $9 0LORZVN\ 0, %RFKQHU %+ 'DOEDJQL *
'RQDW 60 HW DO 0XOWLFHQWHU 3URVSHFWLYH 3KDVH ,, 7ULDO RI
1HRDGMXYDQW 'RVH'HQVH *HPFLWDELQH 3OXV &LVSODWLQ LQ
3DWLHQWV :LWK 0XVFOH,QYDVLYH %ODGGHU &DQFHU - &OLQ 2QFRO
-&2
>@ 6HLOHU 5 $VKDE +$' (UKR 1 YDQ 5KLMQ %:* :LQWHUV %
6WXGLHV *URXS (XURSHDQ 2UJDQLVDWLRQ IRU 5HVHDUFK DQG 'RXJODV - HW DO ,PSDFW RI 0ROHFXODU 6XEW\SHV LQ 0XVFOH
7UHDWPHQW RI &DQFHU *HQLWR8ULQDU\ 7UDFW &DQFHU *URXS LQYDVLYH%ODGGHU&DQFHURQ3UHGLFWLQJ5HVSRQVHDQG6XUYLYDO
$XVWUDOLDQ %ODGGHU &DQFHU 6WXG\ *URXS 1DWLRQDO &DQFHU DIWHU1HRDGMXYDQW&KHPRWKHUDS\(XU8URO
)UHQFKFF$)8JXLGHOLQHVîXSGDWHEODGGHUFDQFHU 6

Annexe 5. Compte-rendu ,QÀOWUDWLRQ ODPLQD SURSULD PXVFXODLUH PXTXHXVHPXV-

FXOHXVH LQWHUQH H[WHUQHJUDLVVH SpULYpVLFDOHSURVWDWH
anatomopathologique utérus/autre)
7\SHGHWXPHXUYDULDQW
type pour la cystectomie (PEROHVO\PSKRYDVFXODLUHV
$XWUHVOpVLRQVOpVLRQSODQHV&,6
*UDQXORPHV
5HFRXSHVOLPLWHV
Renseignements *DQJOLRQVGDQVODJUDLVVHSpULYpVLFDOH
,PPXQRKLVWRFKLPLH
(notamment traitements antérieurs) 6LDXWUHWXPHXUDVVRFLpHIDLUH&5FRPSOpPHQWDLUHSURVWDWH
utérus/…)

Macroscopie
Curages
7DLOOHGHODSLqFHHWORQJXHXUGHVXUHWqUHV
Localisation(s) tumorale(s) (uni/multifocale) 1RPEUHGHJDQJOLRQV
7DLOOHGHODWXPHXUYRLUODSOXVJUDQGHSDUH[ Taille des ganglions
$VSHFWGHODWXPHXU 6L1WDLOOHGHODSOXVJURVVHPpWDVWDVHJDQJOLRQQDLUHHW
Urètre : longueur SUpFLVHUVLUXSWXUHFDSVXODLUH
6LSURVWDWHWDLOOHDYHFHQFUDJH
9pVLFXOHVVpPLQDOHV
8WpUXVDQQH[HVRYDLUHVODPEHDXYDJLQ Diagnostic/conclusion

6HORQODFODVVLÀFDWLRQS710RX\S710VLOHSDWLHQWD
Histologie UHoXGHODFKLPLRWKpUDSLHQpRDGMXYDQWH

7\SHGHWXPHXU
*UDGH